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ABSTRACT 
 Heart valve diseases affect nearly 8 million people every year in the United States. 
Of these patients, 72% are affected by mitral valve diseases. Stenosis, regurgitation, and 
prolapse of the mitral valve are the primary pathologies affecting valve function resulting 
in atrial fibrillation, arterial thromboembolism, pulmonary edema, pulmonary 
hypertension, cardiac hypertrophy and heart failure. Surgical options to repair or replace 
the mitral valve are only palliative, especially for children with congenital defects, and do 
not exclude the need for reoperation. A tissue-engineered option is feasible and holds great 
potential through the combination of decellularized scaffolds, patient stem cells, and heart 
valve bioreactors.  Development of living tissue engineered mitral valves have not been 
reported in the recent literature. The primary focus of my research was threefold: 1) 
develop an acellular ECM scaffold which is mechanically robust, and allows for sufficient 
bioactivity for cellular seeding and signaling by use of a non-toxic matrix-binding 
polyphenolic antioxidant, pentagalloyl glucose (PGG); 2) confirm this scaffold to be 
biologically compatible with future hosts and limiting inflammatory responses in vivo by 
virtue of PGG’s antioxidant properties; 3) achieve recellularization of the mitral valve 
scaffold and direct differentiation and maturation through bioreactor preconditioning. 
 First, a complete decellularization of porcine mitral valves was established and 
optimized to remove all cellular and nuclear material from the scaffolds while still 
preserving ECM components and basal lamina proteins. Treatment with PGG recovered 
lost mechanical integrity due to the decellularization process. Seeded cells were able to 
grow and proliferate on and in the acellular scaffold confirming cytocompatibility. 
iii 
 
 An in vivo rat study was conducted to evaluate the scaffolds’ biocompatibility. In 
comparing non-treated and PGG-treated groups, PGG –treatment regularly and 
significantly showed increased resistance to degradation, polarization of macrophages to 
the pro-healing M2 phenotype, discouragement of inflammatory markers, and no 
limitations towards cell infiltration. 
 Lastly, PGG-treated acellular scaffolds were recellularized with pre-differentiated 
fibroblasts and endothelial cells and placed in a newly developed mitral valve bioreactor. 
Design of the bioreactor required a full understanding and appreciation for the four tissue 
types present in the mitral apparatus. Preconditioning of the seeded constructs yielded a 
mitral construct similar to a native valve. 
 The overarching goal of this research was to develop a stable mitral valve construct. 
It is expected that the progress made by this project will have a positive impact on those 
that suffer from mitral valve pathologies. Our translatable approach towards this tissue 
engineered mitral valve should allow clinicians to readily adopt this regenerative 
replacement and contribute as a whole to the field of cardiovascular tissue engineering. 
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CHAPTER ONE: REVIEW OF LITERATURE 
1.1 Anatomy of the Mitral Valve: 
1.1.1 Introduction: 
The mitral valve, named so due to its likeness to that of a Bishop’s miter, is an 
intricate atrioventricular valve located on the left side of the heart. The mitral valve 
prevents backflow from the left atrium to the ventricle during systole. Housing a 
complicated anatomy, the mitral valve is built from four different tissue groups each 
performing different functions for this valvular apparatus. In its open state, the valve 
resembles a funnel extending from the hinge line at the atrioventricular junction and the 
ends of its two leaflets. Proper function of the valve not only requires normally functioning 
leaflets but also their coordinated interaction with the annulus, chordae tendinae, and the 
papillary muscles. Due to its placement within the heart, the effectiveness and function of 
the mitral valve is closely tied to its surrounding environment, namely the aortic valve and 
the left ventricular wall. Integrity of the valve is critical for the maintenance of normal left 
ventricle size and function.  
Figure 1.1: Anatomy of the mitral valve including its four major components, the mitral annulus, leaflets, 
chordae tendinae, and papillary muscles.(1) 
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1.1.2 Mitral Annulus: 
The foundation for proper mitral valve shape and function is established by the 
annulus, a thin, nonconductive, fibro-fatty transition region from the myocardia of the 
atrium (posteriorly) and fibrous aortic annulus (anteriorly) to the valve leaflets(2). The term 
annulus implies a solid ring-like fibrous cord to which the leaflets are attached; however, 
this is not the case. The mitral annular region is indistinct since the fibrous continuity is an 
extensive sheet(3). Some in literature distinguish the annulus as a tissue plane at the 
confluence of adjacent structures as opposed to a separate anatomical entity(4). The annulus, 
like the leaflets, is split into two regions, the anterior and posterior annulus. Each of these 
portions is different in size and purpose. The anterior annulus, which constitutes one-third 
of the annular surface area, is anatomically coupled with the aortic annulus and is flanked 
by the left and right trigones(2,4). This connection with the aortic annulus is termed the 
aorto-mitral curtain or intervalvular fibrosa(2). This attachment elevates this portion of the 
annulus as the aortic-mitral continuity comes up to meet the lower edges of the left and 
non-coronary sinuses and the interleaflet fibrous triangle(5). The posterior leaflet comprises 
the other two-thirds of the annular area and is externally related to the musculature of the 
left ventricle inflow region and internally to the left atrium where it merges with the 
leaflet(2). This area tends to be “weaker” due the lack of a formed fibrous cord(3).  
The geometric shape of the annulus approximates to that of a hyperbolic 
paraboloid(2,4,6–8). More simply, this shape resembles a saddle with peaks(“riding horns”) 
located anteriorly and posteriorly and valleys located medially and laterally at the 
commissures(9). Computational modeling has shown that as annular height (measured at 
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the peaks) increases relative to width of the valve (at the commissures), peak leaflet stress 
decreases, becoming maximally attenuated once this height to width ratio exceeds 
0.2(4,6,7,10,11). A higher ratio implies that the annulus is more saddle-shaped, while a lower 
ratio infers a flatter annulus. Although this nonplanar shape’s origins are not fully described 
in literature, it is understood that this shape is the determinant of optimal force distribution 
in the leaflets and chordae tendinae(4,8,12). Changes in annular shape and dynamics have 
been observed in patients with functional mitral regurgitation, acute ischemic mitral 
regurgitation, and different types of cardiomyopathies(8). Therefore, when anatomically 
correct, the annulus provides an optimal foundation for the remaining components of the 
valve. 
Figure 1.2: The hyperbolic paraboloid shape of the mitral annulus. (13)
Movement of the annulus is heavily influenced by its surrounding environment 
during atrial and ventricular filling and emptying. The mitral valve however is not entirely 
passive in its movement, as it contains smooth muscle cells and nerve fibers(14,15). The 
atrioventricular conduction bundle passes through the right fibrous trigone(3). This well-
defined network of nerve fibers work to contract the valve tissue. Three types of motion 
have been described for the annulus, translation between the left ventricular apex, 
sphincteric contraction, and folding across the intercommissural axis(4). During diastole, 
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the annulus acts as a conduit for blood flowing from the left atria into the left ventricle. 
During this period, when the left atrium is progressively relaxing, the annular area is 
allowed to increase where it reaches its maximum annular area at the end of diastole. Also 
during this time, area is increased by movement of the anterior horn towards the aortic 
annulus. When systole begins, the mitral valve begins to contract and it reaches its 
narrowest during mid-systole. During this moment, the posterior horn shifts apically, where 
the anterior horn shifts towards the left atrium. The narrowing of the annulus allows for 
curvature of the leaflets and therefore optimal coaptation. Note that the annulus is smallest 
during mid-systole, while contraction of the heart continues, annular circumference 
progressively increases to allow unobstructed flow from the atria to the ventricle during 
diastole(13). Sphincter-like contraction is also key to leaflet coaptation. Contraction of the 
annulus draws the free margins of the leaflets together in anticipation of the sharp rise in 
pressure during systole. The annular circumference decreases by 25% during diastole 
reaching its smallest at the very beginning of systole (end of diastole)(2,13). Folding of the 
annulus also occurs during ventricular systole. This conformation promotes normal 
function without wrinkling or distorting the leaflets. This folding action blunts the rise in 
leaflet closing stresses during the rise in pressure during left ventricular systole(4). 
 
Figure 1.3: Anatomy of the mitral valve leaflets. (13) 
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1.1.3 Mitral Leaflet: 
Similar to the annulus, the mitral valve leaflets are also divided into anterior and 
posterior positions. Due to the oblique location of the valve, strictly speaking the two 
leaflets do not technically reside in anterior or posterior positions, therefore these leaflets 
are also termed “aortic” due to its proximity to the aorta, and “mural” due to its attachment 
to the ventricular wall(3). The two leaflets are actually a single continuous structure that 
become confluent at the commissures(2). However, each designated leaflet is unique in 
shape, size, and composition. The anterior, or aortic leaflet, transitioning from the anterior 
annulus, is much more fibrous in nature and comprises about one third of the annular 
circumference. It does however make up a majority of the mitral orifice. In terms of pure 
surface area, the two leaflets are almost equal. The two leaflets meet to form an arc shaped 
closure line. The posterior, or mural leaflet, takes up a much smaller area of the valve 
orifice, but comprises about two thirds of the valve’s circumference. It is worth noting that 
the posterior leaflet is often divided into three or more segments (scallops) described as 
lateral, middle, and medial segments(2,3). The middle scallop is usually the largest of the 
three but it can vary. By having three segments, it allows the leaflets to act similarly to how 
pleats do on clothing, allowing the leaflet to accommodate to the shape of the curved 
closure(3,16).  
In a healthy valve, the leaflets are usually thin, pliable and translucent. Each leaflet 
is exposed to both the atria and the ventricle. The ventricle side of each leaflet can be 
dissected into zones designated so by the insertion of tendinous cords. The anterior leaflet 
has two distinguishable zones, while the posterior leaflet has three zones. Both leaflets have 
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a clear zone, which has no chordal attachments. This zone is closer to the free margin and 
because this zone is at the line of closure, it is the thickest part of the valve. Each leaflet by 
comparison also has a rough zone, where the chordae tendinae attach to the ventricular 
surface of the leaflets. This zone is broadest at the lowest portions of each leaflet but tapers 
toward the commissures(3,14,17). The basal zone, which is specific to the posterior leaflet, 
has insertions from the basal chordae to its ventricular surface. The anterior leaflet lacks 
this region due to the distance from the ventricular wall, and therefore lack of basal cords. 
Closure and function of the leaflets is obviously a product of annular movement and 
contraction and tension from the chordae, however the mechanics have not been fully 
defined. Convention holds that the pressures during ventricular systole force the leaflets 
closed with the chords attached on the ventricular side forbidding prolapse of the leaflets 
into the atrium. Atrial contraction, and the role it may play in leaflet closure has been 
debated(2). Some studies have shown that contraction of the annulus just before systole 
facilitates closure by approximating the leaflets. The stiffness of the anterior leaflet is 
influenced by electrical stimulation from the neurally-rich region of aortic-mitral 
continuity(18). Myocytes, which occupy a portion of the mitral leaflets are activated after 
contraction of the left atrium and this may position the leaflets prior to ventricular systole(3). 
This provides the basis of a paradigm shift from viewing the leaflets as passive collagenous 
flaps and as active tissues with a more complex function. 
Leaflet coaptation, while simple in function, are some of the most stressed tissues 
in the body, opening and closing nearly 3 billion times in a lifetime(19). The biomechanics 
of the leaflets can be broken down into three loading modes: tension, shear, and flexure. 
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These are imposed cyclically, the valve opens (flexure), permits blood to pass (shear), 
closes (flexure), and prevents the reverse flow of blood (tension)(19). Pressure across the 
valve (transvalvular pressure) ranges from 100-200 mmHg, usually averaging about 120 
mmHg(19,20). Valves on the left side of the heart experience pressures 5-8 times as large as 
those on the right(19). Left side heart valves are about 2 times thicker because of this(19). 
These pressures are largely felt during systole on the ventricular side of the valve. Atrial 
pressures are much lower on average, about 10mmHg for the left atrium. Mechanical data 
on leaflets, especially in vivo, is especially difficult. Therefore, most studies on valvular 
mechanics are estimated using some form of computer modeling. For mitral valve leaflets, 
biaxial testing is used frequently since they are thin and nearly incompressible. Radial and 
circumferential strains and stresses are applied during these studies. Due to the 
microstructural makeup of the leaflets and the direction the collagen fibers are aligned, the 
leaflets act anisotropically, yielding stiffer (lower strain rate) results in the circumferential 
direction. In fact, in vivo strains of 10.1 and 30.8% in the circumferential and radial 
directions respectively have been reported(21). This is because the collagen fibers are 
aligned in the circumferential direction in the leaflets. Collagen is known to withstand high 
tensile forces but have low torsional and flexural stiffness(21). Shear experienced by the 
valve is determined by the flow rate of blood passing through them. It has been shown that 
blood flow across the mitral valve is about 5610±620 mL/min(22). The leaflets are also 
capable of large deformations, ranging from 10-60% before reaching physiological stress 
levels(20). 
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1.1.4 Chordae Tendinae: 
The pressures experienced during ventricular systole are too great for the leaflets 
alone to successfully disallow regurgitant flow back up into the atrium. Tendinous cords 
descend on the ventricular side of the leaflets and attach to the papillary muscles where 
they transmit the force necessary to keep the valve closed during systole. In order to 
perform such functions and endure such pressures, the chordae tendinae must contain a 
high degree of strength and elasticity. The chordae are largely composed of parallel fibers 
of collagen and elastin with an outer layer of endothelial cells(23). This arrangement allows 
for an efficient transfer of the contraction forces from the papillary muscles to the leaflets. 
 
Figure 1.4: Chordae tendinae variety and attachments to corresponding leaflets. (24) 
Based on their point of insertion and their size and composition, three types of 
chords have been delineated: the primary (marginal), secondary (basal) and tertiary(2). The 
primary chords attach to the free margins of the leaflets while the secondary chords attach 
beyond the primaries. Primary or first order chords as they are also called, are numerous 
and delicate, often forming networks near the edge. Secondary chords are thicker than the 
primary chords. These two types of chords may rise from the same bifurcating stem 
however. The tertiary chords arise directly from the side of the left ventricular wall and 
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insert only into the posterior leaflet. These chords run only a short distance toward the free 
margin. Some groups have also delineated individual chords such as the commissural 
chords, strut chords, and the cleft chords(3,23). Each however have distinct purposes for the 
valve’s coaptation. Primary chords maintain leaflet apposition and facilitate valve closure. 
The secondary chords help play a role in maintaining normal size in the left ventricle. The 
thicker and longer of the secondary chords, also known as strut chords, act as the interface 
between the musculature of the wall and the mitral annulus (connecting at the fibrous 
trigones)(2). The strut chords are under continuous tension transmitted to the papillary 
muscles and trigones. 
Chordae tendinae however apparently have a paradoxical size-dependent 
mechanical behavior. Thinner chordae, such as the primary chords, were less extensible 
and more stiff than the thicker chordae(14). Thicker chordae have smaller crimp periods 
than thinner chordae, meaning that thicker chords could undergo greater strain before 
collagen was uncrimped. The tensile modulus is also greater in the thinner chordae. It has 
been reported that thinner chordae have a greater fibril density despite their smaller fibril 
diameter(25). Therefore, the smaller chordae, which are responsible for mitral valve 
competence, with greater interfibrillar interactions explains their greater modulus. 
1.1.5 Papillary Muscles: 
The last major component of the mitral apparatus are the papillary muscles. While 
their location can be variable, they are most commonly attached to the middle third of the 
left ventricle wall(2,3). In most cases, there are about two papillary muscles where most 
chordae tendinae are attached. Contraction of the papillary muscles is coordinated with the 
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left ventricle as a whole. Therefore, function of the papillary muscles is largely affected by 
the condition of the left ventricle. This coordinated contraction is essential, because were 
it not for the timely contraction of the papillary muscles, the fixed length of the chordae 
might otherwise permit the leaflets to prolapse into the atrium. Placement of the papillary 
muscles also effects the shape of the annulus through chordal attachment(24). This 
placement effects chordal forces and therefore coaptation of the valve. 
1.1.6 Microstructure: 
Interstitially, the extracellular matrix (ECM) of the valve differs within each 
component, but each is defined by their roles in the valve’s coaptation. The matrix is 
composed of various proteins and polysaccharides that are assembled into a meshwork 
created, organized, and secreted by the surrounding cells. The relationship between the 
matrix and the surrounding cells is dependent upon one another. Cells produce and 
constantly remodel the surrounding matrix. The ECM acts as a ground substance for which 
cells can exist. Inversely, the ECM exerts powerful influence on the cells. These influences 
are exerted through transmembrane cell adhesion proteins that act as matrix receptors. 
These influences can be either mechanical or chemical in nature. The primary membrane 
receptors that bind to ECM proteins are integrins. Through these matrix receptors, 
components of the ECM can affect almost any aspect of the cell’s behavior. Cells also use 
integrins to transmit signals from the cells to the matrix as well. Each component of the 
mitral valve contains a basal lamina or basement membrane, which separates the cells from 
the underlying connective tissue and forms the mechanical connection between them. Also 
formed by the surrounding cells, the basal lamina influences cell polarity, metabolism, 
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organize the proteins in adjacent plasma membranes, promote cell proliferation, migration 
and differentiation. Basal lamina are specific to the specific types of cells that establish the 
basement membrane. The basal lamina in this valve and in many tissues is composed of 
laminin and collagen type IV. 
 
Figure 1.5: Papillary muscles and their corresponding attachments to chordae and left ventricle wall.(26) 
There are two main classes of ECM macromolecules, fibrous proteins and polysaccharide 
chains of the type called glycosaminoglycans or GAGs. Fibrous proteins are largely 
glycoproteins, which have oligosaccharide side chains attached. These glycoproteins play 
an important role in cell-to-cell interactions. One of the most common examples of fibrous 
proteins are collagens and elastins. GAGs are usually found linked covalently to specific 
core proteins to form proteoglycans. These serve as the ground substance of many types of 
connective tissue. Because they are so heavily glycosylated, the balance has shifted close 
to carbohydrates in nomenclature. The carbohydrate chains attached to the core proteins 
are negatively charged due to their sulfate or carboxyl groups bound to their sugars. 
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1.1.7 Annulus: 
As form follows function, the annulus acts as the transition zone from the aortic 
annulus on the anterior side and the myocardium on the posterior side of the valve. 
Anteriorly, collagenous fibers radiate into the annulus form the collagenous root to which 
it is attached. Collagen, a common fibrous protein is a triple stranded helical structure. This 
rope-like structure is perfect for resisting the tension felt on the valves. The annulus, as the 
transition region from the myocardium and aortic root is moving constantly in several 
directions while also allowing for contraction. Resistance to tension is essential for its 
function. To also assist with the tensile stresses, the annulus’s ECM contains elastic fibers. 
The main component of the elastic fibers in the annulus is elastin, a highly hydrophobic 
protein, is elastic and supports tensile resistance while also allowing for stretching or 
contracting. The posterior annulus, which attaches to the myocardium, is muscular while 
also containing collagen and elastin within its matrix. From both annuli, radiates collagen 
and elastin into the leaflets which also have a unique matrix composition 
1.1.8 Leaflets: 
The mitral valve leaflets have a layered microstructure that readily supports the 
environment with which it functions. From top (atrial side) to bottom (ventricular side), 
the primary layers are the atrialis, spongiosa, and ventricularis(14,17). The atrialis layer is 
largely built of elastin fibers providing elasticity to the leaflet. The ventricularis, also called 
the fibrosa layer, is a thick collagenous layer built to withstand the tension caused by the 
high pressures of the ventricle. In the mitral valve, the collagen show a circumferential 
alignment in the leaflets(14,17,18). The inner layer contains proteoglycans and the GAG 
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hyaluronan. GAGs, one of the two main classes of macromolecules in the ECM, are 
unbranched polysaccharide chains composed of repeating disaccharide units. GAGs are 
naturally negatively charged because of the sulfate and carboxyl groups on most of these 
sugars. This high density of negative charge attracts cations like Na+ that are osmotically 
active and therefore attract large amounts of water into the matrix. This causes a swelling 
pressure that enables this GAG layer to withstand the compressive forces experienced by 
the leaflets. It is important to note that these layers are not exclusive to one type of ECM. 
The atrialis and spongiosa both contain some collagen and the spongiosa contains a 
network of elastic fibers(14). These layers are found in both leaflets. There are variations in 
the thickness of the layers. This is especially evident in the anterior leaflet, where the 
proximal third of the leaflet is marked by a very thick ventricularis, rich in highly aligned 
collagen and small leucine-rich PG, with only minor presence in the other layers.  
 
Figure 1.6: Three-layered extracellular matrix of the mitral valve leaflet. (27) 
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1.1.9 Chordae Tendinae: 
The chordae attached to the ventricular side of the leaflets are largely composed of 
collagen with some elastin fibers as well. This combination allows of elastic and highly 
crimped collagen fibers allows for appropriate deformations needed to handle the tension 
brought on the chords from the papillary muscles and translate this to the leaflets to which 
they are also attached. As mentioned, the chordae vary in thickness and collagen density. 
The thinner chordae have a greater fiber density than the thicker chords and thus show an 
increased modulus.  
1.1.10 Papillary Muscle: 
The papillary muscles as expected are largely composed of myocardium due to their 
origins from the muscle in the left ventricle. 
1.2 Valvular Interstitial Cells: 
Valvular interstitial cells (VICs) are the prevailing cell type in the heart valves and 
are found within each fibrosa, spongiosa, and ventricularis layer of the valve(28–33). They 
are a dynamic population of valvular-specific cells and are the living component of heart 
valves. VICs are responsible for synthesizing and preserving the composition of the valve 
matrix, which largely determines the valve’s ability to function as well as its material 
behavior(28). The central role of the VIC is to maintain the structural integrity of the valve 
and to act when the valve is in need of repair. These responsibilities are extremely 
important as heart valves are the most mechanically stressed tissue found in the body. VICs 
also function as key role players in the body’s pathological response to heart valve disease 
as well as regulating processes following valve injury.  
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Figure 1.7: The five phenotypes of valvular interstitial cells(34). 
Current literature supports five heterogeneous VIC phenotypes(14,28). Each of these 
phenotypes exhibits specific sets of cellular functions necessary for proper valve function, 
injury repair, and pathological processes. The five phenotypes would be: embryonic 
progenitor endothelial/mesenchymal cells, qVICs (quiescent VICs), pVICs (progenitor 
VICs), aVICs (activated VICs) and obVICs (osteoblastic VICs). These phenotypes are 
shown in Figure 1.7. It is important to note the differentiating potential for each phenotype 
into another as well as the plasticity that exists between qVICs and aVICs. This relationship 
is crucial for proper valve repair and can result in pathological problems if proper balance 
between them is not achieved. 
Embryonic progenitor endothelial/mesenchymal cells are included in the VIC 
family because the EMT (endothelial-mesenchymal transdifferentiation) paradigm, 
apparent in heart valve development, reappears in adult valves in response to injury(28). The 
endothelial cells involved in EMT actually have properties similar to heart valve progenitor 
cells and may give rise to VICs. As the potential originator of VICs, as illustrated in Figure 
1.7, many have investigated what factors contribute to the transformation of endothelial 
cells into these VICs. Transforming growth factor (TGF)-β and bone morphogenic 
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proteins, particularly BMP-2 have been noted to influence the pathway to VICs(28,35,36). The 
Notch and vascular endothelial growth factor (VEGF) are also well known to have distinct 
regulatory effects on EMT. Armstrong and Bischoff, understanding that VEGF is highly 
suggestive and its expression tightly controlled during development, concluded that VEGF 
facilitates valve formation by establishing an equilibrium between proliferation and 
differentiation(37). Others looking into developmental studies concluded that BMP-2 is 
essential for EMT it devotes progenitor cells into endothelial cells(38). Also, the Notch 
signaling pathway, often interacting with the TGF-β superfamily, is implicated in 
development of endocardial cushions and normal development of the aortic and mitral 
valves(28). 
1.2.1 VIC Phenotypes: 
qVICs are the predominant VIC phenotype in healthy valves and are thought to 
maintain the valves overall structure and function(28,29,32,36,39,40). In this resting state of VICs 
they act similar to fibroblasts(41,42). It is from this phenotype that VIC plasticity stems. From 
here, as shown in Figure 1.7, multiple phenotypes can be achieved by providing certain 
mechanical or chemical factors. To communicate, qVICs show two types of intercellular 
junctional complexes, gap and adhesion junctions(28–30). Gap junctions, commonly 
Connexin-26 and -45, are used to communicate with adjacent VICs. Adhesion junctions 
may be important in allowing gap junction function(28). N-cadherin and desmoglein are 
found faintly in these junctions. While the physiological presence of these junctions is not 
completely understood, it has been theorized that they are used to transmit information 
from mechanical cues for example across the cellular structure network. 
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 Progenitor VICs or pVICs, are essentially valvular stem cells and can be derived 
from various origins such as bone marrow stem cells. Unfortunately, these are the least 
understood VIC. Identification of this phenotype is difficult but some have differentiated 
hematopoietic stem cells into VIC like cells. Others have isolated progenitor cells from the 
pulmonary valves. There is some evidence that the microenvironment of the heart valve 
ECM influences bone-marrow stem derived pVICs once they are present in the valve, 
possibly arriving via microvessels at the base of the leaflets(28). How these pVICs travel to 
injury locations however is less understood. Perhaps it is done through some soluble signal 
molecules arising from the tissue injury and/or pathological effects occurring in a diseased 
valve. 
 obVICs are VICs that undergo osteoblastic differentiation and promote 
calcification within the valve. This phenotype is not typical of normally cultured VICs. 
TGF-β and BMP-2, may regulate valve calcification based on the increased rate of nodule 
formation after their application. Cultured VICs do not normally promote calcification. 
When cultured with media supplemented with organic phosphate, VICs begin to express 
chondrogenic and osteogenic markers and form calcific nodules(28,43,44). The calcification 
process relies on the upregulation of alkaline phosphatase activity because prevention of 
such inhibits in vitro calcification. To evaluate differentiation into obVICs, calcific nodule 
formation is often used as a barometer. TGF-β, as discussed before, promotes migration 
and activation of VICs but it can also promote the formation of these apoptotic alkaline 
phosphatase-enriched nodules. Literature shows us that TGF-β mediates the calcification 
of these VICs through mechanisms of apoptosis(28). Valvular endothelial cells (VECs) may 
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also play a role in encouraging an obVIC phenotype; however, this role is most likely as 
an outside transducer rather than a direct promoter. 
 In response to injury or disease, qVICs become activated VICs (aVICs) and take 
on the features of myofibroblasts. This phenotype is characterized by increased α-smooth 
muscle actin (α-SMA) expression, contractility, stress fiber formation, secretion of matrix 
remodeling enzymes (MMP-1, MMP-2, MMP-9, MMP-13), cytokines (TGF-β), and 
cathepsins(28,40,45,46). aVICs also exhibit heterogeneity in their morphologies. Round aVICs 
have more α-SMA stress fibers, while spindle-shaped aVICs show higher motility and are 
more proliferative(47). Activation of qVICs is brought on by changes in the mechanical 
environment or from several cytokines, often TGF-β. These changes in the ECM 
microenvironment are often due to disease or damage to the valvular tissue. When activated 
these VICs increase their secretion of extracellular matrix while also degrading the existing 
matrix, expressing MMPs and TIMPs. Proliferation and migration of aVICs is also 
increased, which is important for wound repair. After completing the necessary 
remodeling, many aVICs are eliminated by apoptosis or return to qVICs(28). It his however 
this regulation of aVICs that is crucial to valvular homeostasis. Many pathologies result in 
high cellularity and abnormal changes in ECM content; these are often caused by the 
dysregulation of aVICs. By persisting and not returning to the qVIC phenotype, 
pathological fibrosis, angiogenesis, chronic inflammation, and calcification can result from 
abnormal remodeling(28). Therefore, aVICs are crucial to valve remodeling and repair but 
a balance and proper regulation must be achieved or these interstitial cells cause more harm 
than good. 
19 
 
1.2.2 Regulation of VIC Activation: 
 TGF-β, a superfamily of proteins, is a well-known group of peptide growth factors 
that regulate biological processes and cellular systems in the body. It also has well 
documented effects on VICs differentiation into the activated phenotype. TGF-β binds to 
the cell surface to the TGF-β receptors I and II leading to signaling through the Smad 
proteins. Smad proteins reside intracellularly and transduce extracellular signals from 
TGF-β ligands. This pathway may also influence others including MAPK. Overall, these 
pathways regulate the cell cycle, their migration, proliferation, ECM synthesis and 
degradation and cytokine secretion. When VICs are bound to TGF-β, α-SMA, smooth 
muscle myosin and calponin all increase in expression(28). It is important to note that the 
expression of these proteins and the differentiation of the qVIC into the aVIC through 
interaction with TGF-β is unique. Cellular response to TGF-β is dependent on the cell types 
present and the environment with which the interactions are taking place. By becoming 
aVICs, contractility and fibronectin remodeling also increase. Fibronectin and other matrix 
components such as heparin, play important roles in regulating TGF-β’s interaction with 
VICs. When heparin is present, the stability of TGF-β’s binding to the pericellular 
microenvironment increases which causes an increase in α-SMA expression(48). TGF-β 
binds directly to fibronectin and VICs express and actively remodel fibronectin, a major 
ECM component. Because fibronectin can bind directly to TGF-β, it allows it to activate 
VICs. It is important to remember that induction into aVICs corresponds to a significant 
increase in stress-fiber formation and enhanced contractility and increased mechanical 
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stress. These changes can link aVICS to pathological matrix remodeling(28,43). This is one 
reason why bioavailability of TGF-β is tightly regulated by the body. 
 Wound repair is also an essential role of VICs, and is one inducer of the aVIC 
phenotype. TGF-β is well known to play a role in wound repair, but its effects on cell 
growth remain in question, this in part due to TGF-β’s effects varying from cell to cell and 
between environments. VICs, as mentioned have specific reactions to TGF-β, encouraging 
the activated phenotype. Most fibroblast cells proliferate in the presence of TGF-β. 
However for VICs, and also for endothelial cells, TGF-β actually inhibits proliferation in 
aortic VICs.(35) This could be a function of VICs retaining characteristics of endothelial 
cells during EMT. The outcome of TGF-β depends on cell type and local environment. It 
is important to remember that VICs activate and proliferate during valve injury. TGF-β is 
often found at these wound sites. One would question as to how this proliferation of VICs 
could occur given the above comments. Proliferation during wound models may allude to 
the fact that wounds act as an external stimulus that alters this specific qVIC signaling 
profile. Mechanical factors must effect this activation and proliferation. These interstitial 
cells are context dependent. VICs essentially could modulate their Smad signaling due to 
differing external stimuli. This would then mean that VICs proliferate during wound 
(external) and are active, but not proliferating during normal physiological conditions (as 
during normal remodeling) so as not to disrupt the valvular environment(35). If this 
signaling regulation were to malfunction, as it must do in some, pathological valve tissue 
results. 
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1.2.3 VICs in the ECM: 
 As mentioned, VICs are the key modulators of ECM quality and content. In this 
matrix that they remodel, there are variations of amounts of VICs in each layer due to ECM 
stratification and compartmentalization during development. VICs may play a role in this 
spatiotemporal coordination due to embryonic progenitor endothelial/mesenchymal cells’ 
activation, proliferation, and expression of MMPs(28). VICs interact with their matrix by 
focal and fibrillary adhesions. These two distinct adhesion complexes differ in 
morphology, protein composition, and location on the cell membrane. Focal adhesions are 
composed of FAK (focal adhesion kinase), as well as the cytoskeletal markers vinculin, 
talin, paxillin and α-actinin(33). Fibrillar adhesions are small globular or elongated adhesion 
complexes. This complex lacks cytoplasmic proteins paxillin and vinculin. Both adhesion 
complexes utilize the α5β1 integrin, while focal adhesions also use αvβ3(33). These focal 
adhesions make contact with fibronectin, which provides a suitable matrix for cells to 
migrate. VICs secrete Fibronectin; the α5β1 integrin in migrating cells interacts thereby 
linking the actin cytoskeleton to fibronectin via tensin and the α5β1 integrin. Fibronectin 
acts as a means of motility and activation. VICs express it at the wound edge, thus 
facilitating VIC migration. aVICs, known to activate and quickly migrate to these wounded 
areas utilize the fibronectin they produce to move. Therefore, in qVICs, fibronectin 
expression is decreased. VICs also play a significant role in matrix degradation, expressing 
MMPs and TIMPs. MMPs and TIMPs vary among the different valve types, for example, 
MMP-2 is only expressed in the pulmonary and aortic valves. 
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 VICs reside in one of the most mechanically stressed environments. Heart valves 
undergo hemodynamic shear, cyclic flexure and bending, and compressive stresses and 
strains. VICs respond to these mechanical cues and forces altering their cellular stiffness 
and utilizing their influence on the ECM. On the left side of the heart for example, VICS 
show increased α-SMA content and collagen synthesis due to the fact that the heart’s left 
side faces larger transvalvular pressure which poses a larger tissue stress when compared 
to the right side of the heart(32). The degree of collagen synthesis is dependent on the degree 
and duration of the forces encountered. The obVIC phenotype can also be encouraged by 
matrix stiffness(44).  
 Mechanical cues can also be transduced by valvular endothelial cells (VECs) to 
regulate VICs. These cells are directly influenced by shear and hemodynamic stresses of 
the heart. VECs provide a protective and selective boundary between blood and VICs. The 
mechanical influences from the stressed valve exterior make VECs a critical modulator of 
VICs and their phenotype. In fact, VICs that have been co-cultured with VECs show an 
increase in vimentin expression and a decrease in the aVIC marker α-SMA, a possible 
indication that VECs encourage qVECs over aVICs(49). It is likely that VECs function to a 
similar importance that vascular endothelial cells have in regards to maintenance of vessel 
tone and inhibition of pathological differentiation of the interstitial smooth muscle cells. 
VECs can significantly reduce or reverse the activation of VICs(49). 
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Figure 1.8: VICs suppress TGF-β1-induced VEC EndMT. Immunofluorescence staining of a-SMA 
(green), cell nuclei (DAPI/blue)(50). 
 Through paracrine signaling, VECs release factors to affect VIC function, one such 
factor is nitric oxide (NO). NO, a known vasodialator is a free radical with many biological 
uses. NO released by iNOS, (inducible nitric oxide synthase) has been shown to play a role 
in valve wound repair(49,51). Possibly through proper regulation of VIC phenotype and its 
movement or proliferation. Under physiologically relevant stresses, NO has been shown to 
have beneficial effects on VICs. VIC contraction and activation have also been prevented 
through dosage of the VEC produced free radical(51). NO may act through the cGMP 
pathways, which ultimately down regulates Rho kinase (ROCK), which regulates α-SMA 
in VICs. Therefore, NO may act through cGMP to regulate VIC activation(51). It is also 
likely that other factors release by VECs, like c-type natriuretic peptide (CNP) and/or 
prostaglandins may play a role in regulating VIC phenotype(39). VICs may also release their 
own paracrine signaling which could influence VEC protein expression. Even in the 
presence of TGF-β1, which induces EMT, VICs can inhibit the transformation of VECs in 
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EMT(50). Otherwise, these transformed endothelial VICs (eVICs), can differentiating into 
obVICs, contributing to pathological remodeling and calcification. Therefore, 
communication between VICs and VECs remains crucial for the health and coaptation of 
the valve.  
1.2.4 VICs in Aortic and Mitral Valves: 
 VICs are the most abundant cell type within each of the heart valves, however 
transcriptional profiles of VICs varies between mitral and aortic valves. Differences in 
blood flow dynamics between the valves may explain some of this variation. Among the 
differences was expression of transcription factors NKX2-5, an important regulator during 
embryonic development, and TBX-5, which is very important for cardiogenesis. TBX-5, 
expressed significantly higher in mitral VICs, is expressed in developing atrioventricular 
valves and likely accounts for the mitral valve’s structural differences like the chordae 
tendinae(52). Expression of matrix degrading protein, MMP1, was also highly expressed 
only in mitral VICs(52). MMP1 mediates osteoblastic differentiation in osteogenic cells. 
When comparing migration and proliferation profiles between aortic and mitral VICs, both 
interstitial cells shows similar migration abilities, but mitral VICs showed greater 
proliferation than aortic VICs. 
 Regional interstitial cell variation also exists within sections of the mitral valve 
itself. Mitral valve tissue varies regionally when considering the different mechanical loads 
experience on each tissue type. As, previously mentioned, the matrix-VIC relationship is 
crucial in deciding VIC phenotype. Regionally the mitral valve does not possess 
homogeneity in the forces acting on the tissue. There are for example regions such as the 
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chordae tendinae and the anterior leaflet that are stiffer because they need to be stronger 
due to the forces acting upon them. These regions expressed higher amounts of α-SMA 
and vimentin. The α-SMA may be indicative of the contractile nature of these regions, 
which in turn could describe the type of loading experienced by these tissues(32). The “clear 
zone” on the posterior leaflet is a region that does not possess chordal attachment. The 
VICs present within this region expressed vimentin but at a much lower intensity(32). The 
cells in this region are also more like the VICs widely described by literature. GAG content 
also differs regionally, being secreted greatly by the more tensile-intensive regions. 
1.3 Pathology of the Mitral Valve: 
Pathologies of all heart valves affect an average of 2.5% of the population in the 
United States(53). This number drastically increases with age, as many heart valve diseases 
are degenerative in nature. The majority of this 2.5% of the country are sufferers of mitral 
valve pathologies(53). About 44,000 hospitalizations per year are due to mitral valve disease 
and this number represents about 44% of those who would benefit from some form of 
surgical correction(14). As the health of the mitral valve goes, so too does the health of the 
heart. Mitral pathologies can lead to atrial fibrillation, arterial thromboembolism, 
pulmonary edema, pulmonary hypertension, cardiac hypertrophy and heart failure(54–57). Of 
the many ailments that strike the mitral valve, most are degenerative in nature. This is a 
shift from the predominance of rheumatic diseases to degenerative etiologies. In 
developing countries, valvular diseases are still substantially caused by rheumatic heart 
disease. A consequence of acute rheumatic fever, rheumatic heart disease is still prevalent 
in developing nations. It is important to note that developing nations represent about 80% 
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of the world’s population, so while most journals report the importance and the alarming 
rise of degenerative mitral valve disease, the majority of the world’s patients suffering from 
valvular disease are caused by rheumatic heart disease(58). 
 
Figure 1.9: Conceptual model for mitral valve pathologies. Adapted from Levine et al., 2015(27). 
Degenerative etiologies of the mitral valve are however becoming increasingly the 
dominant focus for treating these diseases. Of the heart valves, the mitral valve is the most 
degenerative in nature. Mitral regurgitation, which can be caused by several other 
contributing ailments, is the most common form of heart valve disease in industrialized 
countries. It is especially prevalent in older patients, affecting almost 15% of the population 
that is 75 or older(58). This is largely due to an altered architectural organization of the ECM 
within the components of the valve. Each of these components of the valve are 
interdependent upon the other. This living apparatus, exhibits plasticity in that it can change 
cellular phenotype and behavior to adapt to its current ailment. Adaptive matching of valve 
mechanics to the needs for normal function illustrate the valve’s adaptability. Many of 
these self-incurred adaptations for coaptation, however show themselves in pathological 
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valves. There is a crucial interplay between biomechanics and biology(27). There are three 
major types of mitral valve diseases that can affect any part of the mitral apparatus. These 
include mitral stenosis, regurgitation, and prolapse. Each of these types of disease lead to 
failure of coaptation and could eventually lead to heart failure and death. 
1.3.1 Mitral Stenosis: 
Mitral valve stenosis is the least common valvular disease in industrialized nations, 
however it is the most common valvular disease in developing nations.(58). This again 
represents roughly 80% of the world’s population. Prevalence in these non-industrialized 
regions is largely due to poor socioeconomic conditions. Mitral stenosis is largely a result 
of repeated infection with Group A β-hemolytic Streptococci, which eventually leads to 
Rheumatic heart disease (RHD) from acute rheumatic fever (ARF). This disease primarily 
affects children and young adults, in fact acute rheumatic fever is the leading cause of heart 
disease in children worldwide(59). Given its distribution amongst the population, rheumatic 
mitral stenosis accounts for a large portion of pregnancy-related complications in 
developing countries(58). Based on conservative estimates by the WHO, at least 15.6 million 
people worldwide have RHD, and about 233,000 deaths annually are directly attributable 
to acute rheumatic fever or RHD(60). ARF (and eventually RHD) are a consequence of 
repeated infection with Class I strains of group A streptococcus. The role this virus plays 
in ARF is complex and not fully understood, however it appears that repeated exposure is 
necessary to “prime” the immunological response both qualitatively and quantitatively, 
before ARF occurs(60). It is believed that the autoimmune response caused by ARF could 
be triggered by molecular mimicry between the epitopes of specific human tissues and the 
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virus itself(60,61). Structurally, streptococcal M protein (a major virulence factor) and 
myosin are very similar. Both are alpha-helical coiled-coil molecules(60,61). This similarity 
seems to be essential in the autoimmune response. CD4+ T-cells proliferate in response to 
both the streptococcal M protein and cardiac myosin but not skeletal muscle myosin(60). 
 
Figure 1.10: Example of stenosis in the mitral valve. Clear calcification of the leaflets is visible(54). 
It is important to note however, that only a small portion of the mitral valve is 
composed of myosin, and diseases of the valve rather than acute myocarditis are 
responsible for most cardiac morbidity and mortality of ARF and mitral stenosis. How then 
can an immune response against myosin induce ARF and eventually mitral stenosis? It 
appears that several common valvular proteins including laminin and vimentin have several 
autoantigens that are recognized by T cells. Laminin is also structurally similar to the 
streptococcal M protein(60). Initial streptococcal infection with activation of B and T 
lymphocytes by streptococcal antigens would lead to antibody and cytokine production. 
The presence and increased production of these antibodies and cytokines leads to an 
autoimmune response to the valvular proteins through binding to the valvular endothelium 
leading to inflammation, cellular infiltration and valve scarring(61). The valve endothelium 
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is the prominent site of lymphocytic infiltration in RHD. The lymphocytes that adhered to 
the valve surface expressed VCAM-1, a protein responsible for adhering lymphocytes to 
vascular endothelium(59). Endothelial transmigration of these lymphocytes at the valve 
endothelium is an important step in ARF and mitral stenosis. The presence of activated 
macrophages in rheumatic lesions is characteristic of granuloma formation. These lesions 
are characteristic of mitral stenosis and the presence of CD4+ T-cell proliferation has been 
noted here indicating their role in the pathogenesis of RHD in mitral stenosis. With the 
upregulation of VCAM-1 on the endothelium and the binding of auto-antigenic antibodies, 
the valve becomes a localized microenvironment for continuous cytokine production and 
infiltration from lymphocytes(59). Repeated infection would result in larger and more 
frequent lesions, exposing more autoantigens on valvular proteins. Thus explaining why 
several infections are necessary to prime the immunological response before ARF occurs. 
Scaring is also an important event in the progression of this disease because this leads to 
neovascularization. The mitral valve is largely avascular, therefore, once scaring and 
neovascularization occurs, the transendothelial migration of lymphocytes is allowed(59). 
The activated endothelium and the valvular proteins play a large role in the development 
of ARF and mitral stenosis. It is important to note that the valvular endothelium is 
important in the regulation of phenotype in interstitial cells. It is likely that endothelial cells 
on valves function similarly to that of vascular endothelial cells in regards to maintenance 
of vessel tone and inhibition of pathological differentiation. Therefore, these lesions 
created on the valve endothelium most likely contribute to activation of VICs and 
aggressive remodeling of the valve’s interior. 
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The main pathologic features of mitral stenosis are leaflet thickening, nodularity, 
and commissural fusion(54). All of these features contribute to a narrowing of the valve and 
are a result of the repeated inflammatory response brought on by RHD. The normal mitral 
valve area ranges from 4—6 cm2 and symptoms from the narrowing show roughly, when 
the area has decreased by about 1.5 cm2. Chordal fusion and shortening are also caused by 
mitral stenosis and add further resistance to blood flow. Calcification of the annulus and 
leaflets can also occur, but rarely contributes to severe mitral stenosis. Calcification due to 
stenosis is seen in patients 65 years or older(58). Atrial fibrillation is often associated with 
mitral stenosis as is pulmonary hypertension. Mitral stenosis is also one of the common 
lesions found during pregnancy and is associated with high morbidity(54).  
1.3.2 Mitral Regurgitation: 
Mitral regurgitation is a large-encompassing and prevalent disorder of the mitral 
valve. It affects about 2% of the US population which equates to around 4 million 
patients(53). About 250,000 new patients are diagnosed yearly(57). These sizable statistics 
highlight the many mitral regurgitation (MR) can effect. MR is also however a broad term 
as it includes any mitral valve pathologies that allow regurgitant blood back into the atrium 
during ventricular systole. Regurgitation could be the result of mitral stenosis, annular 
calcification, degeneration, prolapse of the leaflets and other valvular diseases. The wide 
net that this pathology casts can and has caused serious illness and death. When the atrium 
is forced to handle additional regurgitant blood, it becomes dilated overtime and this leads 
to pulmonary edema, heart failure, and death. Degeneration of the valve is a certain factor 
as almost 10% of patients 75 and older are affected by MR(53). A particularity of MR is that 
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it can be the consequence of two primary abnormalities. Functional MR is caused by left 
ventricular remodeling, which results in incomplete closure of the valve through 
anatomical misalignment of the valvular components. The second type of MR, organic 
MR, is a consequence of primary anatomical abnormalities caused by valvular 
degeneration of the mitral apparatus. These two types are totally different diseases in both 
their pathophysiology and in how they are treated(58). Carpentier introduced a functional 
classification of MR based on leaflet movement. Type I with normal leaflet movement 
(e.g., MR caused by annular dilatation or leaflet perforation); Type II with exaggerated 
leaflet movement (e.g., mitral valve prolapse); and Type IIIa and IIIb with restricted leaflet 
movement in diastole and systole, respectively(57). There are varying degrees of 
regurgitation. Those with acute severe regurgitation, the pulmonary venous and atrial 
pressures increase quickly, leading to pulmonary congestion and edema(56). Edema is an 
abnormal accumulation of fluid in the cavities in the body, in this case with obstructions in 
the pulmonary veins, fluid builds in the lungs. Chronic regurgitation leads to a gradual 
increase in atrial size. The atrium compensates and as a result, the left atrium and 
pulmonary venous pressures do not increase until late in the course of the disease. Due to 
this compensation from the body, many patients with chronic or severe mitral regurgitation 
will be asymptomatic for years because the regurgitant volume load is tolerated. In 
addition, as mentioned, the ventricle experiences a significant overload. The ventricle, like 
the atrium will attempt to compensate, becomes hyperdynamic and dilates. Pathological 
hypertrophy also leads to an increase in muscle mass, but the muscle does not increase its 
pumping ability, and instead accumulates myocardial scarring. 
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Figure 1.11: Histological example of degeneration in the mitral valve ECM with an enlarged spongiosa(56). 
Functional MR is a consequence of abnormalities of the segmental left ventricle 
wall motion, dilation of the left ventricle, or papillary muscle displacement(57,58). Many 
times in functional MR, the structure of the mitral valve is normal, however due to its 
attachment to a diseased left ventricle, this can cause an incompetent valve. There are two 
categories for functional MR, ischemic and non-ischemic. Ischemic MR is associated with 
coronary artery disease most often associated with myocardial infarction and non-ischemic 
is associated with idiopathic dilated cardiomyopathies(57). Due to left ventricle dysfunction 
or remodeling, papillary muscles can be displaced laterally, apically and posteriorly. 
Because the chordae tendinae are not extensible enough to compensate for this 
displacement, the leaflets of the valve are affected causing tethering, apical leaflet 
displacement and dysfunction of the valve. This is a vicious cycle because the higher the 
degree of functional MR, the larger the left ventricle; the larger this left ventricle, the larger 
the displacement of the papillary muscles and thus the higher the degree of functional MR. 
It is also possible that the annulus experiences an increase in size due to its attachment to 
other areas of a diseased heart. The posterior leaflet’s insertion to the myocardium of the 
left ventricle is the cause for this. In functional MR, the annulus is dilated along the septo-
33 
 
lateral from about 28.2 to 35.1mm(62). This makes the annulus more circular in shape with 
a larger annular orifice area as well which decreases its ability to contract. The leaflets have 
also been known to increase in size by roughly 35% to cover the increased orifice area due 
to the left ventricle dilation(62). This adaptive mechanism is still insufficient to allow proper 
function of the mitral valve in patients with functional MR. The prevalence of functional 
MR is underestimated because heart failure in patients is often owed to left ventricular 
systolic dysfunction rather than a valvular disease. 
Organic MR is a degeneration of the valvular apparatus. Degeneration in this case 
does not always mean loss or degradation of tissue but rather a disruption from the 
homeostasis of the mitral valve’s ECM. Organic MR includes mitral valve prolapse, the 
most prevalent form of mitral valve diseases(55,57,58,63). Prolapse of the mitral valve means 
that the leaflets are allowed to billow into the atrium. This incompetence leads to 
regurgitation. However, this will be discussed in the next section. Other forms of organic 
MR include annular calcification, however this rarely becomes clinically important despite 
its high prevalence(58). Most literature however is focused on myxomatous mitral valve 
disease (MMVD), or degenerative mitral valve disease. Age is considered an important 
contributor to these forms of organic MR. 
MMVD is typified by enlarged leaflets and annular dilation(64). Mechanically the 
diseased leaflets are one third less stiff and considerably more extensible compared to 
healthy leaflets(65). It also commonly features thickened chordae, which over time become 
elongated. The chordae are about 75% less strong than normal chordae, thus promoting 
rupture(65). Microscopically MMVD is characterized by expansion of GAG and 
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proteoglycan content in the spongiosa, expanding this region of the ECM. Elastic fibers 
are often appear as granulated and fragmented clusters instead of stretching across the 
valve. It is important to note that there are varying degrees of MMVD causing organic MR. 
Barlow’s disease and fibroelastic deficiency (FED) present very different examples of 
degeneration. VICs dictate many of these changes in the ECM. As the resident response 
team for remodeling and preserving the matrix, VICs are responsible for the quality of the 
valve’s ECM. In MMVD, VICs are found in their activated state meaning they are 
behaving in a myofibroblastic manner and producing large amounts of ECM, particularly 
GAGs and proteoglycans. It has been mentioned in literature that the key to the VIC’s safe 
remodeling of the valve was the cell’s ability to deactivate into a quiescent state. If 
however, these cells remain in the activated state, they can overproduce ECM and MMVD 
can result. In progressively myxomatous valves, VICs can even shift further to a 
myofibroblastic phenotype(64). Activated VICs (aVICs) also secrete matrix remodeling 
enzymes (MMP-1, MMP-2, MMP-9, MMP-13) while collagen synthesis remain 
unchanged(28). This is important to note because it suggests that abnormalities in the valve’s 
leaflet structure and mechanical integrity are not a product of decreased collagen 
production, but rather an increase in collagenolytic activity(46,65). Cathepsins S and K are 
also released by aVICs and are heavily involved in elastin remodeling, especially Cathespin 
K(46). 
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Figure 1.12: A schematic showing the mechanisms of myxomatous degeneration, with activated VICs 
becoming myofibroblast-like which in turn increases matrix production and turnover. This increases MMP 
production and TGF-β production, which cyclically promotes further cell proliferation and activation of 
VICs. 
Endothelial cells will also show atypical phenotypes in advanced stages of mitral 
valve disease. The constantly changing leaflet environment and altered ECM environment 
lead to altered endothelial function(64). As described earlier, aVICs produce significant 
amounts of GAGs that accumulate within the tissue leading to its altered structure. 
Literature shows increases in proteoglycan and elastin content being 59% and 62% 
respectively(64). MR is perpetuated by this accumulation of proteoglycan content 
interstitially due the increasing stiffness of the leaflets. Accumulation of GAGs in the 
fibrosa are a common indicator of degeneration and a sign of the interplay between 
biomechanical forces outside the valve and the biological adjustments made interstitially. 
VICs in MMVD, largely aVICs, act as myofibroblasts which increase matrix production 
and turnover through the release of MMPs. MMPs drive the fragmentation of collagen and 
elastin, which releases peptides and additional TGF-β1 that further encourages 
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proliferation of cells and myofibroblast differentiation(27). TGF-β1 on a stressed valve’s 
exterior will also encourage VECs to undergo EMT, in which VECs retreat interstitially 
and become VICs, thereby increasing the number of matrix-producing cells.  
Also contributing to these aVICs and the dysregulation of ECM homeostasis are 
several signaling pathways implicated in MMVD. It is important to note that inflammatory 
cells are not found in degenerating valves and thus inflammation is not likely a player in 
the pathogenesis of MMVD(66). Much focus in literature has recently centered on the 
pathways that affect MMVD and have identified several signaling mechanisms that control 
the expression of key effector proteins. Meaning that MMVD while clearly associated with 
aging, is not solely a consequence of time. Progressive weakening of the ECM associated 
with aging does provide mechanical stimuli for VIC activation and proteoglycan 
accumulation mentioned above. Many chemical stimuli are being investigated in literature. 
Circulating serotonin has received attention lately not because serotoninergic valvulopathy 
and MMVD are identical, but because they share several features including increased 
GAG/proteoglycan deposition. Serotonin synthesis is governed by tryptophan hydroxylase 
(TPH). TPH1, the peripheral isoform, mediates the release of serotonin(66). Studies have 
shown significant increases in TPH1 expression in MMVD, and inhibition of this factor 
diminishes expression of myxomatous effector proteins in mitral valves(66). It has also been 
shown that serotonin (5-HT) induces an upregulation of TGF-β1 in VICs(67). The TGF-β 
superfamily of growth factors play a role in ECM production. Their overexpression is often 
linked to several valvular diseases including degenerative mitral valves(66,67). BMPs are 
also members of the TGF-β family and are a factor in their expression through Smad 
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phosphorylation(66). It is not only their association with TGF-β and its link to MMVD, but 
BMP2 induces the activation of Sox 9 which mediates expression of cartilage-specific 
structural genes(66,67). The similarities between chondrogenesis and MMVD implies BMP-
Sox 9 signaling as contributing pathways for MMVD. The role of nitric oxide (NO) is 
unclear as it relates to MMVD, however there is evidence of increased endothelial nitric 
oxide synthases (eNOS) activity and NO release in MMVD(66,67). However, this increased 
expression may merely be a response to the disturbed flow associated with MMVD. 
Despite increases in ECM content, there is no increase in mature collagen or elastic 
fibers(64). In fact, the compositionally collagen types change within myxomatous valves. 
The collagen content of a healthy mitral valve consists 74% Type I, 24% Type III, and 2% 
Type V. In myxomatous valves, the collagen type I decreases slightly and type III 
significantly increases by 53%(68). This change in collagen content has been debated in 
literature depending on which methods were used. It has been shown however that with 
higher collagen type III content stiffening can occur and a correlation seems to exist with 
other cardiovascular diseases(69). Also collagen type III has been shown to be more 
associated with GAGs and has more distensible properties than type I(70). Despite continued 
production of collagen, in myxomatous valves much of what is produced is immature 
collagen. Collagen is synthesized as the precursor procollagen containing non-triple-helical 
extensions(71). Formation of collagen fibrils requires an initial linear and lateral aggregation 
that is promoted by these extensions(71). As fibrils mature, they transition from a highly 
soluble material to an insoluble structure. Strong inter- and intramolecular forces cross-
links are the reason for this transition to maturity(71). These cross-links are vital to the 
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tensile strength and integrity to collagen matrices. Cross-links contribute to collagen’s 
mechanical strength. By lacking these cross-links or having abnormal cross-linkages, there 
is a marked decrease in mature collagen output, failure to form collagen fibrils and overall 
loss of mechanical integrity(69,71). The absence of these cross-links results in very weak and 
extensible fibers. In myxomatous valves, immature procollagen expression is upregulated 
by a factor of two(72). Collagen fibers in MMVD are also sparsely and irregularly arranged, 
characterized by fragmentation of the collagenous bundles(73). Often in these myxomatous 
tissues, fibrils had a spiraling substructure. These fibrils are larger in diameter and can have 
a “flower-like” appearance(68). Spiraling collagen is thought to develop due to dissociation 
or fraying of existing fibrils or defective aggregation of collagen filaments(68). Orientation 
of collagen fibrils is also irregular in MMVD. Fiber direction and organization is the most 
effective way to optimize strength without increasing weight and this direction reflects the 
existing forces acting upon the tissue(74). One possible explanation for this haphazard and 
disorganized fiber orientation could be the accumulation of GAGs. GAGs play a role in 
maintaining spatial order in the ECM as they act as space fillers. The significant increase 
in GAG composition in the ECM would certainly disturb this spatial order(74). Also 
overtime, alignment of the fibrils declines in MMVD. Age of the patient, as mentioned 
several times previously, is in clear association with the prevalence of MMVD. Collagen 
is the only protein in humans that shows definite age changes(70). Aging collagen and its 
effects in MMVD are not fully defined in literature; however, a clear correlation exists 
between them. It should be noted that despite this significant correlation, that MMVD is 
not simply an aging process. As mentioned, in MMVD collagen fibrils become 
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disorganized thus endangering the mechanical integrity of the valve. In elderly healthy 
patients however, collagen tends to have the best defined patterns and degree of 
regularity(74). Also depending on the form of MMVD, Barlow’s disease for example, the 
patients most affected by the disease may in fact be younger in age when compared to other 
forms such as fibroelastic deficiency(73).  
1.3.3 Mitral Prolapse: 
Mitral valve prolapse is the most prevalent form of mitral valve disease and is 
largely degenerative in nature. It affects more than 144 million people worldwide and about 
3% of the adult population in the US(75). It is the most frequent cause of chronic, pure and 
isolated mitral regurgitation(75). More specifically, mitral valve prolapse (MVP) is a form 
of organic mitral regurgitation. It is simply characterized by incorrect closure of the leaflets 
resulting in their billowing into the atrium. This inadequacy in function allows regurgitant 
blood to flow back up into the atrium and contribute to the well-known and deadly 
downstream effects. As a form of organic MR, this specific pathology is predominantly a 
result of the degenerative etiologies present in MMVD, described above. 
 
Figure 1.13: A resected mitral valve with prominent leaflet thickening and opacity and a prolapsing and 
domed posterior leaflet (arrow)(27). 
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As a form of MMVD, there are various causes of mitral valve prolapse, all of which 
are some disruption of ECM homeostasis resulting in incompetent valvular components. 
For example, degeneration in a myxomatous valve can result in changes to the annular 
complex. Changes to this or other structures can cause regurgitation from prolapse(76). 
Degeneration of the chordae tendinae can result in chordal rupture, which is in fact the 
most common finding with sufferers of mitral prolapse(63). There are many affected by 
abnormal leaflet structures are well. In fact, there is a spectrum of prolapse diseases that 
result from abnormal leaflet sizes. Common examples include Barlow’s disease and 
fibroelastic deficiency (FED), which range from excessive to insufficient ECM content 
respectively. In fact, MMVD is more currently called Barlow’s disease and is characterized 
by large valvular size with excessive leaflet tissue, dilated annulus, as well as thickened 
and elongated chordae. FED, a less common etiology, is more prevalent in older patients. 
This condition is associated with a fibrillin deficiency that often lead to a rupture of one or 
more thinned and elongated chordae, usually involving the middle scallop of the posterior 
leaflet. The chordae are thin and friable. This can all contribute to regurgitation and 
lessened coaptation(63). Marfan’s syndrome is a common condition of degenerative valves. 
It is a genetic disorder of the connective tissue(63). Similar to Barlow’s disease, a patient 
with Marfan’s will also experience a dilated annulus; however, unlike Barlow’s this 
syndrome involves the aortic root and aorta. It can be a systemic disease than Barlow’s 
often affecting the other connective tissues. 
Another etiology of mitral valve prolapse is bacterial endocarditis. Endocarditis 
occurs when bacteria enter the bloodstream (bacteremia) and attach to a damaged portion 
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of the inner lining of the heart or abnormal heart valves. Only those bacteria that are able 
to stick to the surface lining of the heart and to abnormal valves tend to cause endocarditis. 
The ability of these bacteria to stick to the surface lining is aided by a preexisting 
microscopic clot that often forms at these abnormal sites. This often results in ruptured 
chordae(77). Bacterial endocarditis is associated with necrotizing lesions in the leaflets, and 
annular abscess(55).  
Papillary muscle rupture is also a common cause of mitral valve prolapse. This can 
occur through myocardial infarctions. After infarction, the papillary muscles are displaced 
laterally, apically and posteriorly, pulling the leaflet into the left ventricle. Distortion is 
prominent in the basal anterior leaflet, creating a bend(57). Papillary muscle dysfunction 
plays only a minor role compared with apical and inferior papillary muscle displacement 
caused by ischemic LV remodeling and dilatation. As described above, due to the 
mechanical limitations of the chordae, the displacement of the papillary muscles is 
distributed to the leaflets, causing apical leaflet displacement, and impaired coaptation. 
Together with annular flattening, enlargement, and reduced contraction, mitral valve 
tenting affects leaflet coaptation and causes functional mitral regurgitation(57). 
1.4 Current Solutions for Mitral Valve Insufficiency: 
 Dysfunction of the mitral valve (MV) apparatus is a common ailment of the global 
population. It is especially common with advanced age, affecting almost 10% of 
individuals 75 years of age(78). The sheer number of sufferers of mitral valve pathologies 
warrant a myriad of solutions aiming for the reestablishment of proper function for the 
valvular apparatus. Pathological prevalence has driven demand from both the clinical and 
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engineering spheres to develop a solution for dysfunctional mitral valves. Over the course 
of several decades, beginning in the 1960’s, advancements in engineering and material 
sciences led to advances in treating these diseases. Annually there are more than 300,000 
people worldwide, 44,000 from the United States alone, that undergo open heart surgery 
to treat mitral valve diseases(79). Many of these operations utilize replacement prostheses 
or advanced repair techniques. Replacement of the mitral valve has been available to 
patients for the greater part of 4 decades. Mitral valve replacement is still the gold standard 
in developing countries(55,80–82). During these decades of prosthetic mitral valves, advances 
in surgical techniques and improvements in imaging and material development have paved 
the way for the successful restoration of mitral valve function using surgical repair. While 
there are various methods for repair, generally all repair methods aim to achieve the best 
leaflet coaptation area during systole and reduction of any regurgitant flow(83). Recent 
advances in repair have focused on restoring and/or reducing the annular area, preserving 
the 3D annular geometry. Due to the success of surgical repair of the mitral apparatus, rates 
for repair have gone significantly up in recent years. Currently MV repair represents over 
60% of surgical cases compared to valve replacement(84). In developing countries, however 
this number is reversed largely due to the lack of education, experience and therefore skill 
to repair the MV. Of the 44,000 MV surgeries in the US, this represents less than half of 
the patients with severe MV regurgitation and could benefit from some form of 
intervention(14,78,85). This is a similar statistic in most of the world due the pathology’s 
asymptomatic presentation. 
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 Predictable and reproducible results are considerable motivators when choosing 
repair vs replacement. Thanks to the work of Carpentier, Duran, and others, MV repair is 
generally the accepted alternative to valvular prostheses with most surgeons recognizing 
its superiority in both early and late results. However as there are many pathologies of the 
MV, there are several general considerations that must be made to determine the best 
course of action. Surgeons must bear in mind the continued degeneration of the valve. How 
will functional vs organic regurgitation affect the choosing of the repair or replacement? 
Will this surgical correction need to grow with the pediatric patient? The left ventricle is 
remodeling, will a repair now serve the patient years from now? Surgeons must tailor their 
solutions to the patients they have. Trends in MV dysfunction however due point to a heavy 
increase in reparative methods as compared to replacement, at least in the western world. 
1.4.1 Mitral Valve Replacement: 
 Heart valve prosthetics were born from concomitant developments in engineering 
and material science that solved a basic engineering question, how to fix a leaking valve. 
The first valve replacement, the ball and cage model, was used in 1960 and improvements 
upon the design and the materials used were completed over the next decade(81). Alongside 
the advancements of mechanical prosthetics, so too did the advancement of fixative 
techniques on tissue. Glutaraldehyde was initially used to fix porcine tissue, thus creating 
bioprosthetic mitral valve replacements with much improved hemodynamics(86). These two 
avenues for MV replacement, mechanical and bioprosthetic, are still the current treatment 
options several decades later. During their tenure, minor yet important improvements on 
their designs were achieved with advancements in polymer science and tissue fixation. 
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Mitral valve replacement surgery is most commonly performed using a vertical 
sternotomy(86).  
 As mentioned, mechanical prosthetics evolved originally from the ball and cage 
model, current models consist of pyrolytic carbon, a material similar to graphite. This 
material helps limit blood clots from forming on the material. Most models for MV 
replacement utilize a bileaflet design, with two semicircular disks surrounded by a suturing 
ring(83). There are several large companies that offer their own take on this general bileaflet, 
pyrolytic carbon design. Each of these companies which include Medtronic, St. Jude, On-
X, Sorin Group, etc. claim to have advantages over the other, many of which are minute 
changes in the hinges or use of an open pivot design which is intended to minimize the 
recesses or cavities present for example. Due to its design and material properties, 
mechanical replacements, as compared to bioprosthetics, tend to be more durable as a 
replacement(83). Three important factors that define mechanical valves’ durability are 
closing load, material fatigue and cavitation(81). Transvalvular pressures are the major load 
placed on mechanical valves, which is generated at and after closure. This can lead to 
impact wear and friction wear in the prosthetic. This load is felt the most at the hinges and 
joints associated with the bileaflet design. Use of pyrolytic carbon largely alleviated the 
material fatigue that metals and alloys experience as the initial mechanical valves. The 
third mode of failure, cavitation, is due to the formation of microbubbles due to pressure 
reduction. 
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Figure 1.14: Examples of variability in mechanical heart valves. Ball and cage, tilting disk and bileaflet 
valves are and have been used(81). 
 
 Bioprosthetic valves were developed to answer the thromboembolic complications 
found with mechanical valves. Animal tissues had to be chosen due their availability and 
the quantity needed for commercial use, therefore antigen-masking techniques were 
developed. Glutaraldehyde was chosen as the cross-linking chemical to treat either porcine 
valve leaflets or bovine pericardium. By extracting any un-bound glutaraldehyde from the 
treated tissues, improvements were seen in allowing endothelial growth and calcification 
was markedly decreased in patients(81). While not as durable as a mechanical valve, 
bioprosthetics generally last between 15 to 20 years(87). 
 Due to their differing material compositions and benefits each affords, choice of 
the surgeon to choose a mechanical or bioprosthetic valve is largely patient specific. 
 
Figure 1.15: Bioprosthetic heart valves from four of the major manufacturers(83). 
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 There are many criteria that must go into this selection including symptomatic 
status, occurrence of thromboembolic episodes, and myocardial function(86). Evaluating the 
patient’s age, whether they have co-morbidities, and the risks associated with reoperation 
are all criteria that need to be determined before a surgeon decides on the proper valve 
prosthetic to use. Age is one of the most important criteria when determining valvular 
prostheses. For example, elderly patients (65 years or greater), are often given bioprosthetic 
valves due to lack of anticoagulant therapy needed for this valve. Younger patients often 
receive mechanical valves instead. Surgeons will also need to look into the lifestyle of the 
patients, their body size and thus their left ventricle function(88).  
 
Figure 1.16: Decision tree for valvular prosthetic options(88). 
 Mechanical valves are preferred when the patient has no contradiction to 
anticoagulant therapies or is already on one, the patient is at risk of accelerated 
bioprosthesis structural deterioration due to their age (young patients) and the patient is 
younger than 65 years and has a long life expectancy. The bioprosthetic valve is preferred 
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on the other hand if an anticoagulant regimen is unavailable for them due to compliance 
problems or lifestyle, and the patient is at or greater than 65 years of age and has a limited 
life expectancy. Also worth noting is that bioprosthetics are preferred for woman of 
childbearing age. This is due to the fact that these women, who are or may become 
pregnant, cannot undergo anticoagulant regimens. It is also important to note however, that 
bioprosthesis degenerate more rapidly during pregnancy and in younger patients(88). 
 Despite some success from mitral valve replacements, improvement in their design 
and functionality stalled several decades ago and remain an unsatisfying option for valvular 
replacement. Given the fact that these prosthetics are foreign objects in a high stress 
environment consisting of living cells and rapid fluid flow, evidence has shown that these 
replacements cannot avoid cascades of biological events. For example, shearing and fluid 
flow across the mitral valve leads to platelet activation, which launches the coagulation 
cascade. Despite small advances in material science, the body still chronically reacts to 
these nonnative devices. This has been confirmed in mechanical valves’ continued 
vulnerability to thrombus formation due to high shear stress (activating platelets), flow 
separation, and blood damage. The most commonly used mechanical valve, the bileaflet 
valve, encourages thrombus formation at its hinges due to high stress, leakage regurgitation 
and stagnant flow in this area(81). Due to this risk of thrombus formation, anticoagulation 
is still required for patients. The rate of embolic events ranges from 0.6 to 6.5% with 
bileaflet prosthesis(89). Due to the need of long-term anticoagulation, there are inherent 
risks for hemorrhagic complications(81,90). Total rates of major bleeding were between 3.2 
and 12.9%(91). Thromboembolic events showed up in about 4.4% of pregnant women(92). 
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The anticoagulants used ranging from Coumadin, heparin and warfarin, were also 
associated with fetal malformation(92).  
 
Figure 1.17: Example of thrombus formation on a bileaflet mechanical valve replacement(93). 
 Another risk associated with mechanical heart valves is pannus overgrowth. 
Excessive tissue growth can occur at the sewing ring and can lead to insufficiency of the 
prosthetic. Pannus overgrowth is associated with obstructive valve failure in 53% of 
cases(94). Mitral valves show pannus formation on both the atrial and ventricular sides. This 
pannus formation is largely caused by macrophages and foreign giant body cells reacting 
to the sewing ring material. 
 Pediatric patients are also sufferers of the consequences of mechanical MV 
prostheses. When replacement is elected as the best option for pediatric patients, mortality 
rates range between 10 and 20%(95). This is due to the complexity of the surgery and 
coexisting cardiac abnormalities. It also goes without saying that long-term results for these 
children are difficult to obtain due to somatic growth of the patient. There is not a solution 
that exists for replacement options that can withstand normal growth of the patient. Tissue-
derived bioprosthetics were supposed to solve the issue of thrombogenicity presented from 
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the mechanical valves by using tissue that was much more hemodynamically efficient. This 
risk undoubtedly went down, although the rate of thrombus formation during the initial 
three months post bioprosthetic insertion occurred at a rate of 55% often incurring an initial 
anticoagulant regimen(96). This rate steadily declines at rate of about 10% and falls to 2.4% 
thereafter(96). Despite this apparent alleviation of the mechanical valve’s Achilles heel, 
bioprosthetic valves face other inherent complications. Due to the absence of living tissue 
and the attempt to mask xenogeneic antigens, faults in this valve’s design are numerous. 
Similar to the triggers mechanical valves put forth to initiate tissue overgrowth on the 
sewing ring, this process is also experienced by tissue valves due to insufficient masking 
of antigens and the onset of inflammation. This is not a new problem however as low-grade 
glutaraldehyde used in commercial fixation has long known to reduce immunogenicity but 
not abolish it(97). In addition to the immune response elicited by the patient, degradation of 
the prosthesis is common through inflammation. In the majority of explanted bioprosthetic 
valves, inflammatory cells are found rampant within and covering the surface of the 
tissue(98). Macrophage-mediated degradation is then shown to break down these tissue 
valves over time. Mechanically speaking, bioprosthetics are also not very stable. The VICs 
inside the tissue are devitalized due to crosslinking and therefore cannot repair or remodel 
the tissue due to the harsh mechanical stresses these valves endure. As many as 75% of 
failed porcine prostheses in the mitral position show a rupture on one of the free edges(81). 
Structural degradation is also due to calcification of the valve. For one, glutaraldehyde is a 
known promoter of calcification. More importantly though is that this chemical treatment 
destroys the viability of the resident cells in the tissues. These nonviable cells are incapable 
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of remodeling collagen and therefore ongoing repair of bioprosthetic valves is impossible. 
Also, devitalized VIC fragments serve as nuclei for calcification(90). Calcification is 
initiated predominantly at the devitalized VICs membranes and at areas where mechanical 
stress is concentrated. Normal VIC function involves maintaining a proper calcium 
gradient in the cytoplasm, and this cannot happen in nonviable cells(99). Initial calcium 
deposits will eventually enlarge and coalesce grossly affecting the bioprosthetic valve. The 
biochemical differences in younger patients disallows long implant survival due to 
advanced calcification in the prostheses. It has also been shown that denuding of VECs 
during the handling process increased availability for infiltration by host cells.  
 
Figure 1.18: Mechanisms of calcification in bioprosthetic heart valves(90). 
 Overall, heart valve replacements have aided many patients. However, these 
prostheses have many drawbacks and are not permanent solutions. In fact the ten year 
survival rate following mitral valve replacement is about 50%(86). While structural 
degradation is not relevant in mechanical heart valves, thrombus formation and chronic 
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reaction from the host limit its lifespan within the patient. Structural degeneration is quite 
relevant with bioprosthetic valves as it typically affects 20-40% of recipients after 10 years 
and over 60% after 15 years(86). Due to their unreliability patients often must undergo 
repeated surgeries to replace these failing prosthetics, and with each successive surgery 
patient mortality can increase up to 20% each time(100). Therefore, pediatric patients face a 
dire future with heart valve replacements. Lack of progress in this field of cardiovascular 
engineering has especially hurt developing nations, who represent about 80% of the 
world’s population and cardiovascular disease sufferers. Many of these countries do not 
have the socioeconomic capabilities to support heart valve surgeries for its citizens and 
once they do reach this point, heart valve replacements will dominate their options as 
complicated reparative techniques are out of the question. Therefore lack of innovation and 
improvements for these designs have really hurt the developing world. 
1.4.2 Mitral Valve Repair: 
 To combat the well-known and chronicled failures of replacements, surgical 
correction of the mitral valve apparatus through repair has risen in support. While the 
complicated anatomy of this “valvular machine” presents an intricate case for any surgeon, 
success rates and usage rates of these techniques have risen as replacement technologies 
decrease in use. 
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Figure 1.19: Carpentier’s classification of mitral valve regurgitation(101). 
The overarching goal of surgical repair of the MV is to restore the gross natural 
geometry of the mitral valve to allow for coaptation. Some of the advantages of mitral 
valve repair include low rates of thromboembolism, reduced need for anticoagulation, good 
long term prognosis and a decreased risk of endocarditis(102). As mentioned, Carpentier, 
Duran and others developed several surgical techniques and classifications for mitral 
valvuloplasty. Many of the advantages with surgical repair parallel the disadvantages of 
valvular replacement. Long term results for repair also appear to show good results with 
valvuloplasty having lower operative mortality, better preservation of left ventricular 
function and superior survival rates(103). Many of these corrections pioneered by Carpentier 
were based on a classification system. Because of the apparent advantages, the threshold 
for patients has been lowered to allow those patients with asymptomatic or early symptoms. 
Trends in mitral valve surgeries have shown a significant increase in the use of repair over 
recent years. This however represents less than half of those that would benefit from some 
form of surgical intervention(14). This, as mentioned, is often due to mitral pathology’s 
tendency to be asymptomatic and show itself in the later decades of life. It is important to 
note however, that valvuloplasty is far from being the norm in the developing world. Due 
to socioeconomic difficulties, lack of experience and education in these regions, surgical 
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repair of the mitral valve is unpopular. It could be argued that first world countries are at 
fault for this in that they had not developed innovative solutions for decades regarding 
mitral valve pathologies. Whatever the case, replacement surgeries still dominate the 
regions of the world that have the most patients that need such interventions. 
According to the classifications defined by Carpentier, general considerations must 
be taken when evaluating which type of repairs would best benefit the patient. This is 
dependent on the pathology afflicting the patient and the severity. Type I is present when 
there is dilation of the annulus due to endocarditis or some cardiomyopathy. Type II 
pertains to rupture or elongation of chordae tendinae, often due to degeneration or papillary 
misalignment. Type III has two sub-types, type IIIa occurs with commissural fusion, 
leaflet, and chordae thickening as in myxomatous valves or rheumatic disease. The second 
subtype, type IIIb, is often due to chordal retraction (rheumatic) or papillary retraction 
(ischemic) or displacement due to functional or ischemic cardiomyopathy(101). For a repair 
to be successful, proper preoperative or intraoperative work, such as a transesophageal 
examination, are imperative for full evaluation of dysfunction. Overall, the goal of any 
mitral repair is to first address the dysfunctioning motion of the valve, and secondly to 
correct and stabilize the shape of the annulus by an annuloplasty ring. Therefore providing 
a valve that no longer leaks while achieving anatomical restoration. 
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Figure 1.20: Trends in mitral valve surgeries favor reparative techniques in recent years(84). 
 One of the drawbacks of mitral valve repair that will be discussed later is that there 
are many different ways to repair a mitral valve. This can differ between each of the 
classifications mentioned above and even within each classification. Therefore, to avoid 
creeping of the scope in this review, concentration will be placed on several general areas 
and common reparative techniques. The first of which is the use of the annuloplasty ring. 
It is important to remember that the hyperbolic paraboloid shape of the mitral annulus is 
crucial for optimal force distribution throughout each of the valve’s components. 
Therefore, reestablishment of this shape is paramount in mitral repair. This is the goal of 
the annuloplasty ring, to restore mitral valve competence by reestablishing anatomical 
equilibrium in the valvular apparatus. Originally the annuloplasty ring used by Carpentier 
was rigid and flat, this was called the “French Correction”(104). However, it was apparent 
that the annulus moves dynamically during normal function, therefore the Physio ring was 
developed and more surgical techniques surrounding these annuloplasty ring like the 
“American Correction” were designed(83,104). Today, all manner of annuloplasty rings exist, 
including rigid, flexible, semi-rigid, incomplete or complete, planar or saddle-shaped, 
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adjustable and non-adjustable(83). In general, flexible incomplete bands are designed to 
preserve the contour of a healthy annulus, semi-rigid rings are to maintain coaptation and 
integrity of the valve especially during systole, and finally rigid valves are used to provide 
solid support to reshape very dilated annuli when the patient has significant ventricular 
dilation(79). Overall, the mitral annuloplasty has become the gold standard for treatment of 
most mitral etiologies.  
 Prolapse of the leaflets can often be a result of degenerating or ruptured chordae 
tendinae(105). Originally reparative techniques centered on chordal transfer where one 
chordae would be removed and then re-sutured where the surgeon saw fit(101). However, 
results from this procedure were not optimal and therefore other sources of chordae had to 
be used. Expanded polytetrafluoroethylene or ePTFE, was then discovered to provide 
adequate mechanical strength and host incorporation. ePTFE is a thermoplastic polymer 
used first in several other applications. It has great physical, chemical, thermal and of 
course mechanical properties. It is highly flexible with a high tensile strength and is also 
resistant to fatigue(105). ePTFE is a nonabsorbable monofilament that along with its 
micropores allows for great mechanical and biological properties. The pores allow for the 
covering of these neochordae in fibrous endothelial tissues and it provides attachment for 
fibroblasts(105). Chordal length for surgical repair is often decided using transesophogeal 
echocardiography. While mid-term results seem promising for this avenue of repair 
however long term results are very limited(105).  
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Figure 1.21: Variability in annuloplasty ring design for various pathological classifications(85). 
 As mentioned, mitral repair methods were used to parallel the disadvantages of 
replacement. One example of this is the utilization of catheter-based interventions as 
opposed to vertical sternotomy used in replacement surgery. There are two areas of the 
mitral valve where catheter interventions are used, the leaflet and the annulus. The Mitra-
Clip™ from Abbott Laboratories is the only FDA approved that is alternate to mitral 
regurgitation surgery(83). This device used a small clip to grasp the two leaflets of the mitral 
valve thus emulating the edge-to-edge repair instigated by Dr. Alfieri. Edge-to-edge repair 
essentially creates a tissue bridge between the two leaflets alleviating some regurgitation 
in patients with decent efficiency(57,85). Intervention of the annulus via catheter is for 
reduction of annular dilation, attempting to restore the optimal valvular shape. 
Percutaneous valve replacement and treatment are also growing minimally invasive 
surgeries. Percutaneous mitral balloon valvutomy has emerged as a choice for patients with 
severe mitral stenosis brought on by rheumatic fever(106). Complete valve replacement 
through transcatheter mitral valve replacement has also been attempted. Several products 
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including the Tiara™ from Neovasc, The Mitralign™ from Mitralign, and FORTIS from 
Edwards Lifesciences to name a few(83). Other minimally invasive surgeries include the 
use of robotics to repair an insufficient mitral valve(107). 
 In this review of literature regarding mitral valve repair, many of the articles report 
large success with the majority of corrections quite durable while still avoiding the apparent 
disadvantages of valvular replacement. However, a very recent review by the New England 
Journal of Medicine on the two year outcomes of patients with mitral repairs paints a 
different picture(108). Overall, patients who received repairs had significantly more 
reoccurrence of moderate or severe regurgitation two years after surgery. In fact the rate of 
reoccurrence for replacement patients was 3.8%, while the rate for the repair group was 
58.8%(108). Part of these discrepancies may lie in the controversy surrounding the most 
effective surgical strategies. Many clinicians prefer differing strategies for mitral valve 
repair. Not only that, but many articles in current literature note that repairs should only be 
conducted by experienced centers and surgeons as mitral valve repair surgeries are 
inherently complicated(107). Therefore severely bottlenecking opportunities for patients to 
receive treatment. A recent review also noted severe practice gaps in clinicians pertaining 
to mitral valve repair, proper identification of pathological classifications, and preferred 
choice of treatment for their patients(109). Annuloplasty treatment, the current gold standard 
for repair, can result in function mitral stenosis and is associated with a high rate of 
recurrent regurgitation(108). The much maligned mitral valve replacement on the other hand 
has shown less reoccurrence of mitral regurgitation with favorable ventricular remodeling. 
Compared to replacement, reparative techniques had significantly higher incidence of heart 
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failure, reoccurrence of moderate or severe mitral regurgitation(108). Reoccurrence of 
regurgitation is of course directly related to a predisposition to heart failure, atrial 
fibrillations and repeated visitations to the hospital for treatment. Replacement chordae 
have also show to rupture over time(105). In addition, it goes without saying that reparative 
techniques are difficult to perform on pediatric patients due to their smaller valve anatomy. 
Also, any repairs such as an annuloplasty ring or artificial chordae cannot grow with the 
patient overtime, still opening these patients up for reoperation in their near future. Overall, 
from this two-year study, replacement techniques are largely more reliable long term 
compared to reparative techniques and shows significantly less reoccurrence for mitral 
regurgitation. 
 
Figure 1.22: Cumulative failure of mitral valve repair or replacement(108). 
 This revelation regarding mitral valve repair leaves one surely disconcerted. On the 
one hand, mitral valve replacements have a long history of complications including 
thrombogencity, anticoagulant therapy, degradation, calcification and many more. On top 
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of this replacement techniques and devices have largely remained unchanged for 4 decades. 
To combat this reparative techniques were developed and while these do report in some 
cases improved success in treating mitral insufficiency, it appears that these positive results 
were short lived as reviews show that patients who undergo surgical repair are significantly 
more likely to have recurrent regurgitation resulting in reoperations, higher chances for 
related heart failure, ventricular remodeling and more. Neither option offers optimal results 
for pediatric patients who are in need of a more permanent solution for their growing 
bodies. This is nothing to say that developing countries are also far worse than first world 
nations that at least have opportunities for repairs. These countries’ patients, who are the 
bulk of valvular disease sufferers, often have no access to heart surgery. Cardiac surgery is 
only available to about 11% of Chinese citizens and 6.9% of the Indian population(81). 
There is serious deficiency is satisfactory and long lasting solutions for patients with mitral 
valve pathologies. Considerable progress must be achieved for all patients due to the lack 
of ideal solutions and the rising prevalence of mitral valve diseases. 
1.5 Heart Valve Tissue Engineering: 
Current treatment options for mitral valve insufficiency are limited in their 
duration, functionality, and true benefit to patients around the world and in any age range. 
This is true despite the enormous demand for permanent solutions to mitral valve diseases. 
Mitral valve replacements are thrombogenic, elicit pannus overgrowth, and calcification. 
Similarly as noted, reparative techniques offer significantly worse results regarding 
reoperation which leads to a steep slope of dangers for the patient. Also, it is important to 
remember that there are no true options for pediatric patients. No current option in mitral 
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valve repair or replacement can survive growth of the patient. Therefore, researchers have 
turned to tissue engineering to deliver an ideal solution to combat mitral valve pathologies. 
1.5.1 Introduction to Tissue Engineering Paradigm: 
 
Figure 1.23: The general tissue engineering paradigms. (Pathway A) This is the conventional 
incorporation of seeding cells into a scaffold, an in-vitro phase for preconditioning and an in-vivo phase of 
tissue growth and remodeling. (Pathway B) This modified paradigm does not utilize the in-vitro phase but 
instead depends on resident, circulating cells of the patient in-vivo to repopulate the scaffold and spur tissue 
growth and remodeling(110). 
Tissue engineering is a cross-disciplinary science between engineering principles 
and biology to overcome the limitations of artificial heart valves. The aim of tissue 
engineering is to utilize a 3D scaffold as a specific tissue template to develop new, healthy 
tissues from their specific cellular components(111). The scaffold, which provides the crucial 
microenvironment, allows for cell attachment and tissue growth. Specific cells are 
incorporated in these matrices to develop or regenerate new tissue to replace diseased or 
damaged tissues. The ultimate goal of tissue engineering is to fabricate a patient-tailored 
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neotissue from the combination of matrix and specific cells. Thus utilizing the 
characteristics of the original tissue, such as adequate mechanical properties, optimum 
hemodynamics, non-inflammation, non-immunogenic, and durability due to the capacity 
to remodel and heal. Tissue engineered constructs for mitral valve tissue engineering 
(MVTE) should be non-thrombogenic, non-obstructive, non-immunogenic, self-repairing, 
it should allow growth with the patient, allowing for a pediatric solution, and these 
constructs should be a permanent, integrated tissue replacement(110,112–115). As discussed, 
the general tissue engineering paradigm follows the incorporation of 3D scaffolds, with a 
cell-source specific to or with the potential to, differentiate to the neotissue, in-vitro 
preconditioning of the constructs to encourage cell attachment and development, finally 
followed by implantation into the patient and in vivo remodeling. As defined by 
Mendelson’s review, the more traditional, paradigm of scaffold, cells and maturation 
before implantation into the patient is widely accepted as framework from which most 
tissue engineering ventures follow. 
In above the classical paradigm, there are specific design criteria that must be met 
for a tissue engineered mitral valve. Considerations for these must include their overall 
function as a valve, the extreme stresses and strains experienced repeatedly by this tissue, 
cellular function, surgical considerations, and risks during implantation like infection and 
thrombogenesis. Many of these design criteria are a function of the environment with 
which these tissues would experience. Rapid and repetitious opening and closing 
corresponding to the pressure and shear forces acting on the valve define the needs for 
durability and resistance to degradation. Also, to be successful as a tissue engineered 
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construct, the living cells within the scaffold should inhibit thrombosis, resist degradation, 
resist calcification, have remodeling potential, and function as healthy quiescent VICs and 
VECs. 
Table 1: Design criteria for tissue engineered mitral valve(112). 
 
 
 
 
 
 
 
Specific to the mitral valve, each of these design criteria must apply to the four 
tissue types working cohesively in the valvular apparatus. While unique in their role for 
mitral coaptation, the annulus, leaflet, chordae tendinae, and papillary muscles making up 
the mitral valve scaffold must be able to function under each of those design criteria. It 
could also be added that in addition to functioning under these criteria, it is imperative that 
they all function together as unit. Difficulties in developing a mitral valve scaffold may in 
fact lie in the complexity of its anatomy. Literary searches for mitral valve tissue 
engineering to date yields 145 search results in PubMed, many of which are found in review 
articles. This is compared to the 518 for aortic valve tissue engineering and 1223 for heart 
Design Parameter Tissue Engineered Mitral Valve 
Closure of leaflets Rapid and complete 
Fluidic function Identical to the native valve 
Risk of thrombosis Inhibition by functioning VECs 
Surgical insertion and 
considerations 
Easy and permanent insertion 
using current surgical methods 
Risk of structural degradation Resistant to degradation and 
calcification 
Risk of infection Resistant 
Cellular function Quiescent VIC and VEC function 
Tissue function Durable and stable 
In-vivo monitoring requirements Cellular physiological and 
phenotype 
Changes in mass and/or tissue 
components 
Structure and mechanical 
properties 
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valve tissue engineering in general. This discrepancy isn’t for lack of need as mitral valves 
are the most diseased and degenerative in the world(53). The rise of successful surgical 
repairs in treating mitral valve insufficiency has probably driven this shortage. However, 
recent literature as mentioned, draws the durability of these repairs deeply into 
question(108). The potential for a tissue engineered mitral valve is great. 
1.5.2 Scaffolds in Heart Valve Tissue Engineering: 
To achieve each of the above design criteria and produce a functional, durable valve 
tissue, choice of scaffold is critical. Scaffolds provide cells a microstructure that guide their 
growth, differentiation and synthesis of extracellular matrix(116). Therefore, knowledge of 
how the native valvular environment controls cell fate and function should serve as a guide. 
It is also important to note that these environments also play a large role in progression of 
mitral valve pathologies and therefore knowledge of the role this microstructure plays in 
mitral valve disease can be useful. The mechanical and biochemical makeup of the VIC 
extracellular matrix are developed and defined by the specific cells that populate it. VICs 
are very sensitive to this environment. Regulation of these cells is often determined by the 
mechanical properties or ECM elasticity which can regulate the pathological differentiation 
of these cells(117). For example, depending on the elasticity of the ECM, VICs can remain 
fibroblast-like on soft substrates or differentiate to osteoblasts or myofibroblasts on 
intermediate to stiff substrates(44,116,118). Aside from mechanotransductive cues provided by 
the microenvironment, scaffold choice is also influenced by protein interactions providing 
biochemical information and direction for the incorporated cells. Myofibroblast 
differentiation is generally promoted by adhesive proteins like fibronectin, fibrin, elastin 
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and adhesion peptides RGDS(119–121). Incorporation of growth factors like TGF-β1 can also 
be utilized within scaffolds to encourage the desired activation or differentiation of the 
VICs. Interest in the customization of scaffold properties has led to the development of 
synthetic scaffolds for heart valve tissue engineering. 
The popularity of synthetic scaffolds lies in their advantage of control over their 
material properties. These properties should encourage cell attachment, migration, 
proliferation, differentiation, and eventually matrix formation. Bioresorbable scaffolds 
serve as a temporary scaffold which cells can remodel and develop their own ECM. The 
chemical and physical properties determining how long this scaffold lasts are tailored to 
the cell types and applications of the finished tissue. Structurally, these scaffolds should 
have an extensive network of pores and channels not only for cellular attachment, but also 
for the delivery and diffusion of nutrients and oxygen. As mentioned these materials should 
all be biodegradable and biocompatible. Mechanically speaking, the properties of a 
synthetic scaffold should be prepared to handle the large and repeated loads experienced 
billions of times in one’s life. Synthetic materials are easily reproducible and well 
conceived which allows for a more customizable and easily translatable scaffold material. 
There are several common polymeric materials used to develop synthetic scaffolds for 
tissue engineered heart valves. These include polylactic acid (PLA), polyglycolic acid 
(PGA), polycaprolactone (PCL), Polyfumarates (PF), and polyglycerol sebacate (PGS). 
Each of these has been reported for use in cardiovascular uses and are all approved by the 
FDA as biocompatible polymeric materials(111). PLA and PGA are probably the most 
commonly used for tissue engineering purposes. PCL and PF are largely used for drug 
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delivery purposes and have a long degradation rate of about 3 years, while PLA has a 
degradation rate of 2 years. This is in comparison to the 2-3 months it takes for PGA 
scaffolds to degrade(111). Unfortunately, studies have shown that these common copolymers 
were thicker and less flexible than natural valves(122). This rigidity would not allow for 
proper coaptation. To solve this, application of P4HB (poly-4-hydroxybutyrate) was used 
to enhance the flexibility and plasticity of these polymers(123). This combination allows for 
much greater flexibility of these polymeric heart valves. Use of these synthetic materials 
for a tissue engineered valve however introduces several challenges. PGA and PLA for 
example are considered poor substrates for cell growth in-vitro(110). In addition, ECM 
proteins are not usually constituents in a synthetic environment. To combat these 
disadvantages, bioactive synthetic materials are being developed to mimic the natural ECM 
and its function(124). Recent advances show the incorporation of synthetic polymers that 
carry spatial and biochemical information affecting cellular function and remodeling(125). 
These scaffolds can also be used as a vehicle for drug delivery. Growth factors, known to 
influence cell growth, proliferation, and migration, can be incorporated into these synthetic 
scaffolds(114). Mostly synthetic hydrogels can also be used as an injectable scaffold. Despite 
some of their advances, there are some drawbacks to using these synthetic scaffolds. These 
scaffolds still have difficulty controlling cell adhesion and tissue reorganization, this is 
shown partly in the limited diffusion of cells into the scaffolds. If the polymers do not 
completely degrade, there is a risk of inflammation. After and during degradation, any 
space that was formerly occupied by the synthetic material is often replaced with scar 
tissue(110). 
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There are four common methods for fabricating synthetic scaffolds. One of the 
more common methods is solvent casting. In this method the polymer solution is cast with 
water soluble particulates into a mold(111). The evaporation of the solvent makes the pores. 
Extensive use of this solvent may affect cell attachment and proliferation. Electrospinning 
is also used as a versatile yet straightforward technique. With this approach, a high electric 
field is used for the ejection of the conductive polymer jet from a needle which is connected 
to the solution containing the polymer(111). Using this technique, electrospun scaffolds are 
highly porous with a high density. Diameter of the electrospun fibers can be tailored to the 
scaffolds requirements. Process factors include polymer and solvent, voltage, flow rate 
from the needle, and the distance from the needle and collector. Electrospinning is probably 
the preferred scaffold generating technique due to its customizability and porosity for 
VICs. The fourth most common approach for synthetic scaffold fabrication is solid free 
form. This translates computer data from drawings or MRI data for example and is 3D 
printed. 3D bioprinting has begun to rise in popularity due to the flexibility and tailoring it 
allows using the CAD programs on the computer. 
Issues surround biocompatibility; a low degradation rate and inflammation are 
major drawbacks of synthetic scaffolds. Therefore, utilization of natural materials present 
within the mitral valve ECM have been used for scaffold fabrication. These biologically 
derived materials are inherently recognizable by cells which are susceptible to the receptor 
binding ligands and cell-triggered proteolytic enzymes presented by biological 
scaffolds(124). Constructs composed of collagen for example have been used to generate 
tubular blood vessels, chordae tendinae, and of course heart valve leaflets(126). Scaffolds 
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made from natural materials give cells, in both their material properties and application 
type, a familiar environment. Valvular interstitial cells are very conscious to the chemical 
and mechanical environment surrounding them. Natural scaffolds utilize ECM components 
familiar to VICs to encourage a controlled, healthy proliferation, migration, and 
differentiation. 
One of the most commonly used natural scaffold materials collagen, comprises the 
largest percentage of material in the valvular ECM. It is therefore one of the most 
commonly used platforms for developing living tissue engineered constructs. Due to 
collagen’s less than ideal mechanical characteristics as well as antigenicity concerns, other 
materials are often used in conjunction. Elastin for example, one of the other major players 
in ECM makeup. Collagen and elastin scaffolds have elicited much improved mechanical 
properties(111). Fibrin gels are another commonly seen natural scaffold. Easily prepared 
from the patient’s blood, despite its poor mechanical properties, fibrin utilizes its bioactive 
nature to enhance cell growth and attachment(111,127). Fibrin and its common partner 
fibrinogen, play large roles in blood clotting, cellular matrix interactions, and wound 
healing(128). It is also useful as a sealant in a variety of clinical applications(127). 
Glycosaminoglycans (GAGs), a common element in the heart valve ECM, can also be used 
as a scaffold for tissue engineering. Hyaluronic acid, like other natural scaffolds, relies on 
its bioactivity and the familiarity seeded cells have with it as an ECM component. 
Hyaluronic acid (HA) is largely presented as a hydrogel and can bind to proteins and cells 
through cell receptors. It is a key component in the wound healing process, and can 
maintained in hydrated environments conducive to cell infiltration(129). As briefly 
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mentioned, hydrogels have often been used as a natural and as a synthetic 3D matrix in 
tissue engineering. Natural hydrogels like those composed of hyaluronic acid and fibrin, 
are inherently bioactive but also biocompatible(130). Due their cell-friendly characteristics, 
production of ECM and an increase in cell proliferation are seen when using natural 
hydrogels for scaffolds or used to fill the interstitial space of other scaffolds(111). VIC have 
also been incorporated in natural and cross-linked hydrogels facilitating good viability and 
providing a physiological representative environment to study VIC behavior(40). Fibrin 
hydrogels are also common scaffolds for heart valve tissue engineering. They are 
constructed from purified fibrinogen and thrombin. It is common to include other plasma 
proteins such as fibronectin and other growth factors in fibrin gels to assist cellular function 
and proliferation(127). One of the pitfalls of hydrogels however is their lack of mechanical 
stability(115). This is especially critical for heart valves due to their incessant opening and 
closing. They also lack the anisotropic mechanical properties and topographical cues that 
provide mechanotransductive direction to seeded cells.  
Another commonly utilized technique for scaffold fabrication is the 
decellularization of xenogeneic or allogenic heart valves. The goal of a decellularized 
scaffold is to take advantage of the ECM environment it can provide to seeded cells while 
also providing a collagen and elastin based scaffold that cells are inherently familiar with. 
The benefits of using the niche ECM for tissue engineering are great as this matrix provides 
the mechanical framework for the heart valve. The ECM acts as an inductive scaffold both 
mechanically and chemically. Mechanically speaking, this tissue was developed, repaired, 
and remodeled by the specific cells that inhabited it. Therefore structurally, it provides the 
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correct rigidity, porosity, insolubility and topography that heart valve tissues should 
possess(131). The ECM also contains many functional components within it including 
collagens, glycoproteins, proteoglycans, elastic fibers and growth factors(131). The 
specificity of this local microenvironment can also influence the maintenance of stem cell 
phenotype and differentiation. This ability allows decellularized matrices to be open for 
regenerative medicine applications. The process of decellularization is a technique that 
varies widely across the tissue engineering field. The overall goal of this technique is to 
eliminate the cellular content of a tissue while retaining the ECM structure and its proteins. 
To achieve this end, various methods of decellularization are used including physical, 
chemical and biological agents. Many researchers use a combination of detergents and 
biological agents including SDS, trypsin, EDTA, Triton X-100, sodium deoxycholate, 
sodium hydroxide, DNase/RNase(132,133). Criteria for a successful decellularization have 
been established by several researchers for tissues to contain: less than 50ng dsDNA/mg 
ECM, less than 200 bp DNA fragment lengths, and no nuclear material in histological 
samples(132,133). Any lack of confidence surrounding decellularized scaffolds centers on the 
danger of a residual cellular presence and lack of control over remaining ECM quality and 
defined components. However it is important to point out that there are at least 30 products 
currently on the market, including small intestinal submucosa (SIS), placed in thousands 
of patients that have gone successfully(134). Potential for recellularization for seeded cells 
is also a recent design criteria, especially for decellularized scaffolds(135). Overall, 
decellularized scaffolds have yielded the fasted method clinically through animal and 
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human studies and thus promises the most clinically translatable scaffold for tissue 
engineering(135–137).  
Scaffold durability is of prime importance when considering scaffold potential. The 
mitral valve opens and closes an estimated 3 billion times during the average lifetime. 
Constant and repeated loads from transvalvular pressures also act on the valve. As 
mentioned, the mitral valve is hit with 120mmhg during ventricular systole and 10mmhg 
during diastole requiring an unparalleled resistance to cyclic failure(115). Cardiac valves are 
also subject to large blood shear forces. The average peak systolic blood velocity usually 
averages about 1m/s through heart valves. These pressure and shear forces experience by 
the tissue engineered constructs must be a serious consideration. 
1.5.3 Choice of Cells in Heart Valve Tissue Engineering: 
In the traditional paradigm for tissue engineering, the incorporation of cells into 
scaffolds is critical for creating a vital construct. For a tissue, engineered mitral valve the 
obvious choice of cell type would be the VIC. This is the chief resident cell within the 
valvular matrix and therefore would be primed for utilization in a valvular scaffold. A 
similar sentiment would be made for VECs. However in no way could these cell types be 
used in a successful or clinically translatable fashion. To obtain these cells would require 
risky invasive surgery, and would damage the already diseased valve structure. Therefore, 
other sources of cells must be considered. Some researchers argue that there may not be a 
need to seed cells into or onto scaffolds prior to in-vivo transplantation. Long-term animal 
experiments have to clarify the need for pre-vitalization of the scaffolds is necessary to 
demonstrate growth and remodeling(135). Difficulties lie still however with the efficiency 
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of cell seeding. There have been many attempts at recellularization of heart valve leaflets, 
but due to inadequate penetration of the cells or the length of time this scaffold-infiltration 
took, researchers are still looking for a more optimized approach(138). Nevertheless, 
scaffolds recellularized with various cell types, to then be preconditioned in bioreactor 
systems is the current paradigm most researchers are following. 
Choice of cell type is relegated to the specific applications researchers choose. 
There are however, several commonly utilized cell types used often. Stem cells offer a 
unique avenue for scaffold revitalization due to their capabilities of self-renewal and ability 
to differentiate into a variety of cell types. Ideally, for a clinically translatable option, 
autologous stem cells are used to eliminate the risk of immunorejection. Several common 
stem cell types are used in heart valve tissue engineering. Because stem cell differentiation 
can be directed by mechanical and biochemical stimulation, there are few constraints as to 
which type of stem cell should be used. The more important question becomes which 
microenvironmental cues will be used to induce the desired cellular behavior. One is the 
mesenchymal stem cell, which has the ability to differentiate into chondrogenic, 
adipogenic, myogenic and osteogenic lineages(139). This lineage of cells has been used 
successfully in other cardiac tissue engineering applications(110). They have also shown to 
be able to differentiate into endothelial and cardiac myocytes. Mesenchymal stem cells 
have also been used for their VIC-like phenotype and their ability to overcome 
immunogenicity barriers associated with donor cells(115). Despite their ethical concerns, 
embryonic stem cells could allow for production of specific tissues in scaffolds(114). They 
have a well-known pluripotency and can be maintained for long periods of time and in 
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large quantities. Their differentiation methods are similar to those like bone-marrow 
derived stem cells. Bone-marrow derived stem cells (BMSCs) can be isolated from bone 
marrow and has been shown to have good differentiation potential. BMSCs have been 
shown to engraft into heart valves and synthesize collagen as part of normal valve 
homeostasis(140). Induced pluripotent stem cells (iPSCs) represent another cell source for 
tissue engineered mitral valves. It is important to note that while their ability to differentiate 
to the same lineage of as the somatic cells that they derive, more research needs to be 
conducted to evaluate whether these are trusted cell source. Human adipose derived stem 
cells (hADSCs) have also shown great promise and feasibility for mitral valve tissue 
engineering. These cells are easily and minimally-invasively obtained, can be 
cryogenically stored, and possess multipotent mesodermal, ectodermal and endodermal 
potentials(141–145). Such tri-germ layer potential makes this cell-type an excellent choice for 
translational applications. hADSC’s yield significantly large and clinically relevant cell 
numbers when isolated from adipose tissue. In fact, as a source for regenerative stem cells, 
adipose tissue may have no equal(146–149). A recent study found in fact that hADSC’s 
yielded tenfold more CFU-F units compared to bone-marrow derived stem cells, a 
characteristically similar stem cell(146). Current literature also supports hADSC use in 
organized ECM remodeling. Colazzo et al. stated that hADSCs have the ability to 
synthesize and process ECM components suitable for tissue engineering a heart valve(143). 
This was largely based on their ability to differentiate hADSCs into VIC-like cells, thus 
allowing for remodeling of heart valve ECM(150,151). Adipose-stem cells also possess a 
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unique secretome containing angiogenic cytokines such as VEGF, FGF-2, and HGF, which 
allow it to more fully integrate in vivo(141,152–154). 
One of the major drawbacks of both types of scaffolds are their inclusion of cells. 
Synthetic scaffolds have a greater chance of recellularization due to the ability to control 
their pore size. However even with this level of customization, efforts are still difficult. 
Natural scaffolds, despite their success and obvious biological advantage, lack the ability 
to alter their physical properties to the extent synthetic scaffolds can. Therefore, a myriad 
of different recellularization techniques exist in an effort to bring cells into the matrix either 
forcibly or through biochemical coaxing. There are various researchers attempting to coax 
migration of seeded cells using growth factors and other proteins like fibronectin(155–159). 
Vacuum seeding has also been utilized in vascular grafts successfully(160). Hydrogels are 
also used both as a chemical attractant and as a physical means to get cells into the matrix 
utilizing the gel’s space-filling capabilities(130,158,159,161,162). Despite various methods and 
attempts for recellularization of scaffolds, there does not exist a gold standard for seeding 
cells in valvular scaffolds. This is especially true for the mitral valve and its four 
components. Most research literature is solely focused on revitalization of the leaflets. 
Regardless, there are various ways to attempt cell seeding depending on the application of 
the construct. 
1.5.4 Bioreactor Conditioning in Heart Valve Tissue Engineering: 
Historically, mechanical conditioning of heart valve constructs has been considered 
an essential step for the maturation of the cells within the scaffold, thus promoting a 
structurally and mechanically competent construct. Maturation of the scaffolds can be 
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achieved in-vitro using a bioreactor which provides the necessary mechanical and 
biochemical cues these constructs would experience in the human body but in a controlled, 
sterile environment. Forces such as cyclic stretch and flexure, oscillating fluid shear stress, 
pressures and flexural deformations(115). Such indications for maturation directs cell 
proliferation, differentiation, attachment and alignment(115). By pointing these cells in the 
proper direction, researchers can develop constructs that eventually will mimic the mature 
ECM and overall properties of the tissue they are attempting to replace or regenerate. This 
in-vitro preparation allows for immediate implantation of a functional construct in the 
native hemodynamic environment. Through this in-vitro adaptation in a bioreactor system, 
scaffold material turnover will occur, thus circumventing this response and other adverse 
host-tissue reaction that would have occurred post-implantation. 
The primary goals of a bioreactor system are: offering uniform cell distribution, 
keeping concentrations of gas and cell-culture nutrients available to the construct, offering 
mass transport to and from the construct, and of course, being able to provide adequate and 
accurate mechanical cues to induce the seeded cells to differentiate and remodel the 
scaffold thus producing an adequate ECM(163). Dynamic seeding through use of a 
bioreactor has shown to greatly improve cell attachment to the scaffold(163). Depending on 
the purpose for the construct, different pressures and shear stresses may be applied. This 
of course would affect the needs and design of the bioreactor system. 
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Figure 1.24: Mitral valve bioreactor used in our laboratory. 
There are three main categories for bioreactor design, each depending on the 
amount and types of mechanical stimulation being applied. These include: flow-based 
whole valve conditioning bioreactors, strain-based whole valve conditioning bioreactors, 
and isolated cusp stimulation bioreactors(164). Flow-based whole valve conditioning 
bioreactors aim to mimic both diastolic and systolic phases in the bioreactor. This type of 
bioreactor, originally conceived by Hoerstrup et al., utilizes a pulsatile flow that exposes 
the developing construct to all of the mechanical cues that would be experience in the 
body(165). Sierad et al. have greatly improved upon this design and have achieved 
anatomical pressures in the aortic position(166). In-vitro findings for this type of bioreactor 
have shown cell migration into the scaffold, an increase in ECM deposition, and increase 
in construct stiffness, and lamellar tissue organization(115,164). The second type, the strain-
based whole valve bioreactor, mimics only one component experienced by native heart 
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valves, strain. This is done by periodically pressurizing the media around the valve 
constructs in line with transvalvular pressures a native valve would face. In-vitro findings 
are similar for this bioreactor. Cell migration was not increased, however ECM deposition 
and stiffness were increased. Lamellar tissue organized and the construct showed 
mechanical anisotropy(115,164). Bioreactors have also been made to isolate one cusp and 
stimulate this part of the construct; the third type is the isolated cusp stimulator. Bioreactors 
in this category expose their constructs to cyclic stretch flexure and oscillating shear 
stress(115). Within these three major categories are several popular designs utilized in the 
valvular tissue engineering space. These include spinner flasks, rocker platforms, rotating 
walls, compression, and perfusion systems. 
While there are many different designs for heart valve bioreactors, most are 
designed specifically for aortic valves. Very few flow-based bioreactors accommodate for 
each component of the mitral valve. However, for proper in-vitro preconditioning, the 
entire apparatus must be considered. One bioreactor from Barzilla’s group utilizes a 
“splashing bioreactor”(167). This is placed on a rotating wheel and uses gravity to open and 
close the leaflets. While this bioreactor did encourage improved cell density of the mitral 
valve leaflet, proper mechanical cues must be applied for an environment mimicking the 
native mitral valve. First, transvalvular pressures have to be achieved using a system that 
incorporates the entire valve, exposing it to these pressures along with shear forces. In 
addition, annular shape should be considered as a foundation for mounting the valve. This 
unique shape provides optimal force distribution throughout the valve. Lastly, tension must 
be applied to the chordae tendinae. These tensile forces are critical in developing mature 
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chordae tissue, as well as functional leaflet tissue. Overall, bioreactor development in this 
tissue engineering paradigm can resolve many of the issues and limitations of currently 
available options. Complexity in design, assurance of sterility and providing monitoring 
capabilities hinder the application of tissue-engineered heart valves. There is also a balance 
that must be achieved when using heart valve bioreactors that the in-vitro conditions used 
do not overstimulate the living constructs to then stimulate pathological over production of 
ECM and over-activation of seeded cells. 
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CHAPTER 2 – PROJECT MOTIVATION, SPECIFIC AIMS, SIGNIFICANCE 
2.1 Introduction and Clinical Relevance: 
In the United States alone, 2.5% of the population suffers from some form of 
valvular disease(1). Degenerative etiologies are largely responsible for these statistics(2). 
The most degenerative of the four heart valves is the mitral valve making it the most 
frequently diseased valve in the heart (2, 3). Approximately 41,000 hospitalizations per year 
are due to surgical corrections of mitral valve regurgitation (MR) in the United States, yet 
this number represents only 44% of persons with severe MR who would benefit from 
surgical correction(3). The prevalence of mitral valve disease increases substantially with 
age, from less than 2% before the age of 65 to 8.5% in those aged 65-75, and 13.2% after 
the age of 75(3). The lethality of mitral valve diseases stems from the three primary 
pathologies that affect the valve, i.e. stenosis, regurgitation, and prolapse. These three 
pathologies can result in atrial fibrillation, arterial thromboembolism, pulmonary edema, 
pulmonary hypertension, cardiac hypertrophy and heart failure(4–7). Prevalence of mitral 
valve insufficiencies is clear and thus verifies its significance as a crucial area for 
further research and development for translational solutions. 
2.2 Current Standards of Care and Limitations: 
Current clinical solutions available to patients with mitral valve pathologies are 
surgical repair or total valve replacement. Replacement strategies include mechanical 
valves and chemically-fixed xenogeneic valves. Each of these prosthetic devices however 
has often resulted in thromboembolic complications, calcification, and most require 
additional reoperations due to their limited functioning lifespans. Because the body 
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chronically reacts to the artificial valves, the lifespan of bioprosthetic and mechanical 
valves ranges from 15 to 20 years. This poses a difficult decision for surgeons if their 
patients are younger. Each additional replacement surgery causes an enormous increase 
(almost 20% in some cases) in mortality risk(8–12). Determination of reparative or 
replacement therapy is often based on the age of the patient and other health related factors. 
Women who are or are planning to become pregnant must weigh their safety and the child’s 
safety because they cannot undergo anticoagulation therapy during this time(13). Also, 
children with congenital heart defects have limited options for mitral valve replacement. 
Small diameter mechanical valve replacements are rare due to high mortality and morbidity 
rates. Mitral valve repair is the preferred solution due to its less invasive nature and higher 
success rates when compared to replacement(14,15). Anatomical complexity however is a 
limiting factor when repairing the mitral valve. There are four tissue types present in the 
valve’s entirety: the annulus, the leaflets, the chordae tendinae, and the papillary muscles. 
Reparative technologies center on band annuloplasty and artificial chordae made of PTFE. 
Both are used to reconstitute the correct physical anatomy of the valve, thus optimizing 
force distributions and overall coaptation(16,17). Despite the successes of mitral valve repair, 
recent studies have shown that the rate of reoccurrence in patients following repair (58.8%) 
was significantly larger than patients who underwent valve replacement (3.8%) after two 
years(18). Overall, mitral regurgitation recurred more frequently in patients receiving repair 
treatments, resulting in more heart failure-related events and cardiovascular admissions(18). 
A tissue engineered mitral valve could provide patients with a permanent regenerative 
solution. These could provide a living valve replacement using already existing surgical 
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techniques. With the advancement of stem cell capabilities, one can employ them along 
with growth factors and engineered matrices to eventually create an autologous implant 
that can not only grow with the patient but also create a superior alternative to repair and 
replacement therapies. There has been considerable research into heart valve tissue 
engineering, but limited clinical testing, especially with the mitral valve. This may be a 
result of the mitral valve’s complicated anatomy or the prevalence of other diseased valves 
like the aortic valve. A mitral valve tissue engineered solution is an exciting concept, yet 
very early in practice. 
The overall goal of this project is to develop a biocompatible and clinically 
translatable tissue engineered mitral valve. To realize this goal, the engineered construct 
must be mechanically robust, biologically compatible with future hosts, and should allow 
sufficient bioactivity for cellular seeding and signaling. The valve should allow for rapid 
opening and closure, no need for rigid support, and maintain correct physiological structure 
from annulus to papillary muscle. Because ECM and biochemical composition are crucial, 
our construct will be an acellular, non-immunogenic collagen and elastin-based scaffold. 
To impede degradation of the tissue, the decellularized xenogeneic scaffolds, will be 
treated with penta-galloyl glucose (PGG), an antioxidant polyphenol and matrix 
stabilizing agent, with high affinity for collagen and elastin, to slow down matrix 
degradation (19). 
We hypothesize, that this tissue engineered mitral valve consisting of a 
decellularized porcine mitral valve scaffold, treated with PGG, recellularized with relevant 
VIC-like cells, and finally pre-conditioned in a mitral valve bioreactor will immediately 
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provide a working and living valve construct. Pre-conditioning of the revitalized construct 
will allow for maturation of the seeded cells and allow for initial and essential remodeling 
of the mitral construct. In addition, due to PGG’s ability to stabilize collagen and elastin, 
and its antioxidant, anti-inflammatory, and anti-calcification activities, the polyphenol will 
protect the scaffold from degradation and prevent degradation of the valves structures. 
Translationally, this approach is patient specific and should immediately integrate and 
grow with the host. 
2.3 Specific Aims 
Three overlying and interrelated aims were established toward achieving the overall 
goal of this research, and they are directed at understanding: 1) How to develop a stable, 
acellular, cytocompatible scaffold capable of supporting cellular infiltration, limiting 
protease degradation, and maintaining adequate mechanical properties; 2) Achieving an 
effective and optimized recellularization approach, while determining PGG’s beneficial 
effects on limiting scaffold degradation and reducing over-activation of the seeded cells; 
3) Development and utilization of a mitral valve bioreactor that takes into account the 
mitral valve’s unique anatomy while providing physical cues and proper force distribution 
from the annulus, closure of the two leaflets, and adequate tension provided to the chordae 
tendinae. 
Aim 1 (Chapter 3): Develop an acellular scaffold with ECM and mechanical properties 
similar to the human mitral valve. 
Hypothesis: A detergent based decellularization method will remove all cellular 
materials from a porcine mitral valve while retaining sufficient extracellular matrix 
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content, including basal lamina proteins. Chemical treatment with PGG will stabilize the 
matrix scaffold and yield physiologically similar mechanical strength. 
Approach: Scaffolds will be generated using a decellularization protocol that 
employs Triton X-100, SDS, EDTA, Deoxycholic Acid, NaOH and a treatment of 
RNase/DNase. In doing so, the scaffolds should: 1) have all xenogeneic cellular and 
nuclear components removed; 2) retain ECM architecture and composition while also 
preserving all ECM proteins (e.g. collagen type I and IV, elastin, laminin, and fibronectin); 
and 3) Maintain necessary mechanical properties for leaflets and chordae tendinae while 
incorporating PGG. 
Innovation: We will develop a decellularized, non-immunogenic collagen and 
elastin scaffold for mitral valve tissue engineering. Through decellularization of porcine 
tissue, we will able to conserve the niche valvular microstructure of the ECM.  
Aim 2 (Chapter 4): To characterize host response and determine resistance to 
degradation of the scaffold treated with PGG. 
Hypothesis: The stabilizing, anti-inflammatory, anti-calcification function of PGG 
will limit scaffold degradation and mitigate immune rejection. 
Approach: As shown in previous studies and in current literature, treatment with 
PGG, a well-characterized matrix binding polyphenol, will protect scaffolds from 
calcification, discourage degeneration from proteases, and mitigate immune rejection. 
Decellularized scaffolds will be treated with PGG and degradation by collagenase and 
elastase will be evaluated and compared to fresh and untreated decellularized scaffolds. 
Also, PGG-treated scaffolds will be implanted subdermally in rats. At 4 and 8 weeks, 
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scaffolds will be explanted and immune response to these treated scaffolds characterized 
using immunohistochemistry. Host response as well as degradation will be evaluated and 
compared to non-treated scaffolds.  
Innovation: Utilization of scaffolds in tissue engineering, while a part of the 
classical paradigm, still are hindered by questions concerning their fate once implanted in 
patients. How long these scaffolds will last within the patient, should the scaffolds be 
remodeled, and will the patients’ body accept them are all common inquiries. Our approach 
aims to be some of the first to investigate the stabilizing and degeneration-inhibiting affects 
PGG has on a decellularized mitral valve scaffold. Our novel approach, incorporating PGG, 
aims to solve these questions, determining the degradation of the scaffold and evaluating 
the nature of the host response as being inflammatory or remodeling. 
Aim 3 (Chapter 5): Develop a mitral valve bioreactor able to provide physiological 
loading and biochemical environment characteristic to mitral valves. 
Hypothesis: Optimally seeded constructs will flourish under physiologic 
conditions provided by a bioreactor that provides correct anatomical positioning and force 
distribution from annulus to papillary muscles. 
Approach: Pre-differentiated fibroblasts will be manually injected utilizing a fibrin 
gel as the carrier of these cells. Valves will be first inflated with sterile air, then the fibrin 
and cell mixture injected into multiple areas of the tissue. Pre-differentiated endothelial 
cells will then be drop-seeded onto the scaffolds. Recellularized constructs will then be 
placed in the mitral valve bioreactor with flow, pressure and viscosity conditions gradually 
increased to allow maturation of cells until reaching physiological levels. 
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Innovation: Recellularization of any scaffolds into a living construct has been a 
crux in the paradigm of tissue engineering, especially in ECM-derived scaffolds. Our 
approach aims to achieve an acceptable level of cellular infiltration and migration initially, 
which then allows for full recellularization after pre-conditioning in a custom made mitral 
valve bioreactor. This novel bioreactor will recreate an appropriate force distribution 
throughout the entire construct. 
2.4 Project Significance: 
A central motivation for tissue engineering is the regeneration of diseased tissues. 
With the advancement of stem cell capabilities, one can employ them along with growth 
factors and engineered matrices to eventually create an autologous implant that can not 
only grow with the patient but also create a superior alternative to repair and replacement 
therapies. There has been considerable research into heart valve tissue engineering, but 
limited clinical testing, especially with the mitral valve. This may be a result of the mitral 
valve’s complicated anatomy or the prevalence of other diseased valves like the aortic 
valve. A mitral valve tissue engineered solution is an exciting concept, yet early in practice. 
However, we expect the results of this translational research to have a positive impact on 
patients suffering from the many forms of mitral valve insufficiency. Success in this project 
would also lead to a much deeper understanding in the realm of stem cell and ECM 
interactions, especially in valvular tissues. Overall, this research will greatly contribute to 
the field of cardiovascular tissue engineering and enable clinicians to provide permanent, 
living solutions for their patients. 
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CHAPTER 3: DEVELOPMENT AND CHARACTERIZATION OF A 
DECELLULARIZED MITRAL VALVE SCAFFOLD 
3.1 Introduction: 
At its core, the prevailing paradigm in heart valve tissue engineering has been the 
integration of scaffolds and specific cells to develop mature constructs with regenerative 
potential. As the foundation for these living constructs, scaffolds provide the framework 
for housing cells whether they are seeded onto the scaffolds or are repopulated in vivo. 
These cellular infrastructures can range in their originating materials, mechanical 
properties, and fabrication. While synthetic scaffolds provide easier customizability, 
support has risen for the use of naturally derived scaffolds using materials like fibrin and 
other degradable materials. Acellular tissue matrices derived from the heart valve 
extracellular matrix (ECM) are rising in popularity due to many of its advantages. Various 
tissues have been rendered acellular through the process of decellularization which 
employs chemical, physical, and enzymatic agents to remove any and all xenogeneic 
cellular and nuclear material from the tissue(1). In a successful decellularization, the ECM 
components are largely preserved including structural proteins like collagen type I and 
elastin, as well as basal lamina proteins collagen type IV and laminin. These are largely 
conserved across species and thus permits their compatibility as biological scaffolds 
derived from xenogeneic sources(2,3). After removal of these components, the remaining 
structure is a tailor-made structure specific to that tissue and the specific cells that built it. 
The ECM is a complex of both structural and functional biomolecules that are produced by 
the resident cells. As a custom built microstructure, the ECM can provide an enormous 
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amount of information in molecular and mechanical signals to their cellular inhabitants(3). 
Therefore, creating a “niche” microenvironment and an inductive scaffold for the 
repopulating cells, providing the architecture, mechanical properties and binding sites 
needed. 
Detractors of decellularization are the risk of an incomplete removal of cellular and 
nuclear material from the scaffolds. History has shown that the immunogenic response can 
be deadly for patients receiving improperly decellularized scaffolds(4). The host response 
of an incomplete decellularization will lead to a pro-inflammatory response, invasion of 
type M1 macrophages and eventual dense scar formation(5). These responses will disallow 
constructive remodeling of the scaffold and proper degradation of the scaffold and eventual 
replacement of anatomically appropriate and functional tissue will not occur. However, 
decellularized ECM scaffolds have been used in thousands of patients successfully without 
rejection from their hosts. Current literature has established criteria for a successful 
decellularization of tissue: 1) no visible nuclei per histological staining, 2) less than 50ng 
of DNA per mg of dry weight ECM, 3) any remaining DNA content should not exceed 200 
base pair in length(3). 
Of all the successfully decellularized scaffolds used today including lungs, skeletal 
muscle trachea and small intestinal submucosa (SIS), the heart valve proves to be uniquely 
challenging. This largely due to the complex anatomical requirements and the extreme 
environment for which it resides. The mitral valve resides in one of the most mechanically 
stressful environments in the body. Therefore, the mitral valve must endure the harsh and 
repetitive openings and closings during systole and diastole and the valvular ECM must 
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also withstand these extreme stresses for the lifetime of the patient. As a result, the average 
decellularization, constructive remodeling and eventual recellularization must be critically 
evaluated and optimized because this tissue will immediately be put to the test upon 
implantation. Currently, tissue engineering of the mitral valve utilizing a decellularized 
scaffold has just begun to scratch the surface with only a handful of groups reporting 
methods of decellularization(6,7). This gap is worrying despite the apparent prevalence of 
mitral valve diseases. 
An optimal decellularization for the mitral valve should fulfill the following 
criteria: 1) current literature standards for removal of xenogeneic cellular and nuclear 
material should be met as mentioned above, 2) mechanical testing should show 
preservation of mechanical characteristics, 3) Safeguarding of the ECM should be a top 
priority. Structurally, the collagen and elastin integrity within the scaffold should remain 
intact. Basal membrane proteins, which facilitates cellular attachment and migration, 
should also be present post-decellularization, 4) Degradation of the scaffold should be 
limited through treatment with PGG. 
To achieve this, we decellularized porcine mitral valves using an optimized 
approach. A hypotonic shock followed by treatment with NaOH assures basic hydrolytic 
degradation of biomolecules(1). Extraction of remaining cellular components, including the 
Gal-α(1,3) Gal epitope, are done with a 5-day immersion in a detergent-based 
decellularization solution. Additional enzymatic treatment with an RNase/DNase solution 
is used to remove all the remnant nuclear components. Histological analysis as well as gel 
electrophoresis and nanodrop techniques were used to evaluate complete removal of 
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cellular and nuclear material from the scaffolds. Biaxial mechanical testing was performed 
to evaluate the mechanical integrity of the scaffold. ECM preservation was evaluated using 
several histological techniques. Overall, we sought complete characterization of the 
decellularized mitral valve scaffold. 
3.2 Methods and Materials: 
3.2.1 Mitral Valve Decellularization: 
Porcine mitral valves were collected from a local abattoir and transported to the 
laboratory on ice. After cleaning and trimming extraneous heart muscle, the valves were 
immersed in ddH2O overnight at 4°C to induce hypotonic shock and cell lysis. The next 
day, the valves were treated with NaOH 0.05M for 2 hours, then incubated for 5 days under 
agitation, in a solution containing 0.2% SDS, 1% Triton X100, 1% deoxycholic acid, 0.4% 
EDTA, prepared in 20mM TRIS pH 7.4. To remove the detergents, the valves were rinsed 
10 times for 15 minutes with ddH2O, then treated with 70% ethanol for 20 minutes to 
reduce the bio-burden, and rinsed again 4 times for 15 minutes with ddH2O. Nucleic acid 
removal was completed by incubation in a 720 mU/mL deoxyribonuclease, 720 mU/mL 
ribonuclease mixture in PBS for 2 days at 37°C. Finally, scaffolds were rinsed in ddH2O 
(3 times for 15 minutes), and incubated in 70% ethanol overnight at room temperature. The 
mitral valve scaffolds were stored in sterile PBS with 1% protease inhibitors and 1% 
antibiotic/antimycotic (Pen-Strep) at 4°C. 
3.2.2 DNA Extraction: 
DNA was isolated from tissues following the instructions provided in the DNeasy® 
Blood & Tissue Kit from Qiagen (Germantown, MD). Concentration was measured using 
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a Nano Drop 2000, Spectrophotometer, UV-Vis; (Thermo Scientific) and by ethidium 
bromide agarose gel electrophoresis, using the Sub-Cell® GT electrophoresis instruments 
and instructions (170-4402) provided by BioRad. 
3.2.3 Histology and Immunohistochemistry: 
Rehydrated paraffin sections (5µm) were stained with Hematoxylin and Eosin 
(H&E), Movat’s Pentachrome, and Verhoeff-Van Gieson (VVG), according to the 
instructions in the kits purchased from Poly Scientific R&D Corp. (Bayshore, NY). 4',6-
diamidino-2-phenylindole (DAPI) was purchased from Sigma-Aldrich Corporation 
(Lakewood, NJ). 
Immunohistochemistry (IHC) was performed on formalin-fixed and paraffin-
embedded sections using heat-mediated antigen retrieval (10mM citric acid at pH of 6, for 
10 min at 90°C), followed by exposure to 0.025% Triton X-100 for 5 minutes. After 
incubation in normal blocking serum for 45 minutes, the primary antibodies diluted to 
2μg/mL were applied overnight at 4°C in a humidified chamber. The following antibodies 
were used: rabbit anti-Collagen IV (Abcam, Ab6586), rabbit anti-Laminin (Abcam, 
Ab11575), rabbit anti-Vimentin (Abcam, Ab92547). Negative controls were obtained by 
omitting the primary antibodies. The Vectastain Elite kit and the ABC diaminobenzidine 
tetrahydrochloride peroxidase substrate kit were purchased from Vector Laboratories 
(Burlingame, CA). Sections were counterstained with a diluted hematoxylin prior to 
mounting. Images were obtained at various magnifications on a Zeiss Axiovert 40CFL 
microscope using AxioVision Release 4.6.3 digital imaging software (Carl Zeiss 
MicroImaging, Inc. Thornwood, NY). 
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3.2.4 Penta-Galloyl Glucose (PGG) Treatment: 
High-purity 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose (PGG) was a generous gift 
from N.V. Ajinomoto OmniChem S.A., Wetteren, Belgium (www.omnichem.be). The 
acellular scaffolds were treated with sterile 0.3% PGG in 50mM Na2HPO4, 0.9% NaCl, pH 
5.5 containing 20% isopropanol overnight at room temperature under agitation and 
protected from light. Scaffolds were then rinsed with sterile PBS 3 times, and then stored 
in sterile PBS with 1% protease inhibitors and 1% antibiotic/antimycotic (Pen-Strep). 
3.2.5 Mechanical Testing: 
The evaluation of biaxial mechanical properties of valve tissues was described 
previously(8). Briefly, square tissue samples (~ 12 mm × 12 mm) were trimmed from the 
anterior leaflet with one edge of the sample aligned along leaflet circumferential direction 
and the other edge aligned along leaflet radial direction. Thickness of each sample was 
measured three times using a digital caliper. Four markers were placed in the center of the 
sample and were tracked with a CCD camera to obtain biaxial tissue deformation. Samples 
were attached to eight loops of 000 polyester suture of equal length via stainless steel hooks 
(two loops each edge) and mounted on the biaxial testing system. Membrane tension 
(force/unit length) was applied along each orthogonal axis (aligned with circumferential 
direction or radial direction of tissue sample), and was ramped slowly from a 0.5 N/m pre-
load to a peak tension of 60 N/m. For testing, tissue sample was preconditioned for ten 
continuous cycles and followed by a 60 N/m equibiaxial tension protocol. Maximum 
stretch ratios along the circumferential direction (λcirc) and radial direction (λrad) were used 
to assess the tissue extensibility. The biaxial testing was performed with samples immersed 
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in a PBS bath (pH 7.4). For tensile testing, 50 mm-long samples were cut and thickness 
was measured using digital calipers. Samples were analyzed at a constant uniaxial velocity 
of 0.1 mm/s until failure using a 10 Newton load cell on a Synergie 100 testing apparatus 
(MTS System Corporation, Eden Prairie, MN). 
3.2.6 Differential Scanning Calorimetry: 
Thermal denaturation temperature (Td), was determined by differential scanning 
calorimetry (DSC, model 131 Setaram Instrumentation, Caluire, France) at a heating rate 
of 10°C/min from 20°C to 110°C in a N2 gas environment. Td was defined as the 
temperature at the endothermic peak(9). 
3.2.7 Cell Seeding and Cytocompatibility: 
PGG-treated scaffolds were equilibrated overnight in DMEM with 50% FBS, 1% 
antibiotics and seeded with human adipose tissue-derived stem cells (ASCs) internally and 
externally. For internal seeding, the base and free edges of the leaflets were inflated with 
sterile compressed air using a 33GA x 1½-inch needle, and then injected with 0.5 mL of a 
1x106 cells/mL cell suspension. For external seeding, a 0.5 mL of 1x106 cells/mL cell 
suspension was added dropwise to scaffolds and cells allowed to adhere for one hour; then 
each scaffold was submerged in media (DMEM with 50% FBS, 1% antibiotics, sterile 
filtered) and statically incubated for days. The viability of the cells after incubation was 
tested using the Live/Dead Viability/Cytotoxicity Assay Kit (Invitrogen) was used. 
3.2.8 Resistance to Collagenase and Elastase: 
Tissue degradation by collagenase and elastase was described previously36. 
Briefly, approximately 15 mg scaffold fragments were lyophilized and the dried samples 
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weighed. The samples were then incubated with 1 ml of 6.25U/mL type 1 collagenase in 
100mM Tris, 1mM CaCl2, 0.02% NaN3, pH 7.8 at 37°C, for 24 and 48 hours with agitation 
(n=6 per group). Similarly, 10U/mL elastase was used to test elastin stabilization. After 
removing the enzymes by centrifugation and rinsing in ddH2O, the samples were 
lyophilized and weighed. Resistance to enzymes was calculated as percent weight loss. 
3.2.9 Statistical Analysis: 
Results are expressed as means ± standard deviation (SD). Statistical analysis was 
performed using one-way analysis of variance (ANOVA). Differences between means 
were determined using the least significant difference (LSD) with an alpha value of 0.05. 
3.3 Results: 
3.3.1 Scaffold Preparation: 
Scaffold color and appearance were indicative of an effective removal of cellular 
material from the dissected mitral valves. Initially, these valves showed a red and brown 
color in each of the four tissue types, but after the decellularization procedure they became 
progressively paler, eventually becoming white and translucent (Figure 3.1A, B). Porcine 
mitral valves were treated with alkali, detergents, and nucleases in order to remove the 
cells, but maintain the fibrous matrix composition of leaflets and chordae; the resulting 
scaffold preserved all the valve components. 
Histological analysis of the decellularized scaffolds (Figure 3.2C) illustrated the 
removal of cells from the valve. To visualize the elimination of cells, sections of scaffolds 
and fresh mitral valves (leaflets and chordae) were stained with H&E and DAPI, which 
confirmed the complete removal of cellular components. In addition to these nuclear stains, 
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an immunohistochemistry (IHC) for actin, a common cellular protein, was performed for 
both the acellular scaffolds and fresh tissue. Decellularized scaffolds did not show positive 
for this protein, while fresh tissue did display the positive brown stain. To further validate 
the completeness of the decellularization, DNA was extracted from scaffold tissues and 
compared to the DNA content of fresh mitral valve tissues by electrophoresis, followed by 
densitometry. This analysis showed more than 96% DNA elimination from leaflets and 
chordae (Figure 3.1D). Quantification of DNA in the decellularized scaffolds with 
additional solutions, including DNase/RNase as described, resulted in further reduction of 
DNA content. Nanodrop analysis showed a significantly higher DNA content in the fresh 
mitral leaflets and chordae, about 500ng/mg fresh leaflet and chordae, and less than 
50ng/mg of ECM for both decellularized the leaflet and chordae. 
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Figure 3.1: Mitral valve decellularization. A) An aspect image of a fresh mitral valve still embedded in the 
left atrium of a porcine heart. B) A macroscopic aspect of a decellularized porcine mitral valve. Lack of 
coloring in the valve is indicative of removal of cellular material. C) Histological images indicating removal 
of all cellular components in the mitral valve leaflets and chordae tendinae. Fresh (native) and decellularized 
cross-sections of each tissue type are shown for comparison. These sections were stained with hematoxylin 
and eosin (H&E), which shows cell nuclei and background. Nuclei are shown in dark purple while 
background is shown in pink. Next sections were stained with DAPI, which also reveals nuclei in fluorescent 
blue dots. Last, and IHC for actin, a common cellular protein, was performed. Brown is an indicator for a 
positive stain, nuclei are stained purple. D) Ethidium Bromide agarose gel electrophoresis analysis was used 
from DNA extracted from fresh and decellularized leaflets and chordae. A standard was also included. Fresh 
samples are indicated with a “FL” for fresh leaflet, and “FC” for fresh chordae. Decellularized samples are 
indicated with a “DL” for decellularized leaflet and “DC” for decellularized chordae. No bands were detected 
for decellularized tissue verifying removal of all nuclear material from scaffolds. E) To quantify DNA content 
in each tissue type and for fresh and decellularized samples, a Nanodrop was used. Quantities of DNA for 
decellularized samples were significantly lower than fresh samples. In addition, each decellularized tissue 
was below 50ng of DNA. 
3.3.2 Evaluation of Scaffold Structure and Matrix Integrity: 
For a scaffold primarily comprised of collagen and elastin, preservation of these 
ECM components is critical for success of the scaffold. Collagen and elastin fibers, both 
crucial for maintaining valve shape and function, maintained their integrity in both leaflets 
and chordae after decellularization, as observed in sections stained with Movat’s 
Pentachrome (Figure 3.2A, F). VVG, a specific stain for elastin, showed intact elastin 
fibers in the atrial and ventricular side, as well as in the structure of chordae (Figure 3.2B, 
E). Glycosaminoglycans were removed together with the cells, forming typical “pores” in 
the tissue, necessary for cell repopulation; this is illustrated in the Movat’s Pentachrome 
108 
 
images for each tissue type. Basal lamina components, collagen IV and laminin, essential 
for cell adhesion, were detected using specific antibodies (Figure 3.2C, D). 
 
Figure 3.2: Histology of Mitral Valve Scaffold. To illustrate preservation of the extracellular matrix in the 
decellularized scaffolds, histology of fresh and decellularized leaflets and chordae were stained with Movat’s 
pentachrome, which shows nuclei (dark red), collagen (yellow), elastin fibers (maroon), and cytoplasmic 
proteins (red). To further illustrate the conservation of elastin fibers, these sections were stained with 
Verhoeff-Van Gieson’s (VVG) stain for visualization of nuclei (grey/black), elastin fibers (black), and 
collagen (pink). Loss of nuclei is illustrated as shown before, but these cross-sections show conservation of 
elastin and collagen in the decellularized scaffolds. An immunohistochemistry (IHC) for basal membrane 
proteins collagen IV and laminin were also performed with a positive stain showing in brown and nuclei 
showing in purple. Decellularized scaffolds stained positive for both basal membrane proteins. 
3.3.3 Scaffold Stabilization and Crosslinking Evaluation: 
The acellular scaffolds were treated with 0.3% PGG in order to stabilize the tissues 
and increase their strengths and resistance to degradation. Biaxial testing showed that 
decellularization significantly decreased the tissue stiffness in both the radial and 
circumferential directions, compared to fresh tissues (Figure 3.3A, B). Treatment with 
PGG, a polyphenolic compound that binds to proline-rich regions and induces the 
formation of crosslinks within the collagen and elastin molecules, contributed to the 
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increase of tissue stiffness, showing a doubling in elastic modulus for the chordae tendinae 
(from 23.4+/-4 MPa to 49.7+/-7 MPa) (Figure 3.3C). Differential scanning calorimetry 
(DSC) showed a slightly lower but statistically significant denaturation temperature (Td) 
for decellularized scaffolds when compared to the fresh tissue (66.4+/-6oC vs. 70.7+/-8oC) 
due to tissue destabilization after removal of cells). PGG-treated scaffolds exhibited 
significantly higher Td (84.5+/-9oC) possibly due to the increase in number of crosslinks 
(Figure 3.3D). 
 
Figure 3.3: Matrix stabilization in acellular mitral valves. Fresh, decellularized, and PGG-treated 
scaffolds were compared. A, B) biaxial stress-strain analysis of leaflets from each treatment type, were tested 
in the radial (X) and circumferential (Y) directions. Avg., average values for n=5. C) The elastic moduli of 
fresh, decelled and PGG-treated chordae were also measured. PGG-treated chordae had a significantly higher 
moduli than the other two groups. D) Differential scanning calorimetry (DSC) evaluation of fresh, decelled, 
and PGG-treated acellular leaflets was conducted. This measure of cross-linking in the scaffolds showed 
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PGG-treated samples to be significantly higher than fresh and decellularized groups. Td is the thermal 
denaturation temperature. *p<0.05 compared to fresh. 
Stabilization of the acellular mitral valve leaflet and chordae scaffold with PGG 
was further evaluated on its resistance to degradation by proteases. PGG-treated scaffolds 
were treated in collagenase and elastase for 24hr and 48hr treatments. These results were 
compared to fresh and untreated decellularized leaflet and chordae scaffolds. Results 
indicate that PGG significantly increases the resistance to degradation. Untreated decelled 
scaffolds were more readily degradable by both collagenase and elastase even compared 
to fresh tissues (Figure 3.4A, B). Treatment with PGG significantly reduced the scaffolds’ 
susceptibility to enzymes: by 5-fold to collagenase and more than 2-fold to elastase. This 
trend was true for both the 24 and 48-hour time points, but more pronounced in the 48-
hour time point. 
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Figure 3.4: Resistance to Proteases. Fresh, decellularized, and PGG-treated acellular mitral valve leaflets 
and chordae were compared based on their resistance to proteases. There was a 24 hour and 48 hour exposure 
time and these were compared for each tissue type and group. Values are expressed as percent dry weight 
loss after exposure to enzyme. # p<0.05 compared to fresh. A) Resistance to collagenase was evaluated. 
PGG-treated tissues showed significantly lower percent weight loss from exposure compared to fresh tissues. 
Decellularized tissues showed the greatest capacity to degrade for both time points. B) Resistance to elastase 
was evaluated. PGG-treated tissues also showed significantly lower percent weight loss from exposure to the 
enzyme when compared to fresh. # p<0.05 compared to fresh. Fresh tissues showed the greatest capacity to 
degrade from elastase for both time points. 
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3.3.4 Cell Seeding and Cytocompatibility: 
To evaluate the capacity for cells to survive on the PGG-treated scaffold, cells were 
seeded into and on the exterior of the scaffold. The acellular mitral valve scaffolds 
exhibited excellent compatibility toward hADSCs as demonstrated by the presence of 
viable cells after 3 days of incubation under static conditions (Figure 3.5A). Injected cells 
spread between the fibers of leaflets, as seen in the DAPI, H&E, and the Movat’s 
Pentachrome stained sections (Figure 3.5B, C, E). An IHC for vimentin, a protein known 
to be secreted by mesenchymal cells also showed positive (Figure 3.5D). Cells seeded on 
the surface maintained their viability and attached to the valve. 
 
Figure 3.5: Cell Seeding and Cytocompatibility. Cytocompatibility of acellular scaffolds. Representative 
images of PGG-treated scaffolds seeded with cells and analyzed 3 days after seeding to show 
cytocompatibility. A) Live/Dead staining was performed with green fluorescence showing living cells and 
red showing dead cells. B) DAPI nuclear staining to show nuclei within the tissue. C) H&E staining. D) An 
IHC for vimentin was performed, brown showing a positive stain for the protein. E) A Movat’s Pentachrome 
was also performed. 
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3.4 Discussion: 
3.4.1 Evaluation of Decellularization Efficiency and Characterization: 
 In this study, we have taken a thorough and systematic approach to establish a 
method to develop a tissue engineered mitral valve scaffold using decellularized porcine 
mitral valves. While decellularization of organs and other heart valves, including and 
especially the aortic valve, is not uncommon, very few groups have sought to develop a 
decellularized scaffold for mitral valves(6,7). This is despite a serious need for an improved 
valvular replacement. Utilization of this niche microstructure as an inductive scaffold has 
well established potential, however as mentioned a decellularized scaffold must meet 
several criteria. As mentioned above, the scaffold must remove cellular and nuclear 
materials according to standards set in current literature, conserve the extracellular matrix 
and the corresponding mechanical characteristics of native valve, and stability of the 
scaffold must be ensured. 
 Our choice of chemical agents was predicated on an already existing aortic valve 
decellularization protocol(10). In several pilot studies, we used differing time points and 
eventually different concentrations of the components of the detergent solutions and 
increased the concentration of the DNase/RNase solutions described above. Unique to the 
mitral valve are the four tissue types that one must account for in search for an optimized 
decellularization that removes xenogeneic cellular and nuclear material while still 
preserving the ECM. While not definitive, macroscopically there is a marked difference 
when comparing fresh valves, which have red and brown color to them, with the white and 
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sometimes translucent coloring of a decellularized valve. In our histological analysis, we 
sought to show complete removal of the cellular components. Each histological image 
shows the cross-section of the leaflet or the chordae tendinae. This is to ensure complete 
view of the ECM, especially to view the three layers of the mitral valve ECM. Lacking in 
each of the decellularized samples are the cells from the native valves. Pores are now 
present where these cells used to reside, these pores could eventually be replaced with 
seeded cells. To further elucidate cellular removal, an IHC for actin, a common cellular 
protein was shown to have zero expression in the decellularized scaffolds. As part of the 
criteria established by our group as well as in literature, removal of nuclear material is also 
essential for a successful decellularization. The ethidium bromide agarose gel 
electrophoresis performed showed no presence of DNA in both the leaflets and the chordae 
(Figure 3.1D). Densitometry showed about a 96% removal of DNA when compared to 
fresh controls. To further meet the decellularization criteria, more quantitative analysis was 
required. Therefore, the Nanodrop was utilized to measure DNA quantities in ng/mg of 
ECM. From this, we showed significant differences between fresh and decellularized 
samples when comparing DNA quantities. Badylak and his group have established that 
complete removal of all DNA from a scaffold would be impossible, but that an amount less 
than 50ng/mg of ECM would be acceptable. Both of our samples for leaflets and chordae 
meet these criteria (Figure 3.1E).  
3.4.2 Preservation of ECM and Basal Lamina Components: 
 While the elimination of cellular and nuclear material from the scaffold is 
paramount for the success of the scaffold, preservation of the existing niche ECM is of 
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equal importance. The ECM as mentioned is an inductive microstructure that can direct 
cells to migrate, proliferate, differentiate, or encourage apoptosis and degradation of the 
scaffold. The mechanotransductive cues delivered to cells via an intact mitral valve 
microenvironment are extremely significant to the reasoning in choosing this as a scaffold. 
Simply providing an array of collagen and elastin to seeded cells would inevitably render 
the scaffold useless and undiscernible as a mitral valve scaffold. Therefore, post-
decellularization analysis must evaluate how this process affected the complex collagen 
and elastin matrix after cellular and nuclear materials were removed. This is true for each 
tissue type under consideration within the mitral valve apparatus. 
 Results from several histological stains performed show a preserved mitral valve 
ECM. Movat’s Pentachrome, which stains for many matrix components, showed a loss of 
GAGs; however, this is expected after using the detergent solution used in the 
decellularization protocol. The two main structural proteins, collagen and elastin however 
remained. As seen in the comparison between the fresh and decellularized leaflet and 
chordae, the structure of collagen and elastin remain. A VVG stain was done specifically 
to visualize the elastin in the scaffold. Overall, the quantity and quality of the elastin seems 
to have remained intact after decellularization. This is important because in degenerative 
valves, elastin, as well as collagen, are fragmented and could lead to mitral valve prolapse 
and insufficiency(11). Also pertinent to ECM conservation was retaining the basal lamina 
predominantly collagen type IV and laminin. Studies have shown that an intact basal 
lamina provides a scaffold along which cells can migrate, proliferate and regenerate 
damaged tissues(12–14). An IHC was performed for both of these basal lamina proteins for 
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each tissue type in fresh and decelled samples. As expected, the fresh samples stained 
positively for collagen type IV and laminin. This was also true for the decellularized 
samples. Therefore, our scaffolds after undergoing decellularization are not only acellular 
and lack nuclear material, but we were able to retain basal lamina proteins that are essential 
for a successful recellularization. Not only did we preserve these proteins, but the overall 
architecture of the heart valve ECM in both the leaflets and the chordae tendinae. 
3.4.3 Evaluation of the Scaffold’s Durability: 
 The mitral valve conducts a complex mechanical performance with the mitral valve 
structures and requires the integrity and durability of strong collagen and resilient elastin 
fibers(15,16). As mentioned, a tissue engineered mitral valve would be expected to operate 
in a harsh environment of continual and repetitive stresses brought on by the demands of 
the heart. Therefore, a decellularized scaffold must be able to withstand these forces 
immediately upon implantation. Translatability of this project depends on this immediate 
functionality for patients. Accordingly, after evaluating the preservation of the ECM, we 
tested the durability of the decelled scaffold and the effect PGG treatment had on them. 
PGG, used before for the stabilization of aortic valve scaffolds, was used here for the first 
time for the stabilization of the complex and heterogeneous structure of the mitral valve. 
Biaxial mechanical testing was performed on three groups, fresh, decell, and PGG-treated 
decelled scaffolds (Figure 3.3A, B). From this, we can see that the decellularization 
process does in fact decrease the strength of the tissue when compared to the fresh samples. 
Treatment with PGG increased the mechanical strength of the scaffolds in both the 
circumferential and radial direction slightly higher than native valves. PGG also increased 
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the modulus for the chordae tendinae in comparison to the untreated-decelled chordae. 
Weak and enlarged “floppy” leaflets are often associated with chordal elongation, thinning, 
and/or rupture. Therefore, chordal modulus is important for the valve’s overall coaptation. 
Differential scanning calorimetry (DSC) was used to evaluate crosslinking within the 
scaffolds when compared amongst fresh, decelled, and PGG-treated samples. PGG-treated 
samples yielded a significantly higher thermal denaturation temperature when compared 
to the decelled group. This is related to the preservation of the integrity of the collagen and 
elastin fibers. An evaluation of the scaffold’s durability must also consider withstanding a 
host response from the patient. Most of the natural and untreated tissues used in scaffolds 
elicit a host response and are prone to degradation post-implantation(17). Because the mitral 
must undergo large and repetitious forces during a patient’s lifetime, the scaffold must be 
able to withstand degradation, degenerative pathologies will ensue, or the construct will 
fail altogether. In either case, failure of valvular coaptation would persist and the multiple 
mechanisms in the mitral apparatus would fail to operate properly. Treatment with PGG 
has shown to circumvent these issues. We evaluated (Figure 3.4A, B) the effectiveness 
PGG would have on degradation of scaffolds treated with the proteases collagenase and 
elastase. Fresh, decelled, and PGG-treated acellular scaffolds were compared at both 24 
and 48-hour treatments. Remarkably, PGG-treatment significantly increased resistance to 
degeneration of the scaffolds at both time points. The untreated decelled scaffolds were the 
most prone to degeneration when exposed to collagenase, and the fresh tissues were the 
most prone to degeneration when treated with elastase. It appears the decellularization 
process does affect a scaffold’s degeneration potential and perhaps affects the structural 
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proteins collagen and elastin differently, as evidenced the differences in degradation. The 
increased resistance of PGG-treated scaffolds to the activity of proteases confirms the 
integrity of these macromolecules. These results may be significant as it was demonstrated 
that fragmented elastin is prone to calcify in cardiovascular tissues, such as the aortic 
wall(18). In fact, varying degrees of calcification are found in the mitral valve annulus of 
degenerating valves. PGG in previous studies has shown to significantly decrease 
calcification of implanted tissues, and while this was not tested with the present study, we 
anticipate that the tissue-engineered mitral valve would be protected from in vivo 
calcification(9). 
Besides optimal physical properties and durability, the collagen and elastin-based 
scaffolds proved to be cytocompatible. The paradigm with which our lab operates 
advocates for recellularization of the scaffold and construct pre-conditioning in a 
bioreactor. Therefore, human adipose derived stem cells were seeded into and on the PGG-
treated scaffold to assess their potential to survive (Figure 3.5). Live/Dead images as well 
and nuclear staining showed that not only can cells thrive on the scaffold, but we also have 
the capacity to seed the scaffold interstitially. This was imperative to the further aims 
presented. In addition to their survival, the cells appeared to synthesize a layer of GAGs, 
which we interpreted as constructive remodeling of the leaflets (Figure 3.5E). This cell-
matrix interaction is the key to the success of this scaffold. The positive remodeling 
observed by the initial cell seeding we believe is a result of the well-preserved biochemical 
composition of the scaffolds, as well as its architecture. 
3.5 Conclusions: 
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 An effort was made to develop an acellular scaffold that provided cells with a tailor-
made and inductive scaffold for regeneration of the mitral. To achieve this, porcine mitral 
valves were rid of cellular and nuclear materials successfully without damaging the 
existing extracellular matrix composition and structure. DNA levels remaining in the 
scaffold were well below values established in literature as acceptable. Basal lamina 
proteins collagen type IV and laminin were preserved which will provide a means for the 
eventual recellularization of the scaffolds. After the scaffolds were decellularized, they 
were stabilized with PGG. PGG, by virtue of tis collagen and elastin-stabilizing abilities 
preserved the composition and structure of the ECM of the acellular leaflets and chordae, 
required by the valve’s complex mechanical effort. In mechanical and DSC testing, PGG-
treated scaffolds provided acceptable mechanical and crosslinking characteristics similar 
to native tissues and statistically different when compared to decellularized scaffolds. Once 
implanted, these scaffolds would inevitably undergo a host response and exposure to 
proteases. Treatment with PGG provided significant protection from collagenase and 
elastase confirming their ability to protect against degradation from an expected host 
response. PGG-treated scaffolds also were able to support cell survival and remodeling 
thus confirming their potential as a great mitral valve scaffolds. 
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CHAPTER 4 – EVALUATION OF THE HOST RESPONSE TO IMPLANTED MITRAL 
VALVE SCAFFOLDS 
4.1 Introduction: 
Mammalian host response is an integral consideration and ultimate determinant of 
an implantable biomaterial’s success; this is especially true with tissue-engineered 
constructs. In discordance with the conventional goal for a biomaterial’s “inertness”, a 
tissue engineered construct instead aims to employ the immune response as a means to 
integrate these constructs with the patient for repair and ultimately regeneration of the 
damaged tissue. The advent of tissue engineering has modified the accepted principles for 
a host’s response to implanted materials. These constructs support cellular attachment, 
migration, viability, growth and encourage differentiation of a variety of cell types. 
Decellularized matrices, such as our mitral valve scaffold, need to modulate the innate 
immune response and thereby control the release of bioactive molecules and its own 
degradation to eventually support functional replacement of the tissue(1). The functional 
outcome of this scaffold is ultimately determined by the elicited host response and the 
subsequent effects on the scaffold(1,2). This is especially true for a tissue engineered mitral 
valve, as it undergoes demanding mechanical loading at the immediacy of its implantation. 
These arduous and repetitious mechanical forces, when considered in the realm of tissue 
engineering, are perhaps exclusive to the heart valve. Accordingly, degradation and 
remodeling of the heart valve scaffold must be evaluated within the innate immune 
response. Constructive remodeling, as defined by Badylak’s group, is the process by which 
a construct is completely degraded and eventually replaced by appropriate and newly 
native functional tissue(2). An implanted mitral valve construct must be able to facilitate 
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gradual constructive tissue remodeling within its environment. This outcome is dependent 
upon a favorable response from the host’s immune system, which is largely a function of 
macrophage polarization. 
Immediately following implantation, the process of tissue remodeling begins and a 
robust macrophage response ensues beginning with the infiltration of neutrophils and 
monocytes(2–5). These monocytes will then differentiate into two broad, polarized 
categories of macrophages. Differentiation leads to either the pro-inflammatory, M1 
macrophage, or the pro-healing, M2 macrophage(1,2,6–9). A successful functional outcome 
is conditional upon how these macrophages receive the microstructure they have invaded 
and their plans for degradation and remodeling. Polarization into either phenotype is 
context specific and is contingent upon the highly complex ECM scaffold in which the 
remodeling is taking place. M1 macrophages are the pro-inflammatory and cytotoxic 
macrophage phenotype and promote pathogen killing within the wound site. They also 
function to debride the implant site of dead cells and damaged tissues. This phenotype is 
induced by the well-known pro-inflammatory signals and cytokines IFN-γ and TNF-α.(1,6). 
They in turn produce additional pro-inflammatory cytokines IL-1β, IL-6, IL-12, IL-23, and 
TNF-α(1,8). These activated macrophages produce high levels of induced nitric oxide 
synthase (iNOS) and secrete toxic levels of reactive oxygen species (ROS), while also 
acting as inducer and effector cells for Th1 type inflammatory responses(2). The M2 
macrophage phenotype is characterized as the pro-healing macrophage and is typified by 
expressing IL-12, IL-23, and IL-10(1,8). It can be induced by several different factors the 
most common of which are the cytokines IL-4, IL-13, and IL-10(1,6,8). These “alternatively 
123 
 
active” macrophages express high levels of receptors that resolve inflammation such as 
scavenger, mannose, and galactose receptors(2). More specifically, there are three M2 sub-
phenotypes, M2a, M2b, and M2c each with their own inducers and markers(2,6,10,11). 
Despite these sub-phenotypes, macrophage polarization generally refers to the polar 
extremes of the pro-inflammatory M1 and the anti-inflammatory M2 macrophage(10,11). 
This polarization is driven by cues in the microenvironment from the ECM scaffold(12). 
While the directors of macrophage phenotype are not fully understood, enough is known 
about these populations that specific markers can identify them. M1 macrophages are 
distinguished by iNOS, CD80, and CCR7 while M2 macrophages are identified by CD163, 
CD206, and Fizz1/Ym(7–9). Macrophages are also a plastic cell population capable of 
changing their polarization based on the stimuli they receive during the process of wound 
healing(8). To date, most strategies that employ a more balanced polarization between M1 
and M2 macrophages or a predominantly M2 macrophage presence have shown to illicit 
the most successful functional outcomes(1). Therefore, it would greatly benefit a mitral 
valve construct to tip the scales of immune response to an anti-inflammatory, M2 
phenotype. Knowing too that the presence of an M1 phenotype is necessary and not fully 
discouraged. Therefore to encourage a more desirable and tunable constructive remodeling 
our group turned to Penta-galloyl glucose (PGG). 
PGG, is a well characterized polyphenol which exhibits high affinity for proline-
rich proteins like collagen and elastin(13). PGG has a high affinity towards these proteins 
due to its polyphenol shape(14). As mentioned previously, this gravitation towards collagen 
and elastin made PGG an ideal scaffold stabilizer and actually impeded degradation by a 
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factor of about 50(15). PGG has also has been reported to have many beneficial effects such 
as antioxidant, anti-diabetic, and anti-inflammatory activities(14,16–20). The protective 
effects of antioxidants for endothelial and vascular aspects are well known(21–24). Tannins, 
like PGG, are also good modulators of antioxidants and it can act as a radical scavenger 
and sink. Studies have shown that this free radical scavenging ability can inhibit lipid 
peroxidation induced by hydrogen peroxide(25). PGG has also been shown to debilitate pro-
inflammatory cytokines, TFN-α and IL-6, both of which are pertinent in macrophage 
polarization(26). In addition, the antioxidant properties of this multifaceted polyphenol also 
act as a means of regulating reactive oxygen species (ROS). 
Ultimately, the goal of this study was to evaluate our scaffold’s potential for a 
functional outcome, evaluate constructive remodeling of the construct and of course assess 
biocompatibility of the mitral valve scaffold. This was done by completing a 4 and 8 week 
rat subdermal implant study using PGG-treated and non-treated decellularized scaffolds. 
Our group evaluated cellular infiltration to see what types of cells inhabited the scaffolds, 
macrophage polarization and degradation of the scaffolds. Each of these were compared 
between the PGG and non-treated scaffolds. The host response in this study the key 
determinant of the functional outcome and translatability of this scaffold from bench to 
bedside. By successfully traversing the host response and attenuating a pro-inflammatory 
response in favor of a pro-healing and remodeling response, this mitral valve scaffold with 
the aid of PGG has a chance at a successful functional outcome. 
4.2 Methods and Materials: 
4.2.1 Histology and Immunohistochemistry: 
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Rehydrated paraffin sections (5µm) were stained with Hematoxylin and Eosin 
(H&E), and Movat’s Pentachrome according to the instructions in the kits purchased from 
Poly Scientific R&D Corp. (Bayshore, NY). 4',6-diamidino-2-phenylindole (DAPI) was 
purchased from Sigma-Aldrich Corporation (Lakewood, NJ). 
Immunohistochemistry (IHC) was performed on formalin-fixed and paraffin-
embedded sections using heat-mediated antigen retrieval (10mM citric acid at pH of 6, for 
10 min at 90°C), followed by exposure to 0.025% Triton X-100 for 5 minutes. After 
incubation in normal blocking serum for 45 minutes, the primary antibodies diluted to 
2μg/mL were applied overnight at 4°C in a humidified chamber. The following antibodies 
were used: mouse anti-α-Smooth Muscle Actin (Abcam, Ab7817), rabbit anti-SM22 
(Abcam, Ab14106), rabbit anti-Calponin (Abcam, Ab46794), rabbit anti-Vimentin 
(Abcam, Ab92547), rabbit anti-HSP-47 (Abcam, Ab77609), rabbit anti-P4HA3 (Abcam 
Ab101657). Negative controls were obtained by omitting the primary antibodies. The 
Vectastain Elite kit and the ABC diaminobenzidine tetrahydrochloride peroxidase 
substrate kit were purchased from Vector Laboratories (Burlingame, CA). Sections were 
counterstained with a diluted hematoxylin prior to mounting. Images were obtained at 
various magnifications on a Zeiss Axiovert 40CFL microscope using AxioVision Release 
4.6.3 digital imaging software (Carl Zeiss MicroImaging, Inc. Thornwood, NY). 
4.2.2 Penta-galloyl glucose (PGG) Treatment: 
High-purity 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose (PGG) was a generous gift 
from N.V. Ajinomoto OmniChem S.A., Wetteren, Belgium (www.omnichem.be). The 
acellular scaffolds were treated with sterile 0.3% PGG in 50mM Na2HPO4, 0.9% NaCl, pH 
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5.5 containing 20% isopropanol overnight at room temperature under agitation and 
protected from light. Scaffolds were then rinsed with sterile PBS 3 times, and then stored 
in sterile PBS with 1% protease inhibitors and 1% antibiotic/antimycotic (Pen-Strep). 
4.2.3 In vivo Biocompatibility: 
Acellular leaflet and chordae scaffold samples, treated with PGG and non-PGG 
treated, were prepared as described above. A 10mm diameter sterile biopsy punch was then 
used to cut equally, sized biopsy punch was then cut equally sized leaflet samples for 
implantation. Equally sized chordae samples were also chosen. Before implantation, the 
samples were sterilized in 0.1% (w/v) peracetic acid in PBS for 1h, followed by rinsing in 
four changes of sterile PBS. 
In accordance with an IACUC-approved animal use protocol, 52 juvenile Sprague-
Dawley rats were anesthetized with buprenorphine at 0.03-0.05 mg/kg and acepromazine 
at 0.5 mg/kg administered subcutaneously. A small incision was made in the center of the 
dorsal area of each rat about 2 cm inferior to the scapulae, and, using blunt dissection, two 
pockets were created between the dermis and fascia lateral to the incision (one pocket in 
each direction). A scaffold sample was placed into each pocket, and the incision was closed 
using staples. Thirteen rats received non-treated, decellularized scaffolds, and the 
remaining 13 received PGG-treated decellularized scaffolds. This was true for both tissue 
types, mitral valve leaflet and chordae tendinae. Rats were allowed to recover and were 
housed individually for the remainder of the study. At 4 weeks 24 rats were euthanized and 
at 8 weeks, the remaining 28 were euthanized, both via CO2 gas (Euthanex system) 
followed by pneumothorax. Scaffold samples and small amounts of their adjacent host 
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tissues were excised and fixed in 10% neutral buffered formalin and processed for 
histological examination. 
4.2.4 Gelatin Zymography: 
MMP activity was determined by gelatin zymography: 6µg proteins/lane were 
loaded in triplicated on ready to use BioRad gels, alongside pre-stained molecular weight 
standards. After development and staining with Coommassie Blue, the MMP clear bands 
on a dark blue background were evaluated by densitometry and expressed as relative 
density units. Electrophoresis apparatus and imager, chemicals, and molecular weight 
standards were all purchased from BioRad. 
4.2.5 IHC Quantification: 
Relative quantification for immunohistochemistry stains were performed on 
ImageJ (provided by NIH) using the ImmunoRatio plugin. This was developed by 
Touminen and Isoloa, University of Tampere, Finland. The quantities expressed here are a 
percentage of DAB expressed to the nuclear area or ECM area shown. This depends on the 
stain type used, i.e. a cellular or matrix stain. Each image was individually adjusted for the 
blue threshold (nuclei) and brown threshold (DAB) to fine-tune each component. 
Instructions for how to use this plugin were provided and followed. 
4.2.6 Statistical Analysis: 
Results are expressed as means ± standard deviation (SD). Statistical analysis was 
performed using one-way analysis of variance (ANOVA). Differences between means 
were determined using the least significant difference (LSD) with an alpha value of 0.05. 
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4.3 Results: 
4.3.1 Explantation and Histological Evaluation of the ECM: 
 Decellularized scaffolds, both untreated and PGG-treated, were explanted from the 
52 rats at 4 and 8-week time points. At explantation, there was a marked difference in 
degradation between the PGG-treated and untreated samples with the greatest visible 
difference at the 8-week time point. Macroscopic evaluation of the explanted tissue, as 
shown in Figure 4.1, displays this difference in degradation of the scaffolds. It is also 
apparent that PGG-treatment leaves a distinct coloration of the tissue. This was true at both 
the 4 and 8-week time points. 
 
Figure 4.1: Macroscopic Evaluation of Explants. Following explantation, non-treated and PGG-treated 
groups for each tissue type were examined. PGG-treated groups appeared less degraded and noticeably 
colored as compared to the non-treated samples. This coloration made the PGG-treated groups easier to find 
and retrieve at the end of the in vivo study. 
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Figure 4.2: MMP Activity of Implanted Scaffolds. To evaluate degradation of the non-treated and PGG-
treated acellular scaffolds, a gelatin zymography was performed. Quantities of band volume were determined 
and plotted. At 4 weeks, non-treated samples have a higher MMP activity than PGG-treated samples. 
Similarly, at 8 weeks, non-treated leaflets and chordae are significantly higher than PGG-treated tissues. It is 
apparent that at longer time points the difference in degradation increases as scaffolds are subject to a longer 
exposure to the host response. 
Figure 4.3 displays the zymography gels that were quantified in Figure 4.2. As 
evidence by the gel, non-treated samples expressed both MMP9 and MMP2. However, in 
the PGG-treated tissues, only bands for MMP9 were detected. This is in congruence with 
the quantified data presented above describing the MMP expression to be signifincalty 
higher in the non-treated samples when compared to the PGG-treated groups. 
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Figure 4.3: Gel Zymography for Non-treated and PGG-Treated Implanted Scaffolds. A gel zymography 
was done and quantified in Figure 4.2. The non-treated (NT) samples clearly show presence of both MMP9 
and MMP2 markers. PGG-treated samples display only the expression of MMP9 markers. 
Most scaffolds treated with PGG were easily recoverable, however some untreated 
scaffolds were difficult to find due to their reduced size. Although not shown here, PGG-
treated samples had a brown residue around it from the PGG, while untreated samples did 
not. Aside from this macroscopic evaluation of degradation, a gelatin zymography was 
performed to determine and quantify MMP activity within the scaffolds at each time point. 
As seen in Figure 4.2A, B, non-treated acellular scaffolds exhibit significantly higher 
MMP activity when compared to PGG-treated scaffolds. This was especially true for the 
8-week time points.  
Histological analysis using H&E and Movat’s Pentachrome staining was used to 
evaluate the integrity of the ECM after implantation. As seen in Figure 4.4, PGG-treated 
tissues were well preserved at both the 4 and 8-week time points. Movat’s Pentachrome 
shows good preservation of elastin bands and of the collagen. Similarly, non-treated 
samples largely showed a good preservation of both collagen and elastin.  
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Figure 4.4: Histological Evaluation of Scaffold ECM Post-Implantation. H&E and Movat’s Pentachrome 
were performed on explanted scaffolds. Leaflet and chordae sections are shown here. These scaffolds were 
implanted as either non-treated or PGG-treated acellular scaffolds. Both 4 and 8-week time points are also 
shown here. As evidence by these histological stains, ECM were largely preserved in both the non-treated 
and PGG-treated scaffolds for both tissue types and at both time points. Also, as these were originally 
acellular scaffolds, cellular invasion is apparent in these histological images. 
The presence of cells is clearly visible from each section in Figure 4.4. Since these 
scaffolds were implanted as acellular, it is apparent that invasion of host cells has taken 
place at each time point. Figure 4.5 shows a semi-quantitative measure of the amount of 
cells invading each scaffold, represented as a normalized percentage of the area of the 
section imaged.  
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Figure 4.5: Cellular Infiltration into Scaffolds. A semi-quantitative measure was taken to evaluate quantity 
of cells invading into the implanted scaffolds due to the normal host response. Values here are represented 
as a normalized percentage of the collective area of the cells as compared to the area of the tissue in each 
section imaged. Overall, there were no significant differences between PGG and non-treated groups for each 
tissue type. 
As evidenced by Figure 4.5 there is no significant difference between PGG and non-treated 
scaffolds. Therefore, PGG treatment of our acellular scaffolds did not hinder infiltration of 
cells from the host response. 
4.3.2 Histological Evaluation and Identification of Cellular Presence: 
 To garner a better understanding of how the host cells reacted to the implanted 
scaffolds and whether PGG treatment affects inflammatory cell infiltration, we analyzed 
the scaffolds and stained with CD8, a marker for T-cells, and CD68, a pan-macrophage 
marker. IHC for CD8 showed a presence of T-cells in each scaffold type and under each 
treatment type (Figure 4.6). Although there was a significant difference found between 
non-treated and PGG-treated groups. In both 4 and 8-week time points, CD8 expression 
was found to be significantly higher in non-treated scaffolds. This was especially apparent 
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during the 4-week time point because, while still statistically significant, at 8 weeks the 
contrasting levels of CD8 expression were not so wide. PGG treatment of scaffolds 
appeared to strongly discourage T-cell infiltration, but it did not completely inhibit it. CD68 
expression for macrophages was also found in all scaffolds and treatment types. There were 
not significant differences between groups (Figure 4.7). While not statistically significant, 
there was a lower overall expression of CD68 in PGG-treated tissues.  
 
Figure 4.6: Histological Evaluation and Semi-Quantitative Analysis of CD8 Expression. T-cell 
infiltration was determined using an IHC for CD8. Expression of CD8 at both the 4 and 8-week time points 
is shown as well as each treatment type and tissue type. A semi-quantitative analysis of these images (n=6) 
showed significant differences in CD8 expression. PGG-treated scaffolds showed significantly less 
expression of CD8 at both the 4 and 8-week time points. 
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Expression of smooth muscle cell marker, α-Smooth Muscle Actin (α-SMA), was 
evaluated to determine the infiltration of smooth muscle cells into the scaffolds and PGG’s 
effect on this infiltration. Overall, PGG-treated scaffolds showed a markedly lower 
expression of α-SMA at both time points in the leaflets and chordae when compared to 
treated samples (Figure 4.8). While not shown, similar results for other smooth muscle 
cell markers, SM22 and calponin were found, with PGG treatment significantly reducing 
their expression. Markers for fibroblasts such as vimentin (Figure 4.9), HSP-47, and prolyl 
4-hydroxylase were also shown to be expressed at significantly higher levels in PGG-
treated tissues as compared to their untreated counterparts at both time points. It is 
important to note that these differences in expression do not mean that expression of each 
of the aforementioned markers did not occur. In each of the histological figures presented 
in herein, expression of each marker is clearly present. 
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Figure 4.7: Histological Evaluation and Semi-Quantitative Analysis of CD68 Expression. Macrophage 
infiltration was determined using an IHC for CD68. Expression of CD68 at both the 4 and 8-week time points 
is shown as well as each treatment type and tissue type. A semi-quantitative analysis of these images (n=6) 
showed no significant differences in CD68 expression. PGG-treatment did not seem to hinder infiltration of 
macrophages into the scaffolds at either time point. 
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Figure 4.8: Histological Evaluation and Semi-Quantitative Analysis of α-SMA Expression. α-SMA 
expression was determined using an IHC. Expression of α-SMA at both the 4 and 8-week time points is 
shown as well as each treatment type and tissue type. A semi-quantitative analysis of these images (n=6) 
showed significant differences in α-SMA expression. PGG-treated scaffolds showed significantly less 
expression of α-SMA at both the 4 and 8-week time points. 
137 
 
 
Figure 4.9: Histological Evaluation and Semi-Quantitative Analysis of Vimentin Expression. Vimentin 
expression was determined using an IHC. Expression of vimentin at both the 4 and 8-week time points is 
shown as well as each treatment type and tissue type. A semi-quantitative analysis of these images (n=6) 
showed significant differences in vimentin expression. PGG-treated scaffolds showed significantly greater 
expression of vimentin at both the 4 and 8-week time points. 
4.3.3 Histological Evaluation of Macrophage Polarization: 
 As mentioned above, a statistically significant difference was not found between 
groups using the pan-macrophage marker, CD68. This however does not mean that the 
treatment groups experience the same inflammatory response. Therefore to illustrate the 
different macrophage phenotypes present within each treatment type, an IHC and semi-
quantitative analysis for iNOS (M1) and CD163 (M2) were performed. As seen in Figure 
4.10, expression of the M1 macrophage, with the iNOS marker, was significantly higher in 
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untreated groups at both the 4 and 8-week time points. PGG seems to discourage 
macrophage polarization towards the M1, or pro-inflammatory phenotype. In comparison, 
PGG-treated groups showed significantly higher expression of the M2 marker, CD163 at 
both time points (Figure 4.11). While discouraging the M1 macrophages, treatment with 
PGG seems to encourage the pro-healing M2 macrophages. 
 
Figure 4.10: Histological Evaluation and Semi-Quantitative Analysis of iNOS Expression. iNOS 
expression was determined using an IHC. Expression of iNOS at both the 4 and 8-week time points is shown 
as well as each treatment type and tissue type. A semi-quantitative analysis of these images (n=6) showed 
significant differences in iNOS expression. PGG-treated scaffolds showed significantly less expression of 
iNOS at both the 4 and 8-week time points. 
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Figure 4.11: Histological Evaluation and Semi-Quantitative Analysis of CD163 Expression. CD163 
expression was determined using an IHC. Expression of CD163 at both the 4 and 8-week time points is shown 
as well as each treatment type and tissue type. A semi-quantitative analysis of these images (n=6) showed 
significant differences in CD163 expression. PGG-treated scaffolds showed significantly greater expression 
of CD163 at both the 4 and 8-week time points. 
4.4 Discussion: 
4.4.1 General Observations and Integrity of the Scaffolds: 
 Biological scaffolds comprised of niche ECM proteins have been used in a wide 
variety of tissue engineering applications(2,27). The combination of natural components and 
specific microstructure assist in cell attachment and proliferation while promoting distinct 
functionalities relevant to that tissue type. Cellular residents in the ECM structure are 
depended upon to remodel the scaffold during development and wound repair. As such, 
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matrix composition and organization are a function of the adaptation of the cells and their 
reaction to the mechanical and chemical cues they are receiving from the 
microenvironment(28). This interaction between matrix and cells is crucial for the success 
of the construct due to their codependency(28). Investigating biocompatibility in an in vivo 
study, would allow for an evaluation on how infiltrating host cells respond to an ECM 
scaffold. As mentioned earlier, this reaction between host cells with the ECM scaffold is 
the predominant determinant for the scaffold’s success(2). Biocompatibility is a term that 
has evolved during the advancement of biomaterials from inert to bioactive implants. For 
regenerative medicine applications, biocompatibility could be defined as “the ability of a 
biomaterial to perform its desired function with respect to a medical therapy, without 
eliciting any undesirable local or systemic effects in the recipient or beneficiary of that 
therapy, but generating the most appropriate beneficial cellular or tissue response in that 
specific situation, and optimizing the clinically relevant performance of that therapy”(29). 
In our mitral valve scaffold specifically, a balance must be achieved between slight 
degradation and remodeling by cells. In the studies presented here, we show the critical 
relationship between our mitral valve scaffold and the host cellular response in an in vivo 
rat study.  
 Macroscopically, non-treated scaffolds were noticeably more difficult to retrieve 
upon explantation. This was in large part due to their degradation while subcutaneously 
implanted. PGG-treated samples in contrast, were easy to recover and were significantly 
less degraded at both the 4 and especially the 8-week time point. To obtain a finer 
understanding of the quality of the ECM scaffold after each time point, each sample was 
141 
 
examined microscopically. As evidenced in Figure 4.4, when examined histologically, 
overall the ECM quality did not appear to be significantly disturbed. H&E and Movat’s 
Pentachrome staining showed decent preservation of collagen microstructure. On the 
whole, PGG-treated leaflets and chordae did look the least degraded. Regardless of 
treatment, this is important for the scaffold and its influence on the incorporated cells. As 
mentioned ECM quality is crucial as it acts as an inductive scaffold(28). Upon further 
examination of the ECM in this figure, elastin quality seems to have diminished in the non-
treated samples. This is important to note because degradation of elastin in cardiovascular 
tissues, has shown to encourage calcification at these sites(15,30,31). While we did not find 
evidence of calcification (not shown), it is likely a different model, particularly one with 
mechanical stimulation, would have shown calcification in these non-treated groups. 
 Degradation of an ECM scaffold, such as our own, is an inevitable if not necessary 
outcome for the eventual success of the scaffold. Constructive remodeling, as defined 
earlier, is a process which must occur for our mitral valve scaffold to be successful(6). 
However, for heart valves, this process must be gradual. Upon implantation, tissue 
engineered valves would be expected to face the strong and repetitive forces experienced 
by this tissue. To survive this, degradation of the scaffold must be limited and gradual over 
time. Therefore, we incorporate PGG as a treatment to hinder degradation of the scaffold. 
Several papers from our group alone have shown the benefits of treating with PGG, 
especially its ability to significantly reduce degradation(20,30,32–34). Matrix degradation can 
lead to several compounding effects on the infiltrating host cells and of course the matrix 
itself. Circulating immune cells rely upon matrix degradation for access into the 
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microstructure to encourage an inflammatory response. As such, these cells release 
enzymes called matrix metalloproteases, or MMPs. There are several MMP phenotypes, 
but common types are secreted by T-cells(35–37). Inflammatory mediators like TNF-α also 
stimulate expression of MMP’s in macrophages(38,39). During degradation of the matrix by 
MMPs, many matrikines and cytokines are released upon ECM molecule degradation or 
conformation change. These matrikines have been shown to increase TGF-β1 expression, 
a known activator of fibroblasts, as well as further expression of MMPs(34,35). When 
examining our samples for degradation, a zymography gel was run with PGG and non-
treated samples (Figure 4.2) to examine MMP quantities. Overall, levels of MMP’s were 
significantly higher in untreated samples when compared to PGG-treated samples. PGG, 
while not able to completely inhibit MMP degradation, which we were not aiming to do, 
was able to decrease the amount of degradation by decreasing the expression of these 
matrix-degrading enzymes. A decreased level of MMP could also be indicative of 
decreased levels of T-cells and other inflammatory markers such as TNF-α. The 
stabilization effect of PGG also decreased the availability of degrading matrikines and 
cytokines, which as a result were not able to encourage further degradation of our ECM 
mitral valve scaffold. 
 As shown in Figure 4.4, host cells were in fact able to penetrate the scaffolds at 
each time point and for each treatment of the scaffold. Cellular infiltration is indicative of 
many things including cytocompatibility, porosity, and migration potential with the 
scaffold. Quantification of the infiltrating cells (Figure 4.5), showed no significant 
difference between treatment groups. This was true at both time points. Therefore, PGG-
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treatment of our scaffold does not hinder infiltration of host cells after implantation, thus 
allowing for a normal host response. In this subdermal study, repopulation of these 
acellular scaffolds with host cells is needed for remodeling. 
 While no significant difference was found between the PGG and non-treated 
samples regarding the infiltration of cells, there did seem to be a difference in cell quantity 
between the 4 and 8-week time points. The decrease found for the 8 week time points is 
most likely due to the shift in pro-healing phase of the macrophage polarization. At this 
later time point, most of the initial cellular infiltration and inflammatory response to the 
foreign scaffold had completed and the transition to a pro-healing, and the majority of 
macrophages displayed an M2 phenotype. 
4.4.2 Evaluation of Immune Response: 
 An immune response to an implanted device or material is a key component to 
evaluating biocompatibility. Immune responses can initiate or propagate inflammatory 
action from the host. Significant or prolonged inflammation for an ECM scaffold would 
undoubtedly yield failing results. In our study, macroscopically (Figure 4.4), cardinal signs 
of inflammation were not present. We did not see an extreme density of invading cells in 
the scaffolds, nor did we see the presence of foreign giant body cells (FGBCs). PGG-
treated samples did not see a significant increase in vascularity either. Decellularized ECM 
scaffolds can induce an inflammatory response due to improper or incomplete 
decellularization resulting in the presence of xenogeneic antigens like α-gal. Also, an 
incomplete removal of the treatments used for decellularization can lead to failure of the 
scaffold due to inflammation. Overall, however we did not see any indications of an 
144 
 
aggressive inflammatory response from the host. One measure we also looked at was the 
presence of T-cells in the scaffolds. These T-cells or lymphocytes are present in and play 
important roles in the inflammatory response. These T-cells increase MMP’s within the 
tissue they are invading, actively recruit macrophages to the site, and as a result, a cascade 
of reactions including degradation of the tissue ensues. To investigate whether PGG 
treatment had an effect on T-cell recruitment we looked for CD8 expression, a marker for 
T-cells. As seen in Figure 4.6, at both the 4 and 8-week time points, PGG consistently and 
significantly reduced CD8 expression in the scaffolds. Non-treated scaffolds on the other 
hand showed significantly higher expression of CD8. This correlates with the results 
previously which PGG-treatment decreased MMP expression. Since T-cells and MMPs 
can induce expression of, or recruit the other, these results agree. It is possible that due to 
the treatment with PGG and the resistance it provides scaffolds to degradation, the host 
was presented with less cytokine and matrikines that would invoke an inflammatory 
response. Because of the stability of our mitral valve scaffold, T-cell recruitment was 
discouraged, as were the compounding effects on inflammation and degradation that would 
have ensued. Also examined was the expression of CD68, a pan-macrophage marker 
(Figure 4.7). There were no significant differences between the treatment groups found. 
As discussed earlier, there are differing macrophage phenotypes; therefore, what is more 
important is the ratio of M1 to M2 macrophages. We still however wanted to identify what 
infiltrating cells were macrophages and this figure accomplishes this. Infiltration from 
macrophages was clear in all treatment groups. 
4.4.3 Histological Identification of Infiltrating Cells: 
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 Other than identify degradation and immune-related cells, many other cells did not 
stain positive for these markers, thus more cell types are present with the explanted 
scaffolds. As mentioned earlier, the complexity and specificity of the ECM scaffold is 
critical in cell proliferation, migration, differentiation, etc. Therefore, the types of cells that 
infiltrated our scaffolds in this subdermal study should be indicative of their potential to 
attract the appropriate cell types. These infiltrating cells are the ones that actively 
remodeling the scaffolds in vivo and play an important role in the scaffold’s long term 
success. They can affect matrix remodeling as well as degradation. We looked at several 
markers for smooth muscle cells and fibroblasts. Expression levels for α-SMA, SM22, and 
calponin were evaluated for our smooth muscle cells markers, while vimentin, HSP-47, 
and prolyl-4-hydrosylase were examined for our fibroblast markers. Only results for α-
SMA and vimentin are shown for each of the cell types investigated, however results for 
each are discussed due to the consistency across groups. Overall, expression of α-SMA 
was significantly increased in non-treated samples when compared to the PGG-treated 
groups (Figure 4.8). This was also true for SM22 and calponin expression at each time 
point. We also quantified expression of common fibroblast markers. Vimentin (Figure 
4.9), showed significantly higher expression in PGG-treated groups than non-treated at 
both time points. This fibroblast maker expression was also consistent with HSP-47 and 
prolyl-4-hydroxylase. Therefore, from these results, PGG-treated tissues encourage 
infiltration of fibroblasts over smooth muscle cells, and the opposite is true for non-treated 
groups. A possible explanation for this could be that non-treated samples have shown 
higher expression of CD8, a sign of inflammation and a higher expression of MMPs. This 
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in turn could be activating fibroblasts infiltrating the non-treated scaffolds into 
myofibroblasts. Myofibroblasts are known to cause fibrosis and overproduction of 
ECM(40). They can also increase TGF-β1 levels. Histological inspection revealed more 
vessel formation appearing in the non-treated samples post-explantation. This is not 
normally seen in mitral valve leaflets or chordae. Therefore, it is possible these vessels are 
attributing to some of the rise in inflammatory makers and myofibroblasts. A large 
expression of fibroblast markers in the PGG-treated leaflets we would consider normal and 
beneficial to the matrix remodeling in these scaffolds. Mitral valve leaflets and chordae are 
largely populated by VICs, which are fibroblast-like. Therefore infiltration of similar cell-
types may be an indication that PGG-treated ECM scaffold encourages appropriate cell 
type infiltration. 
4.4.4 Macrophage Polarization: 
 Macrophages play a critical role in the success of ECM scaffolds. Macrophages are 
classically known to play a central role in host defense and inflammatory response. 
However, beyond defense these cells orchestrate tissue remodeling and other crucial 
metabolic functions(41). M1 macrophages are characterized by the expression of high levels 
of pro-inflammatory cytokines such as TNF-α, IL-6, and iNOS(2,6,11,35,41). M1 macrophages 
are also responsible for generating large amounts of reactive oxygen species (ROS) which 
caused further oxidative stress on implants. In ECM scaffolds, this oxidative stress along 
with other factors affective degradation (MMPs, etc.) may induce the formation of oxidants 
since ECM fragments promote immune cell recruitment. Also ROS has been shown to 
recruit additional macrophages and leukocytes(42). M2 macrophages operate as the pro-
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healing phenotype and are characterized by expression of IL-10 and CD163(1,11,28,41). M2 
macrophages have poor antigen presenting potential and possess immunoregulatory 
functions such as actively scavenging debris, tissue remodeling, promoting wound healing, 
and suppression of Th1(41). Two commonly used markers for M1 and M2 macrophages 
were iNOS and CD163 respectively. Using these markers, it was observed that iNOS 
expression was significantly higher in untreated samples at both time points (Figure 4.10). 
Meaning there was a greater presence of M1 macrophages in the untreated samples. In 
contrast, CD163 was expressed in significantly higher quantities in PGG-treated samples 
as compared to non-treated groups (Figure 4.11). This was true at both the 4 and 8-week 
time points. Therefore, M2 macrophages appear in greater quantities in PGG-treated 
scaffolds. As mentioned before, the pan-macrophage expression (CD68) was not 
significantly different between groups, however it appears that the ratios of M1 and M2 
macrophages for the treatment groups was significantly different. PGG’s ability to 
encourage the M2 phenotype is critical for the success of this scaffold. By depressing the 
pro-inflammatory M1 macrophage, further degradation of the scaffold was prevented, 
oxidative stress reduced, significantly less pro-inflammatory cytokines were released and 
more M1 macrophages were not recruited. 
 PGG has shown to have anti-inflammatory qualities and therefore has some effect 
on macrophage polarization due the fact that PGG-treatment greatly encourages M2 
macrophages over M1(13). One possibility for this is due to the antioxidant properties of 
PGG. Antioxidants have been shown to scavenge ROS which are known to increase 
inflammation and oxidative stress in tissues(43). Antioxidants block oxidant-mediated 
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pathways by scavenging ROS. It has also been shown that PGG can significantly reduce 
the expression of TNF-α, which is a major determinant in macrophage polarization(20). It 
has also been seen that ROS production is a function of TNF-α expression(44). By 
decreasing the expression of this pro-inflammatory cytokine, PGG may reduce M1 
polarization. In accordance with our results, we also saw PGG’s effect on scaffold 
degradation and how this affected expression of CD8, smooth muscle cell markers, 
fibroblast markers, as well as vascularity and MMP expression. Combined, we have seen 
that ECM fragments and degradation can encourage inflammation of the scaffold and even 
fibrosis. Each of these factors seem to compliment and encourage the other in the untreated 
samples. M1, macrophages which are associated with increased vascularity, may coincide 
with the higher expression of CD8 and the delivery of these T-cells to non-treated 
samples(45).  
4.5 Conclusion: 
 The host response and biocompatibility of any biomaterial are the most crucial 
factors in determining the success or failure of an implant. As researchers have progressed 
past the use of “inert” biomaterials and into the realm of bioactive scaffolds made from 
natural substances like ECM, there are many questions not only on how a bioactive material 
will respond to the host, but more importantly how the implant will utilize the host response 
to its advantage. For tissue engineered applications, scaffolds derived from ECM have 
become popular due the familiar proteins that make up the scaffold and its ability to 
incorporate cells to eventually become a regenerated tissue. We must understand that the 
cells and their interaction with the ECM scaffold are the only way to remodel and integrate 
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the biomaterial into the host. Therefore, we must appreciate and discover the mechanisms 
by which the host’s cells mediate the immune response around our scaffold. By doing so, 
we will have a better understanding of the effectiveness and potential for our tissue 
engineered mitral valve scaffold. 
 The studies discussed above were all attributed to the scaffold developed in chapter 
3. Our aim was to better understand how our scaffold would affect the immune response 
of the rats and how this in turn affected our scaffolds. We examined our scaffolds at both 
4 and 8-weeks and had two treatment groups, PGG-treated and non-treated scaffolds. 
Results were shown for the leaflets and the chordae tendinae. We focused our results on 
the degradation of the scaffolds, the immune response, overall ECM quality, and 
identification and polarization of macrophages. 
 Our results led us to conclude that PGG-treatment of our scaffolds has many 
benefits to our scaffold. We knew PGG significantly decreased degradation with proteases 
in vitro, however the same was true in vivo. PGG also decreased expression of CD8 an 
immune cell marker and promotor of inflammation. Smooth muscle cell markers were also 
expressed at significantly lower levels in PGG-treated groups. These cells may have been 
fibroblasts that were activated and became myofibroblasts, which can lead to over-
production and mismanagement of ECM remodeling. Fibroblast markers were also 
significantly higher in PGG-treated tissues. Importantly, the M2 phenotype was highly 
encouraged and showed significantly more expression in the PGG-treated tissues. This 
predominance of the pro-healing phenotype of macrophages discourages further 
inflammation and allows for remodeling of the scaffold. 
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 Overall, it is evident that treatment with PGG has significant beneficiary effects on 
our mitral valve scaffold. Any tissue engineered ECM scaffold needs to undergo 
constructive remodeling to become a healthy and regenerated tissue. While the same is true 
for the heart valve scaffold, extra precautions must be taken due to the high stress 
environment the valve resides in. Because this valve is expected to function immediately 
and ideally for the life of the patient, PGG allows for a more gradual remodeling, while 
also discouraging inflammation and degradation of the scaffold. 
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CHAPTER 5 – DEVELOPMENT OF A MITRAL VALVE BIOREACTOR AND 
CHARACTERIZATION OF DYNAMIC CELL SEEDING IN MITRAL VAVLE 
CONSTRUCTS 
5.1 Introduction: 
 Scaffold characterization and evaluation of host response are two critical landmarks 
for a tissue engineered solution. In fact, they are literally the foundation for creating a living 
tissue construct capable of regenerating diseased tissue. However, despite their importance, 
the scaffold is only a part of the larger tissue engineering paradigm(1). To develop a living 
construct these scaffolds must be repopulated with relevant cell types capable of 
remodeling and sustaining the tissue during growth and would healing. The incorporation 
of cells and their process of remodeling the scaffold are important pillars in the world of 
tissue engineering. The scaffold provides the cells with specific biochemical and 
biomechanical signaling which directs cell growth, migration, proliferation and 
differentiation. Recellularization of the scaffold presents unique challenges towards the 
development of a tissue engineered valve. There are roughly two methods to repopulate 
the scaffolds with cells, in vitro cell seeding prior to implantation, or implanting an 
acellular scaffold and waiting for repopulation with endogenous cells. The latter option 
relies heavily on the fact that relevant cell types will infiltrate the scaffold, that the host 
response, which would occur during full operation of the scaffold, would not limit or 
degrade the scaffold, that the remodeling process would not hinder coaptation of the 
valvular apparatus, and that these repopulating cells would be able to function effectively 
and efficiently while under extreme repetitious forces. In fact it has been shown that placing 
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acellular constructs in human patients failed to result in success due to limited to no 
infiltration by host cells into the construct(2). Therefore, to exert more control over the 
recellularization process, in vitro cell seeding of the scaffolds prior to implantation should 
result in a more successful tissue engineered mitral valve. Cell seeding strategies should 
be optimized and the infiltrating cells should be characterized to understand the tissue 
remodeling response(3).  
Static cell culture methods are limited in their capacity to produce the complex 
three-dimensional cues required to develop functioning tissue. Two dimensional cell 
culture also cannot reproduce the physical demands placed on the tissues in vivo. The 
human body, especially the human heart is a harsh environment for healthy tissue to 
survive. In normal activity, the mitral valve experiences pressure changes from 10 to 
120mmHg in less than 0.1 seconds and continues to repeat this for an average of 3 billion 
times in one lifespan. It is important to remember these rigorous conditions as design 
criteria for creating functional tissue. In order to mimic the pressures and flow conditions 
present in vivo, bioreactors have been developed to “pre-condition” seeded constructs. 
Dynamic seeding in a bioreactor has also shown to produce significantly better seeding 
results when compared to statically seeded constructs(4). By exposing cells and scaffolds to 
these relevant forces, remodeling of the scaffold and maturation of the cells can take place 
before being implanted. Bioreactor design is critical for the success of the pre-conditioning 
process in which they must apply proper pH, oxygen concentration, nutrient supply, 
sustained sterility, and mechanical forces. 
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Before mechanical pre-conditioning can be delivered via a bioreactor, the cell type 
for scaffold seeding needs to be determined. The ideal choice of cell would be VICs, as 
they are prevailing cell type in the heart valves and are found within each fibrosa, 
spongiosa, and ventricularis layer of the valve (5–10). They are a dynamic population of 
valvular-specific cells and are the living component of heart valves. VICs are responsible 
for synthesizing and preserving the composition of the valve matrix, which largely 
determines the valve’s ability to function as well as its material behavior(5). The central role 
of the VIC is to maintain the structural integrity of the valve and to act when the valve is 
in need of repair. These responsibilities are extremely important as heart valves are the 
most mechanically stressed tissue found in the body. VICs also function as key role players 
in the body’s pathological response to heart valve disease as well as regulating processes 
following valve injury. Current literature supports five heterogeneous VIC phenotypes(5,11). 
Quiescent VICs, or qVICs, are the predominant VIC phenotype in healthy valves and are 
thought to maintain the valves overall structure and function(5,6,9,12–14). In this resting state 
of VICs they act similar to fibroblasts(15,16). It is from this phenotype that VIC plasticity 
stems. In response to injury or disease, qVICs become activated VICs (aVICs) and take on 
the features of myofibroblasts. This phenotype is characterized by increased α-smooth 
muscle actin (α-SMA) expression, contractility, stress fiber formation, secretion of matrix 
remodeling enzymes (MMP-1, MMP-2, MMP-9, MMP-13), cytokines (TGF-β), and 
cathepsins(5,13,17,18). aVICs also exhibit heterogeneity in their morphologies. Many 
pathologies result in high cellularity and abnormal changes in ECM content; these are often 
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caused by the dysregulation of aVICs. Activation of qVICs is brought on by changes in the 
mechanical environment or from several cytokines, often TGF-β.  
For a tissue engineered solution, adipose tissue derived stem cells (ADSCs) show 
excellent potential for use in heart valve tissue engineering. ADSCs have the ability to 
differentiate into endothelial cells, providing a non-thrombogenic blood tissue interface 
critical to regulating activity of interstitial cells, smooth muscle cells, and fibroblasts, 
which are involved in synthesis of collagen, elastin, and proteoglycans(19–21). ADSC’s also 
have immunomodulatory properties and are able to suppress T-cell proliferation, reduce 
inflammatory cytokines, and stimulate production of anti-inflammatory cytokines(22). They 
are also able to promote regeneration of tissue via expression of VEGF, IGF-1, TGF-β1, 
and hematopoietic factors(19,23,24). Additionally these stem cells are able to suppress M1 
type macrophages, which provide classic macrophage activity and alternatively activate 
M2 macrophages which promote wound healing(23). Due their ability to differentiate into 
smooth muscle cells (SMCs) and fibroblasts, which are both similar to VICs, 
differentiation of ADSC’s into these cell types would be critical for our construct(25,26). The 
niche, valvular microstructure provided from our scaffold should provide cues for 
differentiation along with physiological stresses provided by a bioreactor. However, it may 
also be prudent to pre-differentiate these stem cells using appropriate growth factors to 
encourage specific differentiation of the ADSCs. 
Recellularization of decellularized scaffolds of any tissue, but particularly heart 
valve scaffolds, has been difficult to say the least(4,27). To date, static seeding of scaffolds 
is the most frequent method used in the construction of tissue. However, efficiencies using 
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this technique range only between 10 -25%(28). Static seeding onto scaffolds leads to 
minimal cell infiltration into the scaffolds and has shown low cell seeding competence(28). 
To achieve better results, many groups have started directly placing cells interstitially using 
a variety of methods including perfusion, direct injection, vacuum and centrifugal 
seeding(29). In synthetic and hydrogel scaffolds where material properties such as pore size 
are more customizable, interstitial cell seeding strategies can be more efficient. However 
when using an ECM scaffold which is already customized for specific tissues, preservation 
of the native matrix is paramount. Some groups, such as ours, have found some success in 
direction injection of cells into the scaffolds(28–32). However, this often creates a bolus of 
cells which many times do not migrate into the ECM they were injected to. Therefore, 
many groups have employed growth factors and other cell-homing strategies to encourage 
migration and proliferation within the scaffolds with some success(28,30,31,33,34). One novel 
idea is the use of hydrogels as a means of delivering the cells. These hydrogels provide a 
customizable way to deliver cells and growth factors into a scaffold. Encapsulation of cells 
in a hydrogel also aids during injection due to the rheological properties of the gel. Due to 
their high viscosity, hydrogels exhibit stress-thinning and therefore can protect cells from 
high shear stress during injection(35,36). 
Fibrin hydrogels have been explored for use in cell seeding applications for tissue 
engineering. Fibrin is a natural product of the coagulation cascade and functions as 
temporary scaffold during wound healing. It is formed through the polymerization of 
fibrinogen, which is initiated by the protease thrombin(37). Due to its autologous derivation, 
fibrin gels possess excellent biocompatibility(38). In fact, it can be produced from a patient’s 
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own blood, thereby eliminating the risk of infection or foreign body reaction(39). Due to its 
natural origins and function as a cell-binding matrix, fibrin gels could be used as an 
injectable cell delivery system for interstitial seeding. Well known for its ability to attract 
cells, it is also known to encourage cell migration and adhesion(37,39,40). Fibrin can also bind 
several growth factors, through heparin. Growth factors and cytokines have been used in 
tissue applications to encourage cell migration into more uniform distributions within 
scaffolds(30,33,34,41–43). Therefore, the ability to bind growth factors, both directly and 
indirectly, is a great attribute for cell seeding. One noted disadvantage of fibrin is its rapid 
degradation profile. Fibrin gels, unless chemically inhibited, will undergo degradation 
within several days after implantation. However because fibrin would be used as an 
injectable hydrogel, the relevance of this rapid degradation is questioned. Cells have easily 
been encapsulated in fibrin gels and when incorporated in scaffolds, can rely on the 
mechanical properties of the matrix in which it was injected(40). Therefore, the fibrin gel 
serves only to provide a uniform cell distribution and more efficient seeding. Degradation 
of the fibrin allows for the accumulation of newly synthesized ECM components generated 
by the encapsulated cells. In addition, degradation of fibrin exhibits minimal inflammation. 
In fact, culturing macrophages in fibrin gels stimulates anti-inflammatory cytokines and 
encourages M2 polarization(44). Fibrin has shown to encourage more new collagen and 
elastin production from seeded cells than from other gels such as collagen(37,40,45,46). Fibrin 
has also been shown to be a potent recruiter of endothelial cells and also has potential as a 
means of encouraging endothelial to adhere to the scaffold surface(47). 
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In tissue engineering, the cell seeding of scaffolds is a very complicated process. 
Due to this complexity, static seeding still remains one of the most common methods to 
incorporate cells into scaffolds. As mentioned, dynamic seeding by use of a bioreactor, has 
shown to encourage significantly improved cellular distribution within scaffolds while also 
providing relevant mechanotransductive signals to the cells. Bioreactor design is centered 
upon providing a physiological environment in vitro for the cell-seeded construct. Heart 
valves are dynamic tissues composed of specialized cells and an extracellular matrix that 
responds to these mechanical demands. Beginning at implantation and continuing 
indefinitely after that, the tissue engineered valve must accommodate for these mechanical 
demands but also have ongoing strength, flexibility, and especially durability(1). Therefore, 
the goal to engineer a tissue engineered mitral valve presents unique hurdles to overcome. 
Immediately placing a recellularized construct into a patient would most likely fail due to 
these complex and harsh mechanical conditions. Therefore, pre-conditioning of the MV 
construct is essential preparation for eventual implantation. By providing a physiological-
like environment for the seeded constructs to develop, allows the cells to adhere to and 
remodel the scaffold so that the living construct can withstand the forces and pressures 
expected of it. Our laboratory has developed a pulse-duplicating heart valve bioreactor 
capable of subjecting heart valves to physiological pressures and flows. It consists of a 
three-chambered heart valve bioreactor (1), an optional pressurized compliance tank (2), a 
reservoir tank (3) with sterile filter (4) for gas exchange, one-way valves (5), resistance 
valves (6), pressure transducers (7), a flow meter, a webcam (8), and an air supply that 
cyclically pumps fluid through the heart valve(48). 
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Creation of a mitral valve bioreactor presents unique challenges due to the unique 
anatomy and multiple components of this valvular machine. Shape of the annulus, which 
establishes the form and function of the valve, must be taken into account as it provides 
optimal force distribution to the leaflets and chordae below. The geometric shape of the 
annulus approximates to that of a hyperbolic paraboloid(49–53). Although this nonplanar 
shape’s origins are not fully described in literature, it is understood that this shape is the 
determinant of optimal force distribution in the leaflets and chordae tendinae(50,53,54). 
Chordal attachment is also crucial to provide the necessary tension on the posterior side of 
the leaflets, as well as the chordae themselves. Few groups have been able to produce an 
anatomically correct mitral valve bioreactor, accounting for each of these four major 
components.  
5.2 Methods and Materials: 
5.2.1 Histology and Immunohistochemistry: 
Rehydrated paraffin sections (5µm) were stained with Hematoxylin and Eosin 
(H&E), Masson’s Trichrome and Movat’s Pentachrome according to the instructions in the 
kits purchased from Poly Scientific R&D Corp. (Bayshore, NY). 4',6-diamidino-2-
phenylindole (DAPI) was purchased from Sigma-Aldrich Corporation (Lakewood, NJ). 
Immunohistochemistry (IHC) was performed on formalin-fixed and paraffin-
embedded sections using heat-mediated antigen retrieval (10mM citric acid at pH of 6, for 
10 min at 90°C), followed by exposure to 0.025% Triton X-100 for 5 minutes. After 
incubation in normal blocking serum for 45 minutes, the primary antibodies diluted to 
2μg/mL were applied overnight at 4°C in a humidified chamber. The following antibodies 
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were used: mouse anti-αSMA (Abcam, Ab7817), rabbit anti-HSP-47 (Abcam, Ab77609), 
rabbit anti-von Willebrand Factor (vWF) (Abcam, Ab9378), rabbit anti-VE cadherin 
(Abcam, Ab33168), rabbit anti-P4HA3 (Abcam, Ab101657), rabbit anti-calponin (Abcam, 
Ab46794), rabbit anti-iNOS (Abcam, Ab15323) rabbit anti-Vimentin (Abcam, Ab92547). 
Negative controls were obtained by omitting the primary antibodies. The Vectastain Elite 
kit and the ABC diaminobenzidine tetrahydrochloride peroxidase substrate kit were 
purchased from Vector Laboratories (Burlingame, CA). Sections were counterstained with 
a diluted hematoxylin prior to mounting. Images were obtained at various magnifications 
on a Zeiss Axiovert 40CFL microscope using AxioVision Release 4.6.3 digital imaging 
software (Carl Zeiss MicroImaging, Inc. Thornwood, NY). 
5.2.2 Cell Culture and Pre-Differentiation of hADSCs: 
Human adipose derived stem cells (hADSCs) (#R7788-110, Fisher Scientific, Life 
Technologies, passage 0) were obtained and expanded in StemPro Human Adipose-
Derived Stem Cell Kit with 1% antibiotic solution (#30-004-CI, Corning – Cellgro). 
hADSC’s were maintained and subcultured at subconfluent conditions on tissue culture 
plastic with Trypsin-EDTA 1X (#25-053-CI, Corning - Cellgro). 
For differentiation of hADSCs to endothelial-like cells, ASCs were cultured for up 
to 4 weeks in EC differentiation media comprised of DMEM, 2% FBS, and 1% antibiotic 
solution supplemented with 0.5 ng/mL vascular endothelial growth factor (VEGF, #100-
20B, PeproTech Inc) and 20 ng/mL insulin-like growth factor-1 (IGF-1, #AF-100-11, 
PeproTech Inc). Growth factors were freshly added to the media at the time of each media 
change. 
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For differentiation of hADSC’s to fibroblast-like cells, hADSC’s were cultured for 
up to 4 weeks in fibroblast differentiation media comprised of DMEM, 5% FBS, and 1% 
antibiotic solution supplemented with 5ng/mL transforming growth factor beta-1 (TGF-β1, 
#100-21C, PeproTech Inc.). Growth factors were freshly added to the media at the time of 
each media change. 
5.2.3 Cell Seeding and Fibrin Fabrication: 
Pre-differentiated fibroblasts and endothelial cells were seeded into and on the 
scaffolds respectfully. Before seeding, PGG-treated valves underwent a neutralization step 
where the mitral valves were incubated in DMEM/10% FBS with 1% 
antibiotic/antimycotic and Stromal Derived Factor-1α (SDF-1α, #300-28A, PeproTech, 
Inc.) at 100ng/mL overnight. For seeding, pre-differentiated cells at a density of about 2 
million cells per mL were prepared. To facilitate seeding, about 1mL of sterile air was 
injected into each leaflet through a 33G X 0.5inch needle. The pre-differentiated fibroblasts 
were resuspended in 250µL thrombin (#T7009-250UM, Sigma) and CaCl2(#BP510-100, 
Fisher) and mixed with a sterile 250µL aliquot of fibrinogen (#F4129-1G, Sigma) to get 
final concentrations of 0.5U/mL thrombin, 4mg/mL fibrinogen, and 2mM CaCl2. Cells 
were injected into each leaflet (0.5mL per leaflet) before mixture could become a fibrin 
gel. Seeded valves were placed into mounting rings for the bioreactor with a static control. 
Interstitially seeded constructs were then drop-seeded with pre-differentiated endothelial 
cells, 200µL of thrombin/CaCl2/fibrinogen at the same concentrations, onto each leaflet 
and the chordae tendinae of each valve. Seeded constructs were placed in the incubator for 
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15minutes without media to allow fibrin to gel. After seeding, valves were left in 
DMEM/10% FBS with 1% antibiotic/antimycotic overnight. 
5.2.4 In Vitro Conditioning: 
For pulsatile bioreactor conditioning, valves (n=2) were mounted in the sterile 
mitral valve bioreactor systems in DMEM/10% FBS with 1% antibiotic/antimycotic and 
pressures progressively increased from 10mmHg to 120mmHg over 21 days to reach 
physiological conditions (120/10mmHg) at 70 mL ejection fraction and 65 bpm. Valves 
were kept at these conditions for 7 days and the study concluded after 28 total days in the 
bioreactor. Media was changed once a week, and 5mL of additional antibiotic/antimycotic 
was added in between media changes.  
5.2.5 Mechanical Testing: 
Rectangular 2.5 x 1 cm specimens of tissue from the bioreactor and the static 
control (n=2) were cut. Specimens were secured to a frame with a 10N load cell (MTS 
Systems), and preconditioned for 10 cycles between 0-15% strain at a rate of 3.0 mm/min. 
After 2 minutes rest, samples were pre-strained at 0.2N of load then brought to 10N of 
stress. The stress/strain curve was taken and the Young’s modulus was evaluated for each 
stress/strain curve between the 10-20% strain and were averaged (n=3).  
5.2.6 Penta-galloyl glucose (PGG) Treatment: 
High-purity 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose (PGG) was a generous gift 
from N.V. Ajinomoto OmniChem S.A., Wetteren, Belgium (www.omnichem.be). The 
acellular scaffolds were treated with sterile 0.3% PGG in 50mM Na2HPO4, 0.9% NaCl, pH 
5.5 containing 20% isopropanol overnight at room temperature under agitation and 
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protected from light. Scaffolds were then rinsed with sterile PBS 3 times, and then stored 
in sterile PBS with 1% protease inhibitors and 1% antibiotic/antimycotic (Pen-Strep). 
5.2.7 Development of Mitral Valve Mounting System: 
 The shape of the annular mounting ring was started using a combination of 
measurements reported in literature as well as a 3D-scan of a mitral annuloplasty ring. This 
scan was then imported into SolidWorks where it was modeled and fitted to existing 
parameters for the aortic valve bioreactor. After consulting with Aptus Bioreactors, chordal 
attachment was designed with the mounting system. These pieces were then 3D-printed 
and used in the bioreactor experiments. Several bioreactor chambers and other consumable 
materials were purchased from Aptus Bioreactors: Mitral valve clamping holder, lower 
(MA386), Mitral valve clamping holder, upper (MA396), Bioreactor membrane with 
installation kit (KT430), and the Mitral fittings consumables kit (KT485). 
5.2.8 Statistical Analysis: 
Results are expressed as means ± standard deviation (SD). Statistical analysis was 
performed using one-way analysis of variance (ANOVA). Differences between means 
were determined using the least significant difference (LSD) with an alpha value of 0.05. 
5.3 Results: 
5.3.1 Recellularization Studies Using Fibrin: 
 Recellularization of decellularized scaffolds is a difficult but necessary step 
producing a translatable tissue engineered mitral valve. Several pilot studies were 
implemented to gain insight into how to encourage migration of directly injected cells 
throughout the matrix. Fibrin was used as this vehicle to deliver cells more uniformly 
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interstitially. To aid in this migration, SDF-1, a cytokine well known to encourage 
migration of cells, was used in the scaffolds(55–57). After allowing two weeks for cells to 
spread, various histological stains were performed to evaluate this process. As seen in 
Figure 5.1, an H&E, Masson’s Trichrome, and IHC’s for vimentin and CXCR4 were 
conducted. From the H&E staining it is evident that cells spread from the injection site 
outward into the scaffold. It was also found that cells were spreading in areas away from 
the injection site. In addition, cells were drop-seeded on the scaffold, also using fibrin, and 
a nice monolayer of cells is shown here. Trichrome staining similarly displays the 
improved migration of cells, but more importantly displays remaining fibrin within the 
scaffolds. These pink areas, in a normally collagen (blue) dominated region, designate 
where fibrin spread in the scaffolds and remained during the seeding studies. A small 
monolayer of cells is also found externally as before. IHC’s for vimentin and CXCR4 were 
also conducted. Vimentin stain was positive for all seeded cells. Also identified positively 
was CXCR4, the receptor on the cell for SDF-1, which regulates the cells homing ability 
and affects their migration(33,55,57). 
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Figure 5.1: Cell Seeding Using Fibrin and SDF-1. Scaffolds immersed in SDF-1, a well-known cytokine, 
were injected with fibrin gel. This fibrin gel was used as a carrier to introduce cells into the acellular mitral 
valve scaffolds. Noticeable spreading of cells can be seen. Injection spots, while distinct, did not house a 
bolus of cells as in previous studies. Cells were also found apart from these injection spots indicating 
migration. Cells also readily attached externally after being statically seeded, also with fibrin. An IHC for 
vimentin was positive, as was the expression for CXCR4, an indication that the SDF-1 incorporated into the 
scaffolds had an effect on cell migration. 
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5.3.2 Pre-Differentiation of hADSCs to Fibroblasts and Endothelial Cells: 
After these positive results in encouraging cell migration after injection, we decided 
that instead of injecting hADSCs directly in to the scaffolds, that we would pre-
differentiate the hADSCs using specific growth factors. To verify their differentiation into 
endothelial cells and fibroblasts, an immunofluorescence was performed for various 
markers. Endothelial cells, which used IGF and VEGF, were stained for VE-cadherin and 
vWF. Fibroblasts, which used TGF-β for pre-differentiation, were stained for HSP-47, 
prolyl-4-hydroxylase, and vimentin. In Figure 5.2, these immunofluorescence stainings 
are shown. 
 
Figure 5.2: Pre-Differentiation of hADSCs into Endothelial Cells and Fibroblasts. hADSCs were pre-
differentiated into fibroblasts due to their similarity to VICs. To confirm their differentiation an 
immunofluorescence for fibroblast markers HSP-47, prolyl 4-hydroxylase, and vimentin all showed 
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positively. Likewise, pre-differentiated endothelial cells were confirmed by a positive stain for each VE-
cadherin and vWF. 
5.3.3 Design of a Mitral Valve Mounting Ring for Placement in Bioreactor: 
After approving of cell types and a recellularization protocol, design of the mitral 
valve bioreactor was completed. Our group has already designed an aortic valve bioreactor 
of which we made modifications to fit the mitral valve and its complex geometry(48). 
Developing a mounting system for the mitral valve was perhaps one of the most crucial 
design criteria. As seen in Figure 5.3, a two-piece mounting system was developed. The 
first criteria met for this design was the use of a hyperbolic paraboloid to mount the mitral 
annulus. As mentioned several times, this unique shape provides optimal force distribution 
throughout the valve. Dimensions for this shape were taken from literature and from 
existing annuloplasty rings which were 3D scanned. Also apparent in this design is the “D” 
shape. This allows proper placement of the anterior and posterior sides of the annulus and 
leaflets. Lastly in this design is the incorporation of several bars below the annular clamp 
which was used for chordal attachment. Springs were attached to the papillary muscles and 
then were hooked to these bars. This allowed for proper coaptation of the leaflets and 
provided tension on their ventricular surface. 
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Figure 5.3: Development of the Mitral Valve Mount for Bioreactor Testing. A mounting ring was 
developed for the mitral valve as a modification to the already existing aortic valve bioreactor. The natural 
shape of the annulus was incorporated in this design to provide optimal force distribution throughout the 
valve during in vitro bioreactor testing. Also included were bars used to attach springs to the papillary 
muscles. This spring system allows for coaptation of the mitral valve at physiological pressures, while also 
providing proper tensile forces on the leaflets. This tension is also important for proper force applications in 
the chordae as well. 
5.3.4 Cell Seeding Protocol, Mounting of Seeded Mitral Valve, and Placement in 
Bioreactor: 
 In Figure 5.4, the protocol for how recellularization takes place up until placement 
in the bioreactor is shown. After starting with an acelluar scaffold and neutralized overnight 
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in DMEM (10%FBS, and 1% AbAm) with SDF-1, valves were then taken out and directly 
injected with cells (Panel C). From here, the annulus is placed by properly aligning the 
posterior and anterior sides according to the mounting ring shape (Panel D). After locking 
the annulus in place, metal rings for eventual placement in the bioreactor are positioned 
around the mounting system (Panel E). Then papillary muscles and chordae tendinae are 
attached to springs, which are attached to the lower bars of the mitral mount (Panel F). 
Finally, this completely seeded and mounted mitral apparatus is placed within the 
bioreactor and media is added (Panel G). 
 
Figure 5.4: Mitral Valve Seeding and Mounting for Bioreactor Testing. Recellularization and mounting 
of the seeded scaffold is a several step process. Panel A shows our decellularized mitral valve scaffold. As 
described in panel B, these valves are then treated overnight in serum with 100ng/mL SDF-1. Cells were then 
directly injected into the scaffolds. Pre-differentiated endothelial cells were then seeded drop-wise on the 
scaffold. After allowing the fibrin and cell mixtures to gel in the incubator, the construct is mounted in the 
mounting rings and springs are attached to the papillary muscles (panels D-F). Finally, after allowing cells 
to attach to the scaffold overnight, the mounted mitral valve construct is placed within the bioreactor. 
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5.3.5 Design and Assembly of the Mitral Valve Bioreactor: 
 While the existence of the aortic valve bioreactor provided a foundation to work 
with, the mitral valve the physiological demands it undergoes are different. As a result, 
parts and assembly of the mitral valve bioreactor are unique. Figure 5.5 shows a complete 
mitral valve bioreactor system. In this system are several chambers which are essential for 
holding anatomical pressures. The atrial chamber, significantly shorter than the aortic atrial 
chamber, acts as the atrium for the heart valve. Due to the very low pressures in the atrium 
experienced by the mitral valve (about 10mmHg), this chamber is small to decrease 
pressure here. The valve rests between the atrial chamber and two chambers beneath which 
act as the ventricle. It is here that the high pressures are placed on the valve during systole 
(120mmHg). The extra ventricular chamber is needed here to ensure that the mounting 
system which holds the papillary muscles, is not hit by the silicone membrane below. This 
membrane caps off an air chamber. Air is pumped into this chamber, which forces the 
silicone membrane upwards into the ventricular chamber. This forces flow and pressures 
into the system. Figure 5.5 also shows proper closing of the mitral valve as well as the 
springs of the mounting ring in action. 
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Figure 5.5: Assembly of the Mitral Valve Bioreactor. The overall structure of the mitral valve bioreactor 
is a modification of an aortic valve bioreactor. There are four chambers, an atrial chamber, ventricular 
chamber, air chamber, and an additional ventricular chamber. Also, present in this set-up is a large glass 
reservoir chamber, flow meter and two pressure transducers, which measure pressures in the atrial and 
ventricular chambers. In the center of the bioreactor is the mounted and seeded mitral valve construct. 
Pressure and flow is originated in the air chamber where air is pumped in, thus moving a silicone membrane. 
This membrane creates the flows and pressures desired for experimentation. Gas exchange is allowed through 
a sterile filter. The incubator in which this mitral valve bioreactor is placed controls all temperature, CO2 
levels, and humidity. Flow rate is also measured and can be adjusted using clamps. 
5.3.6 Mechanical Testing of the Seeded Leaflets After Bioreactor Completion: 
 After 4 weeks of preconditioning in the bioreactor, the tissue underwent tensile 
testing to determine the young’s modulus. This was compared to the static control. As seen 
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in Figure 5.6, the static control had a higher modulus of elasticity when compared to the 
leaflets from the bioreactor. This difference was not statistically significant however. 
 
Figure 5.6: Uniaxial Tensile Testing of Static and Bioreactor Conditioned Tissues. Mechanical testing 
was performed on the leaflets and chordae for both static and bioreactor conditioned groups. From this data, 
modulus of elasticity was determined between the range of 10-20% strain. Young’s modulus was calculated 
for both the static control and the bioreactor tissue. Young’s modulus was higher for the static control, but 
not significantly. 
5.3.7 Live/Dead Staining of Static and Pre-Conditioned Tissue: 
 A Live/Dead stain was used to evaluate the amount of living and dead cells present 
within each treatment group. As evidenced by Figure 5.7, living cells (indicated with green 
fluorescence) were difficult to find. Dead cells were indicated using black arrows. Before 
these cells died, it is apparent that there are more cells spread in the pre-conditioned 
construct when compared to the static control. It is possible that more cells could be found 
from other tissue sections within each group. 
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Figure 5.7: Live/Dead Images of Tissue from Static Control and Bioreactor. Small sections of tissue 
from both the static control and the pre-conditioned tissue from the bioreactor were stained with Live/Dead 
solution to visualize dead and living cells. Dead cells are much more apparent within each tissue type, 
however more spreading of the cells is apparent in the tissue from the bioreactor. These cells are indicated 
with black arrows. 
5.3.8 Histological Evaluation of Recellularized Scaffolds Post-Bioreactor Conditioning: 
 After 4 weeks of preconditioning in the bioreactor, cell seeding and migration were 
evaluated histologically in the bioreactor tissue and the static control. As seen in Figure 
5.8, an H&E and DAPI stain were used to identify nuclei. As before, Masson’s Trichrome 
was used to show ECM content, but more importantly any remaining fibrin within the 
constructs. Movat’s Pentachrome was used to show ECM content, but especially GAG 
deposition. Overall, cells did not migrate as well as before. Both static and preconditioned 
tissue show boluses of cells. Bioreactor tissue does show more cells than the static control. 
Areas injected with fibrin are obvious due the contrasting colors in the trichrome stain. 
GAG deposition was found, which is an improvement from previous seeding attempts. Few 
endothelial cells remained after bioreactor conditioning, but this is still an improvement 
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over previous bioreactor studies. A clear dark monolayer is present on the H&E and some 
in the DAPI. Trichrome and pentachrome stains also show similar results here. 
 
Figure 5.8: Recellularization of Acellular Scaffolds. To show revitalization of our acellular mitral valve 
scaffolds, several histological stains were performed. Images shown are from both the static control and the 
tissue preconditioned in the bioreactor. Pre-differentiated fibroblasts and pre-differentiated endothelial cells 
were seeded interstitially and externally respectively. An H&E and DAPI stain were performed to highlight 
nuclei in the tissue. Leaflet tissue are represented in this image since no cells were injected in the chordae, 
only externally. A Masson’s Trichrome was performed to visualize remaining fibrin. Lastly, a Movat’s 
Pentachrome was performed to view ECM quality and deposition of GAGs. 
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5.3.9 Characterization of Cells in Bioreactor and Static Control Tissues: 
 Immunohistochemistry was used to determine expression of smooth muscle cell, 
fibroblast, and endothelial cell markers. In Figure 5.9, some expression is observed for α-
SMA and calponin. An overwhelming positive stain here would have been indicative of 
activation of our seeded cells into myofibroblasts. 
 
Figure 5.9: Characterization of Seeded Cells with Smooth Muscle Cell Markers. The static control and 
bioreactor tissues were stained to see if the seeded cells expressed smooth muscle markers. A positive stain 
here would be indicative of fibroblasts becoming activated within the tissue. Positive expression for markers 
α-SMA and calponin did appear, but were minimal in known injection spots within the tissue sections. 
Figure 5.10 shows an IHC for fibroblast markers vimentin, prolyl-4-hydroxylase 
(P4HA3), and HSP-47. Strong expression for each of these markers, especially vimentin, 
was observed in both the static and bioreactor-conditioned groups. Vimentin expression 
was more spread throughout the ECM in some sections possibly indicating an improved 
migration. 
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Figure 5.10: Characterization of Seeded Cells with Fibroblast Markers. Seeded constructs were 
evaluated on their expression of fibroblast markers vimentin, HSP-47, and prolyl-4-hydroxylase. Positive 
expression was observed in both the static control and bioreactor tissue sections. Expression was clearly 
higher than smooth muscle cell marker expression. 
Lastly, expression of endothelial cell markers vWF, VE-cadherin, and iNOS were 
evaluated. Although not much clear expression was observed, some cells on the construct’s 
exterior did survive and expressed positively for each marker. In Figure 5.11, you can see 
this expression as well as the expression of these markers on the chordae tendinae. This 
was the only cell type seeded on the chordae tendinae and thus they only appear in this 
figure. 
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Figure 5.11: Characterization of Seeded Cells with Endothelial Cell Markers. Scaffolds were seeded 
with pre-differentiated endothelial cells. Markers for von Willebrand Factor (vWF), VE cadherin, and iNOS 
were evaluated. A slight, but obvious staining was observed on both the leaflets and chordae tendinae. 
Chordae, shown here, were only seeded with endothelial cells. 
5.4 Discussion: 
5.4.1 Progress Towards Recellularization of the Mitral Valve Scaffold: 
 Recellularization of an acellular scaffold, perhaps especially ECM scaffolds, is 
difficult to achieve. Ideally, appropriate cells are introduced to the scaffold and they are 
able to repopulate and remodel the scaffold. It is important to note that many groups 
understand the importance of recellularization, but their statically seeded methods take 
many weeks to achieve an acceptable result, which is not translatable for clinical purposes. 
Therefore, we sought to improve this process by incorporating cells into the scaffolds and 
promoting migration throughout. In the past, our group has found that direct injection of 
the cells into the scaffold is a better method to introduce cells interstitially as opposed to 
drop seeding them on the scaffold and waiting for them to migrate throughout. Direct 
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injection however is by no means a successful for producing a revitalized construct flush 
with cells. While cells are inserted within the scaffold, a bolus of cells is created at the 
injection site and these cells do not migrate out either because they physically cannot or 
because there is no reason for them to alter their current dense state within the scaffold. 
 Fibrin, a well-known and natural hydrogel, has been used as cell carrier to seed 
stem cells for various cardiovascular applications(40,58). Also, as mentioned before utilizing 
the increased viscosity of a hydrogel like fibrin significantly improves the survivability of 
cells being injected into a matrix compared to just using cell culture media(35,36). Therefore, 
we decided to take advantage of these properties and the natural cell binding ability of 
fibrin as a means to better deliver cells to the scaffold. To enhance migration into the 
scaffold, we employed stromal cell derived factor-1 (SDF-1). SDF-1 is a well-known and 
powerful recruiter of cells in injury. As a pro-inflammatory cytokine, it is said to be the 
most potent chemoattractive signal for the CXCR4 receptor, which is considered a major 
stem cell homing factor(33). Translationally speaking, usage of an inflammatory cytokine 
sounds incongruous with typical biocompatibility doctrine. However, SDF-1 has a short 
half-life so as to limit over-recruitment of cells to the injury site in vivo(55). Therefore, we 
chose to incorporate this powerful cytokine in the matrix before seeding in hopes that the 
cells in the fibrin gel would be encouraged to venture into the remaining acellular scaffold. 
 Based on the results presented in Figure 5.1, overall cell seeding efficiency was 
significantly improved when compared to previous seeding studies. While an injection site 
was still clearly visible, for the first time we were able to observe a marked improvement 
in migration of these seeded cells into the scaffold. Also important to note is that many of 
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these cells spreading throughout the matrix were not necessarily close to the migration site, 
leaving us to conclude that they had migrated quite far from their original insertion into the 
scaffold. We believe that this success can be attributed to both the fibrin gel and the SDF-
1. 
After this two week seeding study, fibrin remained within the scaffold. The gel did not 
create a bolus of its own; it did seem to perfuse throughout some of the scaffold near the 
injection sites. This is evidence by the pink stain in the Masson’s Trichrome. Fibrin does 
degrade quickly, but it does appear to reside long enough in the scaffolds after two weeks. 
Vimentin stained positive for the seeded cells. Also important to note is there was a positive 
stain for CXCR4, indicating that the cell receptor was in fact engaged most likely due to 
the presence of SDF-1 within the scaffold. Migration of the cells from these injection sites 
is a huge step in the right direction towards complete recellularization. 
5.4.2 Pre-Differentiation of hADSCs into Appropriate Cell Types: 
 As described in our tissue engineering paradigm, an appropriate choice of cells 
should be incorporated into the tissue. Originally, we opted to use hADSCs due to their 
ease of obtainment, ability to harvest large quantities, and their large capacity for 
differentiation. However, recently we decided to alter this approach. By using specific 
growth factors, we can guide these hADSCs toward specific phenotypes. This pre-
differentiation allows one to ensure commitment towards the desired cell type. In our case, 
this ensures that differentiation will be not solely be determined by interactions with the 
ECM microstructure. Pre-differentiation provides more assurance that the desired cell 
types will be achieved. VICs and VECs are the most appropriate cell types for the mitral 
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valve. VECs are endothelial cells and VICs are fibroblast-like in their ability to remodel 
and produce matrix proteins. After treating hADSC’s with TGF-β for fibroblast 
differentiation and VEGF and IGF for endothelial differentiation, an immunofluorescence 
revealed positive expression for markers found in each of the desired cell types. 
5.4.3 Mitral Valve Bioreactor Design: 
 Designing of a mitral valve bioreactor provided many obstacles with the valve’s 
complex anatomy and many moving parts. Some groups have been able recreate some 
aspects of a functioning mitral valve in vitro, but they cannot use these devices sterilely or 
cannot provide anatomical pressures(59,60). Design criteria was also narrowed due to the 
existence of an already well-functioning aortic valve bioreactor from our group. The first, 
and possibly most crucial, design element for the mitral valve bioreactor was establishing 
an approach to mount the valve. As mentioned before, the unique shape of the annulus 
provides optimal force distribution to the other functioning parts of the mitral valve. 
Therefore, dimensions of the annulus were found in literature(61,62). Also, a mitral 
annuloplasty ring was 3D scanned and placed within a CAD program (Solidworks) where 
modifications could be made and other design criteria implemented. 
 One of these other design criteria designing a system for attachment of the chordae 
tendinae. To expect correct differentiation from the seeded valves, the proper forces must 
be observed in the bioreactor. To achieve this, tensile forces must be placed on the 
ventricular side of the leaflets and the chordae themselves. To achieve these tensile loads, 
as seen in Figure 5.3, bars were placed below the annulus mount. Springs were placed on 
the remaining papillary muscles and then attached to these bars. After the recellularization 
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process and placement within the bioreactor, the chordae in conjunction with the springs, 
provided a functioning mitral valve without prolapse into the atrial chamber. 
5.4.4 The Current Recellularization Process and Placement into the Bioreactor: 
 Figure 5.4 illustrates the general approach taken for seeding of the valve and the 
corresponding placement into the bioreactor. As seen, SDF-1 was again used to assist in 
migration of the seeded cells. It is important to note that during seeding, time was allowed 
for the fibrin gel and cell mixture to solidify. Once complete, cells, delivered using fibrin 
again, were drop-seeded on the outside of the interstitially-seeded mitral valve. Springs 
were attached onto the papillary muscles and secured to the bars below the mounting ring. 
After which the entire mounting element easily placed within the bioreactor. 
5.4.5 Overall Bioreactor Design and Testing: 
 Aside from the specific mounting system for the mitral apparatus, several other 
design criteria were used or modified from the aortic valve bioreactor. Readouts and raw 
data on flow rate, heart rate, atrial pressure and ventricular pressure are monitored using 
flow meters and pressure transducers. The pressure transducers are located next to 
chambers that mimic conditions in the atrium of the heart and the ventricle of the heart. 
Unique to the mitral valve bioreactor is an extra chamber attached to the ventricular 
chamber to add room for the chordal attachment on the valve mounting system. Also, as 
noted, the atrial chamber for the mitral valve bioreactor is shorter to allow for the very low 
pressures experience in the atrium. To ensure continued coaptation of the valve in case of 
a spring failure, a suture ring was wrapped around one bar of the mounting system and the 
papillary muscles. Enough slack was allowed in this suture ring so as not to interfere with 
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the movement of the papillary muscles or the corresponding chordae. The valve pressures 
overtime were slowly increased to allow time for adaptation and maturation of the seeded 
cells. During this pressure ramp-up, the leaflets open and closed properly throughout 
indicating that the chordae were providing enough pull-back on the leaflets for proper 
function. 
5.4.6 Mechanical Testing of the Bioreactor Treated Leaflets: 
 A comparison between seeded and preconditioned leaflets from the bioreactor and 
a seeded, static control was completed. From Figure 5.6, it is shown that the modulus of 
elasticity for the static control is higher than that for the preconditioned tissue. This 
difference however is not statistically significant. We believe the explanation for this 
difference however is due to the forces and repetitious extension this valve underwent in 
the bioreactor. These forces acted on the collagen and elastin matrix, most likely 
straightening out these fibers over time.  
5.4.7 Histological Characterization of the Seeded Mitral Valve Tissues: 
 After removal from the bioreactor, several histological stains were performed to 
gain insight into how the cells reacted to the physiological conditions in the bioreactor and 
compare these with the static control. As evidenced by Figure 5.8, an H&E, DAPI, 
Masson’s Trichrome, and Movat’s Pentachrome were performed. Unfortunately, cells 
spreading throughout the matrix was not nearly as successful as the pilot studies discussed 
earlier. While more cells were present and in larger areas in the preconditioned leaflets, 
boluses were still found in both groups. Each histological stain shows these boluses within 
the leaflets. The only condition that differed between the seeding results discussed 
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previously and these results from the bioreactor was the treatment with PGG. It is possible 
that while PGG possesses many properties that have provided significantly improved the 
quality of the mitral valve scaffold, that it may also be hindering migration of seeded cells. 
We have mentioned previously that PGG stabilized the scaffold by binding to the collagen 
and elastin. This increased the young’s modulus for all PGG-treated tissues. This increase 
could be making it physically impossible for the cells to spread from the injection sites. 
Perhaps in the future, steps should be taken to porate the scaffold before treatment with 
PGG to allow a stable scaffold, which also provides avenues for cellular infiltration. 
 Regardless of the lack of migration within the tissue, the pentachrome stain did 
indicate the deposition of GAGs within the scaffold, which is a marked improvement. Also 
of note are the possibility that some endothelial cells did survive the shear stresses from 
the bioreactor treatment. While it is apparent that most of these externally seeded cells did 
not attach or survive, here is some evidence here that certain areas of construct did retain 
the pre-differentiated endothelial cells. Future work should be placed in furthering the 
ability to keep these cells attached to the surface.  
 
5.4.8 Evaluation of Differentiation and Activation of Seeded Cells: 
 As mentioned, VICs and VECs are the ideal source of cells for mitral valve scaffold 
repopulation. Pre-differentiated fibroblasts and endothelial cells were seeded into and onto 
the scaffolds respectively. To evaluate their continued differentiation or activation several 
IHC’s were conducted looking at smooth muscle cell markers for activated fibroblasts, 
fibroblast markers, and of course endothelial cell markers. These can be seen in Figure 
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5.9-5.11. It is important to note that literature has not provided a sure means of identifying 
VICs. However, many papers insist that due to their similarity to fibroblasts, that these 
markers are suitable. Also, markers for smooth muscle cells are indicative of fibroblasts 
that are activated. In the mitral valve these cells, called aVICs, or activated VICS, are 
important players in several mitral valve pathologies as they can quickly deposit ECM, 
which easily disrupts normal valve function. At the injections sites, a slight positive stain 
was found for α-SMA and calponin as seen in Figure 5.9. In contrast to these faint stains, 
expression of fibroblast markers vimentin, HSP-47, and prolyl-4-hydroxylase were quite 
strong as shown in Figure 5.10. This would suggest that most of the interstitially seeded 
cells remained quiescent and non-active despite all of the forces they experienced. Lastly, 
for any remaining endothelial cells, expression of vWF, VE cadherin, and iNOS were 
evaluated. While few in number, Figure 5.11 clearly shows some expression of these 
endothelial markers on both the leaflets and the chordae. This is positive that some 
endothelial cells were able to resist detachment even at physiological pressures. 
 
5.5 Conclusion: 
 The paradigm of tissue engineering in which we model and operate under, describes 
the combination of scaffold, cells, and bioreactor to develop a living construct capable of 
regenerating diseased tissues. As scaffold characterization was described in great detail, it 
was then time to turn to the implementation of cells into the scaffolds and precondition 
these constructs in the bioreactor. Recellularization remains a difficult barrier to cross. As 
mentioned earlier, many criteria must be evaluated for a proper and translatable 
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recellularization strategy. Cells will eventually repopulate a scaffold if given time. 
However, as many papers have reported this process taking months, the time required for 
revitalization of the scaffold is not acceptable for patients in great need of a tissue 
engineered replacement. By directly injecting cells into the scaffold, cells can be 
incorporated immediately; however, these cells often do not migrate from these injection 
sites and create boluses of cells. To combat this, we incorporated a well-known hydrogel, 
fibrin, with great cell attachment properties as a carrier for the cells. We also utilized SDF-
1, a potent cytokine, to encourage migration into the scaffolds. Overall, this process greatly 
improved the recellularization effort in the mitral valve scaffold. 
 To disallow seeded cells time to adapt to a harsh heart valve environment before 
implantation invites sure failure of the construct. Therefore, a mitral valve bioreactor was 
developed and modified from an aortic valve bioreactor to provide physiologic conditions 
for the seeded construct. Shape and function of each distinct tissue type had to be 
considered, none more than the unique annular shape and the need for tension in the 
chordae tendinae. By recreating a mitral valve annulus for mounting of the valve, optimal 
force distribution could be achieved during bioreactor testing. In addition, by using a spring 
and attachment system for the chordae, tension could be felt through the chordae through 
to the leaflets, providing correct anatomical cues to seeded cells and the ECM. Evaluation 
of the constructs post-bioreactor showed limited migration of the cells throughout the 
tissue. This could be a result of PGG stabilization creating a scaffold too strong to allow 
cells to physically migrate into. Therefore, PGG’s role in this process should be evaluated. 
In addition, slight poration of the tissue may provide the necessary avenues for which cells 
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can travel. Despite this insufficiency, IHCs for various markers showed a significant 
expression for fibroblast markers and only a slight positive stain for smooth muscle cell 
markers indicating that these cells were not activated and remained mostly quiescent during 
the bioreactor process. Also important to note were the existence, while small in quantity, 
of endothelial cells along the leaflets and chordae. Positive stainings for several endothelial 
markers were found for preconditioned tissues. 
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CHAPTER SIX: CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE 
WORK 
6.1 Summary of Project Development: 
 There is a clear and significant gap in our ability to care for patients with 
cardiovascular diseases. On the whole, cardiovascular disease is the largest consumer of 
human life in the country. Overall, cardiovascular disease cost the United States about 
$316.1 billion in 2013. By 2030, this cost is expected to rise to about $918 billion. By this 
time, almost half of the population of the United States is expected to have some form of 
cardiovascular disease(1). Diseases and deficiencies of the mitral valve affect a large 
percentage of those sufferers. In fact, of all patients with valvular diseases, 72% have a 
mitral valve disease(1). As is evident, mitral valve disease is a frequent cause of heart failure 
and death(2). The age of the patient is also a critical factor. Most mitral valve diseases are 
associated with some form of degeneration with leads to a malfunctioning heart valve. 
Therefore, older patients, those 75 and older, are especially affected. In fact, about 10% of 
the US population has mitral regurgitation(1,3). The elderly however are not the only patient 
group suffering from mitral valve diseases. Mitral stenosis, caused by acute rheumatic 
fever, is the leading cause of heart disease in children worldwide(4). Prosthetic heart valves 
have remained a constant in patient care, however their design and the issues that follow 
them have largely lasted unchanged since their conception in the 1960’s. Repair of the 
mitral valve has shown improved success, however results are palliative and revisional 
surgery is often required to re-repair the dysfunctional heart valve. 
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 The limitations of treatment and lack of permanent solutions available to patients 
represented an enormous opportunity to innovate. Within the paradigm of tissue 
engineering, we set to develop a novel yet translational approach to replace the diseased 
mitral valve with a living construct, thereby allowing patient-tailored tissue regeneration 
of the valve. Successful strategies as well as failed designs were reviewed and studied not 
only in heart valve tissue engineering but across the entire field to develop our unique 
approach. We sought to develop a stable, fully recellularized and mechanically 
preconditioned tissue engineered mitral valve construct. Our tissue engineered valve 
criteria demanded a design that allowed for repopulation with cells and remodeling of an 
ECM scaffold derived from porcine tissue. This scaffold had to withstand appropriate 
mechanical pressures and degradation from proteases. All of this of course using 
translational approaches that would allow an easy adaptation from the lab bench to the 
hospital bedside. 
6.2 Progress Toward Achievement of Specific Aims: 
 In an attempt to lessen this clear gap in patient care mentioned above, three 
overlaying and specific aims were established to direct our research towards a permanent 
tissue engineered solution. While these aims were discussed in more detail in Chapter Two, 
they are presented here in brief: 
Aim 1 (Chapter 3): Develop an acellular scaffold with ECM and mechanical properties 
similar to the human mitral valve. 
Hypothesis: A detergent based decellularization method will remove all cellular 
materials from a porcine mitral valve while retaining sufficient extracellular matrix 
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content, including basal lamina proteins. Chemical treatment with PGG will stabilize the 
matrix scaffold and yield physiologically similar mechanical strength. 
Aim 2 (Chapter 4): To characterize host response and determine resistance to 
degradation of the scaffold treated with PGG. 
Hypothesis: The stabilizing, anti-inflammatory, anti-calcification function of PGG 
will limit scaffold degradation and mitigate immune rejection. 
Aim 3 (Chapter 5): Develop a mitral valve bioreactor able to provide physiological 
loading and biochemical environment characteristic to mitral valves. 
Hypothesis: Optimally seeded constructs will flourish under physiologic 
conditions provided by a bioreactor that provides correct anatomical positioning and force 
distribution from annulus to papillary muscles. 
 Each of these aims add cohesively towards the development of a tissue engineered 
mitral valve. Each has been discussed at length in the above chapters, but a summary of 
the work and major takeaways from each chapter is as follows: 
6.2.1 Aim 1 (Chapter 3): Develop an acellular scaffold with ECM and mechanical 
properties similar to the human mitral valve: 
1. We developed and optimized a decellularization process that removed all cellular 
and nuclear material from the scaffold. Histological analysis showed complete 
removal of xenogeneic cells and gel electrophoresis and nanodrop show significant 
removal of nuclear material. We showed levels less than 50ng/dry tissue of nuclear 
material remaining in our scaffold, which is under the acceptable limit established 
in literature. 
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2. After development of an acellular mitral valve scaffold, we sought to characterize 
the scaffold and evaluate the effects the decellularization process had on the niche 
ECM. Overall, the ECM was well preserved, with all four layers of the heart valve 
visibly present and intact. We were not able to retain GAGs post decellularization. 
However, we were able to conserve basal lamina proteins collagen type IV and 
laminin which are essential for cell attachment and migration. 
3. Further characterization of the mitral valve scaffold showed that decellularization 
did have an effect on the mechanical properties of the scaffold when compared to 
fresh tissue. PGG, a well-known and well-characterized polyphenol, was used to 
shore up any lost mechanical strength during decellularization. As a result, 
mechanical properties returned significantly closer to fresh mechanical properties. 
4. PGG was also used as a treatment for the scaffold to evaluate the scaffolds potential 
for degradation when in the presence of proteases. If implanted in vivo, our scaffold 
would inevitably be encountered by similar proteases and therefore we evaluated 
our scaffolds at 24 and 48 hours in treatments of collagenase and elastase. PGG 
significantly improved the resistance of the scaffold to degradation. 
5. Lastly, the scaffold was evaluated on its potential for allowing cell growth and 
proliferation. Cytocompatibility results turned out positive in that cells were able 
to survive within and on the scaffold. It was also shown that cells could in fact be 
incorporated within the scaffold via direct injection. This proved vital for the other 
aims in the project. 
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6.2.2 Aim 2 (Chapter 4): To characterize host response and determine resistance to 
degradation of the scaffold treated with PGG: 
1. Host response to an implanted biomaterial is perhaps the most important 
determinant of success or failure of the implant. After conducting4 and 8 week time 
points with PGG-treated and non-treated groups we evaluated how these once 
acellular scaffolds degraded overtime. In looking at MMP levels within the tissue, 
there was a significant difference between the PGG and non-treated tissues. PGG-
treated scaffolds showed much less expression of MMPs, indicating a much lower 
rate of degradation. 
2. The microstructure of our ECM scaffold is perhaps its most important feature. 
Therefore, we sought to evaluate its preservation after implantation. Histological 
results indicate that the ECM was highly preserved at both time points. Clear fibers 
and layers of collagen and elastin were present.  
3. Infiltration with autologous cells from the host are inevitable. Therefore, we wanted 
to evaluate if PGG affected the ability of these cells to infiltrate the scaffolds and 
begin remodeling of the tissue. We found no significant difference between 
treatment groups at both time points. PGG did not have an effect on cells’ ability 
to infiltrate the scaffolds. 
4. An inflammatory response was investigated using CD8, a marker for T-cell 
lymphocytes. Non-treated scaffolds showed a significantly higher expression of 
CD8 than PGG-treated groups at both time points. This is not to say that CD8 
expression in PGG groups was eliminated but the expression of the pro-
198 
 
inflammatory marker was significantly lower. Accordingly, PGG is able to 
decrease infiltration of CD8-positive cells, hindering inflammation. 
5. Next, we wanted to identify the cell types that had infiltrated the scaffold. In PGG-
treated samples expression of fibroblast markers, vimentin, prolyl-4-hydroxylase, 
and HSP-47 all showed significantly higher expression when compared to non-
treated groups. In the non-treated groups, expression of smooth muscle cell markers 
α-SMA, calponin, and SM22 showed significantly higher expression compared to 
the PGG-treated groups. PGG seems to encourage fibroblast infiltration as opposed 
to smooth muscle cells. On the other hand, perhaps both scaffolds allow for 
fibroblast infiltration, but PGG is able to hinder their activation into myofibroblasts. 
6. Lastly, we wanted to understand PGG’s effect on macrophage polarization. M1, the 
pro-inflammatory macrophage, showed significantly higher expression in the non-
treated groups. The opposite was true for PGG-treated groups. M2, the pro-healing 
macrophage, showed significantly higher expression in PGG-treated groups. 
Therefore, PGG encourages M2 macrophage polarization as opposed to the pro-
inflammatory M1 macrophage. 
6.2.3 Aim 3 (Chapter 5): Develop a mitral valve bioreactor able to provide physiological 
loading and biochemical environment characteristic to mitral valves: 
1. In a cumulative effort to revitalize the acellular scaffold with cells, the reseeding 
strategy needed to be more effective. In an effort to avoid creation of boluses of 
cells within the scaffold, fibrin, a well-known hydrogel, was used to assist in the 
seeding efficiency as well as a means to aid in migration of the cells into the 
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scaffold. Also utilized to coax cell migration was the cytokine SDF-1. Efforts for a 
more efficient recellularization were largely successful. Cells noticeably migrated 
from the injection site into the tissue. 
2. Prior to this work, our group developed an aortic valve bioreactor, which provided 
a sterile environment for testing aortic valves at physiological conditions. The 
mitral apparatus having a unique structure required several design points that had 
to be addressed to produce a functioning bioreactor. A system to mount a 
recellularized mitral valve construct into a bioreactor was designed based on the 
particular shape of the mitral annulus. Using this as the foundation for optimal force 
distribution, attachment of the chordae tendinae was also addressed. Springs were 
chosen and wrapped around the papillary muscles to provide appropriate tension 
required for physiological testing. 
3. Overall, the bioreactor and the tissue inside of it ran well. The valve was able to 
properly open and close at physiological pressures. These pressures were slowly 
ramped up for several weeks to assure cell maturation, migration, and 
differentiation. Sterility of the bioreactor was maintained throughout as well as 
conditions such as temperature, CO2 levels and humidity. 
4. After histological analysis, cells were found within the constructs in both the 
bioreactor tissue as well as the static control. More cells were found within the 
bioreactor-seeded constructs. There is a possibility that some of the endothelial 
cells that were seeded on the outside of the scaffolds were able to survive the 
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physiological pressures that the valves endured. Seeding efficiency with the use of 
PGG as well the added forces in the bioreactor was significantly lessened. 
5. Several markers for fibroblasts and smooth muscle cells were used to evaluate the 
phenotypes of the cells after being placed in the bioreactor. While results showed 
positive markers for both, fibroblast markers showed significantly stronger than the 
smooth muscle cell markers. This implies that the majority of the seeded pre-
differentiated fibroblasts remained quiescent ever during bioreactor testing. 
6.2.4 Prospective on Progress Made and Comments on Potential Continued Research: 
 The studies and aims described here were modeled after the general tissue 
engineering paradigm in an attempt to successfully combine an ECM scaffold, appropriate 
cell types and a condition this living construct in a bioreactor. Three aims were established 
from this paradigm and significant progress was achieved if not completed with each aim. 
Aim 1 and 2, largely based on scaffold characterization both in vitro and in vivo, are mostly 
complete. The scaffold itself, along with PGG treatment, yielded successful results in 
creating a stable scaffold capable of supporting cellular proliferation. More studies 
continuing to analyze PGG’s role and longevity within the scaffold would prove to be 
useful information for Aim 1. In addition, the in vivo reaction towards the scaffold was 
successful in limiting an inflammatory response and as a result directing macrophage 
polarization towards a pro-healing phenotype. Continued studies of host response may lead 
to a better understanding of PGG’s biochemical role in direction macrophage polarization 
as well as its hindrance of inflammatory markers. Further studies may highlight PGG’s 
longevity in vivo as well. Information could also be extrapolated here in understanding cell 
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migration into the scaffold. This information could be used to optimize cell-seeding 
experiments in the future. 
 Development of the mitral valve bioreactor presented several difficulties due to the 
complexity of the mitral apparatus. With its hyperbolic paraboloid shape, the mitral 
annulus forms the foundation for force distribution. From this particular geometry, and 
fitting this to the other existing bioreactor system, originally fit for the aortic valve, was 
difficult. Despite these, coaptation of the valve was achieved and we believe optimal force 
distribution was as well. However, significant improvements could be made to optimize 
the process by which the mitral valve bioreactor is set up and run during experimentation. 
These could include an easier mechanism for mounting the valve in the mounting rings and 
attachment of the papillary muscles and chordae to this as well. Despite these challenges, 
this system, now equipped for the mitral valve, should become a valuable tool in working 
toward completion of Aim 3. Recellularization of the scaffolds to create a living valve also 
proved difficult despite the advances made using fibrin as a seeding conduit. More 
evaluation should be taken as to why migration out of the scaffold did not occur. And if it 
did in fact occur, why did these cells not survive the bioreactor process? Overall, as studies 
continue, avoidance of a bolus of cells within the constructs and encouragement of cell 
migration should be prioritized. 
Regardless of the directions this project will take, overall it is the belief of this author that 
the studies and progress herein have had a positive impact upon the development of a tissue 
engineered mitral valve. This valve, whose pathological prevalence is evident, needs a 
tissue engineered solution in the future to provide permanent and patient specific solution.  
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6.3 Recommendations for Future Work: 
6.3.1 Aim 1: 
 As previously mentioned the goals set in Aim 1 were largely completed. 
Characterization of the scaffold proved that we were able to sufficiently remove 
xenogeneic cellular and nuclear material while still preserving the ECM. Cells were also 
able to survive within on the exterior of the scaffold. Moving forward, quantifiable 
characterization of the scaffold should be acquired. Several methods can be used to 
quantify the amount of collagen and elastin in scaffolds. This should be done and compared 
to fresh vs. decellularized scaffolds for both leaflets and chordae tendinae. In addition, 
while not examined before, levels of fibronectin should be explored as well to confirm 
further existence of basal lamina proteins present after decellularization. Most of the IHC’s 
used to establish preservation of ECM quality, should be quantified as done in Chapter 2 
to compare fresh vs. decellularized scaffolds. Also worth evaluating would be to examine 
our current decellularization protocol and seek further optimization of this process. Some 
groups are able to completely decellularize their heart valve scaffolds without removing 
GAG content which would be of serious benefit moving forward(5). Therefore, we believe 
that the decellularization protocol, while it has proven successful by most current 
parameters, could always be improved. 
 The following is a suggested study to establish a better understanding of PGG’s 
staying power within the scaffolds. This information, which is regularly requested by other 
researchers, would provide some insight into how the scaffold retains PGG over time. 
6.3.1.1 In Vitro Longevity of PGG within Decellularized Scaffolds 
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6.3.1.1.1 Scaffold Preparation and Design 
 Decellularization of the scaffolds will utilize the protocol described in Chapter 3. 
After the decellularization process is complete, four groups will be established at differing 
concentrations of PGG. See Figure 6.1 for the study design. Concentrations of zero PGG 
(treated with sterile 1 x PBS), 0.15% PGG, 0.3% PGG, and 0.6% PGG will be used on four 
scaffolds (using an n=6 for each of these groups). Treated leaflets can be placed in 6-well 
plates and covered with basic cell culture media (DMEM, 10% FBS, and 1% AbAm). 
These treated scaffolds will be placed on a shaker at low speeds and allowed to shake for 
several weeks. Media will be changed regularly for each group and saved to evaluate 
leeching of PGG into the media. For each group we will collect samples at each week for 
4 weeks. At these time points, histological evaluation will be used to determine any loss of 
PGG within the scaffolds. Mechanical data could also be obtained from each of these time 
points. 
 
Figure 6.1: Design for Evaluation of PGG Retention in Scaffolds. Several concentrations of PGG as well 
as a negative control could be used to evaluate PGG’s staying power within the decellularized scaffolds. Each 
of these groups (n=6) will be evaluated at four different time points. 
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6.3.2 Aim 2: 
 Biocompatibility and host response are critical barriers that a biomaterial must pass 
to be successful. Overall, in Aim 2, it was shown that our PGG-treated scaffolds limited 
inflammatory responses, had decreased degradation, and polarized macrophages towards 
the M2 phenotype. While these benchmarks were considerable and overall successful, there 
are a number of IHC and IF stainings that could be done to look further at other areas of 
interest. In further studies, we would particularly like to look further into how PGG 
decreases expression of TNF-α in these constructs. This well-known, pro-inflammatory 
cytokine is expressed by M1 macrophages as well encouraging other macrophages to 
polarize towards the M1 phenotype. PGG, a well-characterized phenotype has shown 
antioxidant properties. Antioxidants have shown to decrease expression of TNF-α(6,7). Also 
important in macrophage polarization is the production of ROS. These reactive oxygen 
species can damage tissue if over expressed, but due to their presence in tissue play an 
important role in changing the macrophage phenotype from M1 to M2. However, 
antioxidants are known to cleave ROS production, leaving one to question how, if 
expression of ROS eventually leads to the M2 phenotype, how then would decreased levels 
of ROS due to treatment with PGG, lead to the M2 macrophage(7). This conundrum would 
be worth evaluating and would provide key details into how PGG biochemically affects 
inflammation and macrophage polarization. 
 It might also be interesting to evaluate what stems cells, if any, infiltrated the 
scaffold. An IHC for CD34 or CD29 could be used to identify mesenchymal stem cells 
infiltrating into the scaffold. Other signs of inflammation, other than CD8 and CD68 could 
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be evaluated. In Aim 3, fibrin was used as a cell-seeding conduit. Fibrin has also been 
shown to discourage the M1 phenotype. Seeded scaffolds with fibrin and autologous rat 
cells could provide an interesting insight into this study and its combined anti-
inflammatory effort with PGG(8). Knowing this, there are several different groups that 
could be tested using a similar biocompatibility study that was done in Aim 2. 
 The following is a suggested study to further evaluate PGG’s role in diminishing 
inflammation and encouraging M2 macrophages. This study would also be used to 
determine how fibrin, as a cell carrier for seeding, acts in vivo. We would also seed these 
scaffolds without fibrin to determine if any differences take place after the study. 
6.3.2.1 Study Design and Groups: 
 The design parameters will be similar to the subdermal rat study conducted 
and described in Aim 2. In accordance with an IACUC-approved animal use protocol, 
juvenile Sprague-Dawley rats will be anesthetized with buprenorphine at 0.03-0.05 mg/kg 
and acepromazine at 0.5 mg/kg administered subcutaneously. A small incision will be 
made in the center of the dorsal area of each rat about 2 cm inferior to the scapulae, and, 
using blunt dissection, two pockets created between the dermis and fascia lateral to the 
incision (one pocket in each direction). A scaffold sample will placed into each pocket, and 
the incision closed using staples. Rats will receive non-treated, decellularized scaffolds, 
and the remaining will receive PGG-treated decellularized scaffolds. This will be true for 
each overarching group of which there are four. The first group will comprise of acellular 
scaffolds, the second will be scaffolds seeded with autologous ADSC’s taken from the rats 
previously, the third group will have the same cell types seeded using fibrin, and the fourth 
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group will also utilize fibrin, but the cells will be pre-differentiated into fibroblasts and 
endothelial cells. This is true for both tissue types, mitral valve leaflet and chordae 
tendinae. Rats would be allowed to recover and housed individually for the remainder of 
the study. At 4 weeks rats will be euthanized and at 8 weeks, the remaining rats will be 
euthanized, both via CO2 gas (Euthanex system) followed by pneumothorax. Scaffold 
samples and small amounts of their adjacent host tissues will be excised and fixed in 10% 
neutral buffered formalin and processed for histological examination. 
 In Figure 6.2, the one group example is shown. This map would be the same for 
each of the four groups, which reiterated are: 
1. Decellularized scaffolds 
2. Scaffolds recellularized with autologous rat ADSCs 
3. Scaffolds recellularized with autologous rat ADSCs using fibrin as a carrier 
4. Scaffolds recellularized with pre-differentiated autologous rat ADSCs using fibrin 
as a carrier. 
From these four groups and time points, we will be able to evaluate further how our final 
scaffolds, seeded with cells would survive in vivo. 
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Figure 6.2: Schematic Design of Group Organization. Each of the identified groups would utilize this 
organizational map. Each group has PGG-treated and non-treated groups, time points at both 4 and 8 weeks, 
and each of these uses both leaflets and chordae scaffolds. 
6.3.2.1.1 Scaffold Preparation: 
 All scaffolds will be prepared using the decellularization protocol described in Aim 
1. Before implantation, the samples were sterilized in 0.1% (w/v) peracetic acid in PBS for 
1h, followed by rinsing in four changes of sterile PBS. Sterile PGG treatment will use a 
concentration of 0.3% as seen in each aim described. 
6.3.2.1.2 Cell Culture and Seeding: 
 To obtain autologous ADSCs, a small amount of belly fat would be harvested from 
each rat. The tissue would be minced, washed with ammonium chloride to remove red 
blood cells, incubated in collagenase, and centrifuged. The stromal vascular fraction pellet 
would be plated in tissue culture flasks and cultured for 2 weeks to propagate the cells. 
ADSCs would then be seeded into each scaffold at a concentration of 1x106 cells per 
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scaffold. According to the group, this may or may not include fibrin as a cell carrier. For 
group 4, cells will be pre-differentiated using several growth factors.  
For differentiation of ADSCs to endothelial-like cells, ADSCs would be cultured 
for 2 weeks in EC differentiation media comprised of DMEM, 2% FBS, and 1% antibiotic 
solution supplemented with 0.5 ng/mL vascular endothelial growth factor and 20 ng/mL 
insulin-like growth factor-1. Growth factors would be freshly added to the media at the 
time of each media change. 
For differentiation of ADSC’s to fibroblast-like cells, ADSC’s were cultured for 2 
weeks in fibroblast differentiation media comprised of DMEM, 5% FBS, and 1% antibiotic 
solution supplemented with 5ng/mL transforming growth factor beta-1. Growth factors 
would be freshly added to the media at the time of each media change. 
Fibrin would be made at a concentration of 0.5U/mL thrombin, 4mg/mL fibrinogen, 
and 2mM CaCl2. After seeding, these recellularized scaffolds would then be left overnight 
in media to allow for cellular adhesion. 
6.3.2.1.3 Characterization of Explanted Constructs: 
 After each respective time point has ended, histological evaluation will be utilized. 
H&E, Masson’s Trichrome, Movat’s Pentachrome, and DAPI staining will be used to 
evaluate cellular infiltration and ECM integrity. To evaluate inflammation, CD68 and CD8 
expression will be evaluated using IHC. To identify cell types, fibroblast makers HSP-47, 
prolyl-4-hydroxylase, and vimentin will be used. Smooth muscle markers to be used would 
be α-SMA, calponin, and SM22. To evaluate macrophage polarization, CD163 will be used 
as a marker for M2, and iNOS as a marker for M1 macrophages. Proteins will be isolated 
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from each scaffold and a zymography performed to determine MMP expression. 
Mechanical testing will also be performed. From the isolated proteins, an ELIZA will be 
performed to measure TNF-α expression within each group. ROS expression will also be 
determined for each treatment group to evaluate PGG’s role in scavenging it. 
 We will attempt to evaluate how infiltrating cells migrate into the tissue. A better 
understanding of this migration within the scaffolds could shed light on a more optimized 
cell seeding protocol. We would also be interested in seeing how the fibrin affected the 
cellular infiltration or if it encouraged a larger inflammatory response. How would the host 
respond to the seeded cells? Another graduate student in our lab found that seeded ADSC’s 
encouraged a lower inflammatory response. How would pre-differentiated cells affect this 
outcome? How will PGG affect ROS production and will this correlate with TNF-α 
expression? 
6.3.2.1.4 Outcome Success Measures: 
 A continued resistance to inflammation and a polarization towards the M2 
macrophage phenotype for the PGG-treated tissues would indicate success in this study. 
We are aware that PGG plays a significant role in diminishing inflammation; however, 
another successful output of this study would be to have a fuller understanding of how 
PGG acts to discourage these deleterious events. It would also be interesting to see how 
the ADSC’s reacted in vivo. These cells have shown to possess anti-inflammatory 
properties, to confirm this would also be a success. Another measure of success would be 
to see how the fibrin seeded constructs handled the host response. Fibrin, as mentioned, 
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has shown to encourage the pro-healing macrophage phenotype, it would be very positive 
if this was confirmed, especially with the pre-differentiated cells.  
6.3.2.2 Evaluation of Remodeling: 
 In future in vivo studies, whether sub-dermal or even large animal, remodeling of 
the implanted scaffold should be further evaluated. In our work, we examined the 
expression of MMPs to compare degradation between PGG and non-treated sample groups. 
Remodeling of the scaffold however is also imperative for the success of the scaffold. 
Revitalization of the scaffold with new collagen could be determined using 
immunochemistry. After implantation for 4 to 8 weeks, explants would be histologically 
processed and examined. Stainings could be done for HSP-47 and prolyl-4-hydroxylase as 
before. The difference for this experiment would be to choose antibodies that are species 
specific. These antibodies would of course be porcine and the species chosen for the 
implant group. Identification of new, remodeled collagen from the host’s infiltrated cells 
and original collagen present from the scaffold could be determined. This in vitro 
remodeling of the matrix is imperative for the success of the construct moving forward. 
6.3.3 Aim 3: 
 It is our continued belief that revitalization of the scaffold with appropriate cell 
types and then preconditioning these seeded scaffolds in a bioreactor is the best approach 
towards a tissue engineered mitral valve. The first barrier to this success is finding and 
optimizing a cell seeding process that allows uniform distribution throughout the scaffold. 
The niche microstructure that our scaffolds provide ideal conditions for cell differentiation, 
but are meaningless without a cellular presence. As discussed in Chapter 5, there was 
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marked improvement in our ability to seed scaffolds with cells, however this could be 
greatly improved. This lack of completion of cell seeding was evident in the bioreactor 
experiments when very few cells were found to have migrated into the scaffold. Therefore, 
future pilot studies should be conducted to see what alternative methods should be 
attempted to yield a more efficient and practical cell seeding. Practicality and translatability 
are of course key elements here. Many works in literature reference their uniform cell 
seeding, however many times the cells were statically seeded on the scaffolds and the cells 
allowed 6 to 8 weeks to migrate through the tissue. In a clinical setting, this timetable is 
too long for patients in need of a functioning heart valve. 
 The following are several suggested pilot studies for cell seeding experiments as 
well as some suggested studies using the newly design mitral valve bioreactor. From these 
experiments, hopefully future researchers will be able to efficiently seed our ECM scaffold 
and precondition the heart valve in the bioreactor. To complete these significant steps 
would undoubtedly complete the tissue engineering paradigm and provide a novel heart 
valve to all patients. 
6.3.3.1 Cell Seeding Pilot Studies: 
 As mentioned in Aim 5, significant progress was made in encouraging migration 
of cells into the scaffold. Our group has found that direct injection of cells into the scaffold 
provides the best means to force cells into the scaffold’s interior. Statically seeding cells 
onto the exterior has not proven an effective method for cell migration. We believe that the 
incorporation of the fibrin gel as a cell carrier has been beneficial to the cells. As mentioned 
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previously, the viscosity of the gel allows for a less stressful injection process for the cells 
and has been shown to facilitate spreading. 
 Further pilot studies should be used investigate increasing scaffold porosity to 
allow for greater ease of transport for cells. There are several ways to do this, however 
scaffold integrity, an accomplishment for Aim 1, must not be sacrificed too much. Our 
group has used low concentrations of acetic acid as well as various proteases to provide a 
less dense interstitial barrier for the cells to pass through. Another method for creating 
pores is through lyophilization. This process naturally creates pores when completed. This 
may also offer a clinical translatability benefit in that PGG-treated and lyophilized 
scaffolds would only need to be rehydrated and seeded. Storage and transportation of these 
“dry” scaffolds is much more feasible than storing and transporting “wet” sterile scaffolds. 
Taking advantage of this rehydration step may also allow for greater integration of growth 
factors and other mechanisms for coaxing cell migration. 
 Growth factors as well as cytokines should be used in further pilot studies to 
encourage cells to migrate. Fibrin has been shown to bind growth factors(9,10). We should 
use this property to attach growth factors and to evaluate their effects on cell seeding. 
Cytokines such as SDF-1 have also shown to have drastic effects on cell migration(11–13). 
We should use cytokines such as this to encourage movement outside of the injection site.  
 Pilot studies centering on utilization of fibrin, growth factors and cytokines, and 
slight alteration of the ECM scaffold could very well lead to an optimized cell seeding. 
This project’s design, and our tissue engineering paradigm rely heavily on complete 
recellularization of the scaffolds and eventually, preconditioning in a bioreactor. 
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 Also imperative would be the need to recellularize the chordae tendinae. As 
described above, only pre-differentiated endothelial cells were seeded onto the chordae. 
However as seen in fresh chordae sections, cells do reside in these collagenous chords. 
Therefore, an attempt to inject these chordae with cells, and an evaluation of this seeding 
should be completed. If direct injection of these this small, dense tissue proves difficult, 
recellularization utilizing chemotaxis may be the next best option. 
 In the seeding studies addressed above, it was apparent that non-treated scaffolds 
allowed for better cell seeding throughout the construct. Therefore a better understanding 
of why this would occur is important to understand. However, due the large amount of 
beneficial effects PGG provides to the scaffold, elimination of this stabilizing agent should 
be heavily discouraged. A pilot study can be conducted in which non-treated scaffolds are 
cell seeding using the methods described in Aim 3. PGG treatment can then be applied 
similarly to how Isenburg et al. treated their tissues with very low doses of PGG so as not 
to affect cytotoxicity(14). The efficiency of the seeding and the effects this low dosage of 
PGG would have on the construct would need to be heavily investigated as this protocol 
would greatly vary from the methods of stabilization and cell seeding used previously. 
6.3.3.2 Bioreactor Studies and Modifications: 
 One of the bigger accomplishments for this project was the development of a mitral 
valve bioreactor. As previously mentioned, an aortic valve bioreactor was already 
developed by our lab, however the complexity of the mitral apparatus left not only our 
group, but many other research groups without a proper means to test the mitral valve in 
sterile, physiological conditions. 
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 In the future, we should design a better mounting mechanism for the papillary 
muscles. During our bioreactor experiments, the springs, which were used to translate 
tension through the chordae tendinae to the leaflets, would often cut into the papillary 
muscles. We should develop a method of holding this papillary muscle and attaching this 
mounting device to the springs to allow for proper force distribution and valve coaptation. 
Testing should be done for better placement of these papillary muscles and the 
corresponding chordae to ensure function. 
6.3.3.3 The Mitral Valve Bioreactor as a Pathological Model: 
 After a more optimized cell seeding process is developed, use of the mitral valve 
bioreactor does not solely need to be defined as a preconditioner for seeded cells. This 
novel device could also serve as a means for modeling mitral valve pathologies in vitro. 
Conditions for mitral valve pathologies could readily be created. For example, after 
recellularization and endothelialization of the scaffold, the living construct could be placed 
in the bioreactor with a ruptured chordae tendinae. This common issue in degenerating 
valves could be easily recreated in vitro in the bioreactor. Histological evaluation of how 
the cells react to this misguided force distribution could provide some insight into the 
damage done interstitially during this pathology. Another example might be the altering 
the shape of the annulus. A rounded annulus, as opposed to its natural saddle shape, would 
disrupt optimal force distribution and could cause regurgitation. The effects of this on the 
valve could be evaluated. In addition, not many groups have studied the effects of diabetic 
conditions on mitral valves. By altering media conditions, calcification may build up in the 
valve, and development of advanced glycation end products (AGES) may occur. 
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6.3.3.4 Comparison of Non-Treated and PGG-Treated Preconditioned Constructs: 
 For a large portion of the studies discussed in this dissertation, PGG and non-treated 
scaffolds and seeded constructs were compared and contrasted. Therefore, recellularization 
of a non-treated scaffold and placement of into the bioreactor would present an intriguing 
comparison to our currently PGG-treated scaffold. Treatment with PGG would be the only 
aspect of the study design that would defer from previously described bioreactor 
experiments. Analysis of preconditioned, non-treated valves would provide interesting 
insight into activation of the seeded cells, matrix remodeling, and the mechanical integrity 
of the construct post-bioreactor. Comparing the activation of seeded fibroblasts with those 
of PGG-treated scaffolds would also produce interesting results. 
6.3.3.5 Evaluation of PGG’s Longevity in Scaffold 
 Treatment with PGG has had many beneficial effects on our decellularized scaffold 
and recellularized constructs. However, PGG-does not cross-link with the scaffold and will 
slowly leave the scaffold over time. Therefore it will be important to understand the 
longevity in which PGG resides in the scaffold and the effect this has on the scaffolds 
mechanical properties as well as the effect it has on seeded cells. A Phenol-Ferric Chloride 
stain can be performed on our paraffin sections at different time points post-bioreactor 
treatment. Time points of 4, 8 and 12 weeks can be completed in the bioreactor. At each of 
these points, the sections can be stained for PGG and mechanical properties of the construct 
and be determined. Activation of seeded cells and their behavior and the presence of PGG 
will be compared. Ideally, by the time that PGG leaves the construct, remodeling by the 
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seeded cells will be complete and the construct will no longer need the stabilizing effects 
of PGG. 
6.3.3.6 Considerations for Clinical and Commercial Translation: 
 Clinical collaborators have alluded that some repair methods may be more feasible 
for both the patient and the surgeon if a tissue engineered solution were available. 
Therefore, if a recellularization protocol was optimized for leaflets and even chordae 
tendinae, these parts of the valve could be used to repair damaged or diseased valves. 
Living and thus self-healing tissues would provide far more benefit than synthetic leaflets 
or chordae currently used. Also,, current reparative methods could be utilized for the 
deployment of these tissue engineered repairs.  
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Appendix A 
 
 
Figure 5.11: Read out for Aptus Bioreactor System. This is the computer read-out 
provided by the Aptus software. This system allows changing the parameters for pressures, 
both systolic and diastolic, heartrate, and flow in the settings tab. Pressure and flow outputs 
are displayed on the left in numerical and graphical format. 
